hconc014_sample.csv

patient_id,sku,cancer_type,primary_histology,metastatic_treatment_intent,age_at_metastatic_dx,sex,ecog_ps_at_met_dx,bmi_kg_m2,comorbidity_cci,stage_at_initial_dx,de_novo_metastatic_flag,time_primary_to_met_months,synchronous_vs_metachronous,prior_adjuvant_therapy_flag,prior_neoadjuvant_therapy_flag,site_liver,site_lung,site_bone,site_brain,site_adrenal,site_peritoneum,site_pleura,site_lymph_distant,site_skin,site_spinal,site_pericardium,site_bone_marrow,n_metastatic_sites,metastatic_burden_class,cns_metastasis_flag,cns_lesion_count,leptomeningeal_disease_flag,srs_eligible_flag,bone_metastasis_flag,skeletal_related_event,visceral_crisis_flag,malignant_effusion_flag,peritoneal_carcinomatosis_flag,peritoneal_ci_score,hepatic_tumor_burden_pct,bio_egfr_status,bio_alk_status,bio_kras_status,bio_her2_status,bio_braf_v600e_flag,bio_brca_status,bio_msi_mmr_status,bio_pdl1_tps_pct,bio_pdl1_cps_score,bio_tmb_mut_per_mb,bio_ar_splice_variant_flag,bio_ctdna_vaf_baseline,bio_liquid_biopsy_flag,bio_repeat_biopsy_flag,bio_tumor_heterogeneity_score,bio_acquired_resistance_mechanism,local_therapy_flag,sbrt_flag,sbrt_dose_fractions,sbrt_treated_lesion_count,srs_flag,wbrt_flag,surgical_met_resection_flag,rfa_flag,tace_y90_flag,intrathecal_therapy_flag,palliative_radiation_flag,bone_modifying_agent,palliative_care_consult_flag,hospice_referral_flag,opioid_analgesic_flag,pain_score_vas,nutrition_support_flag,corticosteroid_chronic_flag,palliative_surgery_flag,line1_regimen,line1_best_response,line1_pfs_months,line1_io_flag,line1_targeted_flag,line1_ttnt_months,line2_regimen,line2_best_response,line2_pfs_months,line2_io_flag,line2_targeted_flag,line2_ttnt_months,line3_regimen,line3_best_response,line3_pfs_months,line3_io_flag,line3_targeted_flag,line3_ttnt_months,n_lines_received,treatment_free_interval_months,overall_survival_months,os_event_flag,cause_of_death,landmark_1yr_os_flag,landmark_2yr_os_flag,landmark_5yr_os_flag,bio_hr_status,bio_psa_baseline_ng_ml,bio_hrd_status,bio_ca125_baseline_iu_ml,bio_vhl_mutation_flag,bio_imdc_risk,bio_nras_mutation_flag
HC014-4949905957768471,HC-ONC-014,pancreatic_met,Adenocarcinoma,Oligometa_curativeintent,70,Female,0,20.5,5,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,12.4,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,4.3,0,7.83,0,0,39,None,1,1,5,3,0,0,0,1,0,0,0,None,0,0,0,4,0,0,0,FOLFIRINOX,PD,9.72,0,0,0.5,Olaparib_BRCA,SD,3.02,0,1,4.13,Capecitabine,PR,2.94,0,0,4.52,4,0.0,20.46,1,Disease_progression,1,0,0,,,,,,,
HC014-6672543338069995,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,39,Male,0,22.0,7,III,0,61.4,Late_recurrence,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,G12C,HER2-,0,WT,MSS,73.8,0.0,4.8,0,34.97,1,0,32,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,0,1,6,0,0,0,Pembrolizumab_mono,PD,64.13,1,0,10.21,Docetaxel_Nintedanib,SD,1.26,0,0,2.25,NA,NA,0.0,0,0,0.0,2,0.0,55.51,0,Censored,1,1,0,,,,,,,
HC014-1404195574530961,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,45,Female,2,27.8,7,III,0,32.8,Late_recurrence,0,0,1,0,1,0,0,1,0,1,0,0,0,0,4,Polymetastatic,0,0,0,0,1,Spinal_cord_compression,0,0,1,24,17.5,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,2.9,1.8,0,18.35,0,1,79,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,9,0,0,0,Abemaciclib_Fulvestrant,PR,58.07,0,1,4.3,Capivasertib_Fulvestrant,PD,22.93,0,0,5.88,Eribulin,PD,5.8,0,0,0.91,3,0.0,17.85,1,Disease_progression,1,0,0,ER+PR+,,,,,,
HC014-9288734252387052,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,66,Female,0,25.8,0,III,0,6.6,Metachronous,0,0,1,0,0,0,1,1,0,1,0,0,1,0,5,Polymetastatic,0,0,0,0,0,None,0,0,1,29,31.3,Negative,ALK-,WT,HER2_3plus,0,WT,MSS,0.0,1.3,2.2,0,19.04,0,0,18,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,Trastuzumab_Pertuzumab_Docetaxel,PR,35.89,0,1,1.8,Lapatinib_Capecitabine,SD,14.03,0,0,2.86,NA,NA,0.0,0,0,0.0,2,0.0,92.06,0,Censored,1,1,1,ER-PR-,,,,,,
HC014-1855861734069411,HC-ONC-014,prostate_met,Adenocarcinoma,Best_supportive_care,84,Male,3,26.7,8,III,0,35.2,Late_recurrence,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,4.3,0,10.95,0,0,85,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,1,1,0,7,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,23.07,0,Censored,1,0,0,,93.8,,,,,
HC014-9879683904318897,HC-ONC-014,nsclc_met,Squamous_cell,Oligometa_curativeintent,72,Female,0,38.6,4,IV,1,0.0,Synchronous,0,0,0,0,1,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,1,Bone_pain,0,0,0,0,0.0,Exon19del,ALK-,G12C,HER2-,0,WT,MSS,18.1,0.0,11.9,0,6.17,0,0,45,None,1,1,3,3,0,0,0,0,0,0,1,Zoledronic_acid,0,0,0,5,0,0,0,Gefitinib,PD,14.15,0,0,0.86,Pemetrexed,PD,1.6,0,0,2.19,Docetaxel_mono,PD,6.23,0,0,0.93,5,0.0,32.15,1,Treatment_toxicity,1,1,0,,,,,,,
HC014-7630351196339982,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,62,Female,1,26.1,6,III,0,35.4,Late_recurrence,1,1,0,1,0,0,0,1,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,11,0.0,Negative,ALK-,WT,HER2-,1,WT,MSS,0.0,0.0,6.5,0,38.16,0,0,58,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,9,0,0,0,FOLFOXIRI_Bev,PR,12.77,0,0,0.5,FOLFOX_Cetuximab,PR,6.08,0,0,2.39,FOLFOX_Cetuximab,PD,4.82,0,0,3.2,3,0.0,22.77,0,Censored,1,0,0,,,,,,,
HC014-9256039052965084,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,61,Male,1,30.7,0,II,0,23.3,Metachronous,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,41.6,Negative,ALK-,WT,HER2-,0,WT,dMMR,0.0,0.0,7.3,0,25.8,0,0,71,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,3,0,0,0,FOLFOXIRI_Bev,SD,7.18,0,0,2.77,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,44.4,1,Intercurrent_illness,1,1,0,,,,,,,
HC014-9060713932453271,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,78,Male,2,35.1,6,II,0,28.9,Late_recurrence,1,0,1,1,0,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,1,0,0,0,5.4,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,2.3,0,3.5,0,1,39,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,10,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,12.06,1,Disease_progression,1,0,0,,,,,,,
HC014-3549222399251026,HC-ONC-014,gastric_met,Adenocarcinoma,Palliative_systemic,66,Female,2,31.1,3,III,0,14.6,Metachronous,0,0,1,0,1,0,0,0,0,1,0,0,1,0,4,Polymetastatic,0,0,0,0,1,None,0,0,0,0,20.4,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.6,0,3.75,0,1,82,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,1,0,1,4,0,0,0,Pembro_FP,PR,12.88,0,0,6.3,Ramucirumab_Paclitaxel,SD,17.61,0,0,2.99,Trastuzumab_deruxtecan_HER2,PD,4.97,0,1,5.99,3,0.0,0.91,1,Treatment_toxicity,0,0,0,,,,,,,
HC014-3858720709272055,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,69,Male,1,27.4,1,III,0,74.2,Late_recurrence,1,0,1,1,1,0,0,0,0,1,1,0,0,0,5,Polymetastatic,0,0,0,0,1,Hypercalcemia,0,0,0,0,19.7,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.9,0,30.31,0,1,77,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,0,7,0,0,0,FOLFOXIRI_Bev,PD,28.82,0,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,39.56,0,Censored,1,1,0,,,,,,,
HC014-4411474255335746,HC-ONC-014,gastric_met,Adenocarcinoma,Palliative_systemic,59,Female,2,29.0,4,IV,1,0.0,Synchronous,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,11.9,0,14.93,0,1,73,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,8,1,0,0,FLOT,PR,11.62,0,0,5.25,Ramucirumab_Paclitaxel,PD,3.18,0,0,1.88,NA,NA,0.0,0,0,0.0,2,0.0,3.89,0,Censored,0,0,0,,,,,,,
HC014-5976084286580152,HC-ONC-014,nsclc_met,Adenocarcinoma,Oligometa_curativeintent,28,Female,1,24.2,1,IV,1,0.0,Synchronous,0,0,1,0,0,0,1,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,17.9,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,49.6,0.0,7.3,0,19.42,0,0,13,None,1,1,5,3,0,0,0,1,0,0,0,None,0,0,0,4,0,0,0,Atezo_Carbo_Pem_Bev,PD,42.13,0,0,2.66,Pemetrexed,SD,3.02,0,0,1.52,Osimertinib,SD,1.37,0,1,4.23,3,0.0,55.4,1,Disease_progression,1,1,0,,,,,,,
HC014-3872408451472630,HC-ONC-014,ovarian_met,Clear_cell,Oligometa_curativeintent,47,Female,1,29.2,8,III,0,8.9,Metachronous,0,1,0,0,0,0,0,1,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,1,1,9,0.0,Negative,ALK-,WT,HER2-,0,BRCA1,MSS,0.0,0.0,13.3,0,24.82,0,1,67,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,3,0,0,0,Carbo_Pac_Bev,PD,12.55,0,0,5.61,Topotecan,SD,0.73,0,0,1.1,Gemcitabine_Carbo,PD,6.39,0,0,3.98,3,0.0,8.61,0,Censored,0,0,0,,,HRD-,84.6,,,
HC014-5108069750628444,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,80,Female,1,27.6,4,III,0,7.8,Metachronous,0,1,1,0,0,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,1,0,0,39.7,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,4.7,0,16.44,0,0,45,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,3,0,0,0,FOLFOX_Bev,SD,4.65,0,0,4.19,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,27.6,0,Censored,1,1,0,,,,,,,
HC014-1607666321686735,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,66,Male,1,25.8,0,II,0,51.8,Late_recurrence,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,4.5,0,10.21,1,0,63,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,0,1,5,0,0,0,Apalutamide_ADT,PR,29.56,0,0,1.31,Enzalutamide,PD,6.98,0,1,1.6,Docetaxel,PD,4.2,0,0,2.24,5,8.0,44.67,1,Unknown,1,1,0,,220.4,,,,,
HC014-9737962556911639,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,62,Male,1,27.1,2,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,36.5,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.4,0,11.34,0,0,79,None,0,0,0,0,0,0,0,1,0,0,0,None,0,0,0,2,0,0,0,FOLFIRI_Bev,SD,39.15,0,0,4.01,FOLFOX_Cetuximab,SD,5.22,0,0,2.38,FOLFOX_Cetuximab,PD,6.57,0,0,2.33,3,0.0,23.88,0,Censored,1,0,0,,,,,,,
HC014-8152755025758145,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,52,Female,2,26.0,4,II,0,42.2,Late_recurrence,0,0,0,1,1,0,0,1,1,1,1,0,0,0,6,Polymetastatic,0,0,0,0,1,None,0,0,1,20,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,26.4,4.3,0,19.12,0,1,62,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,2,0,0,0,Palbociclib_Fulvestrant,PR,51.59,0,1,7.73,Capivasertib_Fulvestrant,PR,1.71,0,0,1.57,Capecitabine,SD,6.27,0,0,1.1,3,0.0,8.94,1,Disease_progression,0,0,0,ER+PR+,,,,,,
HC014-9425592384761764,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,42,Male,0,26.0,0,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,32.9,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.2,0,14.68,0,1,66,None,1,1,5,1,0,0,0,0,0,0,0,None,0,0,0,8,0,0,0,FOLFIRI_Bev,PR,0.91,0,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,26.68,0,Censored,1,1,0,,,,,,,
HC014-6962766349295798,HC-ONC-014,nsclc_met,Adenocarcinoma,Oligometa_curativeintent,73,Female,1,29.3,6,III,0,51.7,Late_recurrence,1,0,1,1,0,0,0,0,1,0,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,1,0,0,17.4,Negative,ALK-,WT,HER2-,0,WT,MSS,72.7,0.0,3.9,0,18.64,0,0,21,None,1,1,3,1,0,0,0,0,0,0,0,None,0,0,0,2,0,0,0,Pembrolizumab_mono,PD,9.65,1,0,4.09,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,17.94,1,Disease_progression,1,0,0,,,,,,,
HC014-5969464329739843,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,45,Male,1,30.7,6,III,0,80.6,Late_recurrence,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.3,0,4.54,0,1,34,None,1,1,5,3,0,0,0,0,0,0,0,None,0,0,0,3,0,0,0,Apalutamide_ADT,PR,55.52,0,0,0.5,Docetaxel,SD,14.75,0,0,2.71,Abiraterone_Pred,PD,6.62,0,1,4.4,3,0.0,44.59,1,Treatment_toxicity,1,1,0,,5.3,,,,,
HC014-2215342864506124,HC-ONC-014,nsclc_met,Squamous_cell,Palliative_systemic,52,Male,1,18.1,3,IV,1,0.0,Synchronous,0,0,1,0,0,1,0,0,0,1,0,0,0,0,3,Oligometastatic,1,5,0,0,0,None,0,0,0,0,15.6,Negative,ALK-,WT,HER2-,0,WT,MSS,51.8,0.0,8.9,0,17.79,0,0,76,None,1,0,0,0,0,1,0,0,0,0,0,None,0,0,0,8,0,0,0,Cemiplimab_mono,PR,8.82,1,0,9.86,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,13.33,13.79,1,Disease_progression,1,0,0,,,,,,,
HC014-1278035533324289,HC-ONC-014,gastric_met,Adenocarcinoma,Palliative_systemic,59,Female,0,19.1,6,II,0,32.1,Late_recurrence,1,0,1,0,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,Hypercalcemia,0,0,0,0,11.3,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,21.1,0,15.95,1,1,24,None,1,0,0,0,0,0,1,1,0,0,0,Zoledronic_acid,0,0,0,1,0,0,0,ECF,PR,3.38,0,0,2.45,Irinotecan,SD,2.28,0,0,4.36,Ramucirumab_Paclitaxel,PD,1.96,0,0,10.49,3,0.0,26.3,1,Disease_progression,1,1,0,,,,,,,
HC014-5912184571655171,HC-ONC-014,renal_met,Clear_cell,Palliative_systemic,61,Male,1,32.6,7,III,0,27.5,Late_recurrence,0,1,0,1,0,0,0,0,0,1,0,0,1,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,20.1,0.0,20.9,0,1.35,0,1,42,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,6,0,0,0,Nivo_Cabozantinib,PR,0.72,0,1,3.2,Axitinib,PD,7.9,0,0,7.8,Nivolumab_mono,SD,2.95,1,0,1.34,4,1.41,143.82,0,Censored,1,1,1,,,,,0.0,Favorable,
HC014-9037472362779272,HC-ONC-014,renal_met,Sarcomatoid,Best_supportive_care,63,Male,3,25.1,1,III,0,102.6,Late_recurrence,1,0,0,1,0,0,1,1,0,0,1,0,0,0,4,Polymetastatic,0,0,0,0,0,None,0,0,1,19,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,27.7,0.0,2.5,0,16.1,1,0,74,None,0,0,0,0,0,0,0,0,0,0,0,None,0,1,0,7,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,65.7,0,Censored,1,1,1,,,,,0.0,Favorable,
HC014-8648102780245324,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,76,Female,1,25.4,5,III,0,39.4,Late_recurrence,1,0,1,0,0,0,1,1,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,30,12.3,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,14.7,1.5,0,11.96,1,0,70,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,Ribociclib_Letrozole,SD,56.28,0,1,1.57,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,73.38,1,Disease_progression,1,1,1,ER+PR+,,,,,,
HC014-1123996197646453,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,81,Female,2,27.2,4,III,0,3.0,Metachronous,1,0,1,0,0,1,0,0,0,0,0,0,0,1,3,Oligometastatic,1,3,0,1,0,None,0,0,0,0,13.3,Negative,ALK-,WT,HER2_1plus,0,VUS,MSS,0.0,6.7,10.8,0,17.29,1,0,10,None,1,0,0,0,0,0,0,0,0,0,0,None,1,0,1,10,0,0,0,Abemaciclib_Letrozole,PR,18.16,0,1,0.5,Alpelisib_Fulvestrant,SD,3.5,0,0,1.51,NA,NA,0.0,0,0,0.0,2,0.0,101.75,1,Disease_progression,1,1,1,ER+PR+,,,,,,
HC014-7422279489166756,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,42,Male,0,28.9,4,I,0,52.4,Late_recurrence,0,1,0,1,0,0,0,0,0,0,1,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,1,WT,MSS,28.7,0.0,26.2,0,6.76,0,0,70,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,Vemurafenib_Cobimetinib,PR,14.24,0,0,0.96,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,140.0,1,Disease_progression,1,1,1,,,,,,,0.0
HC014-4720674199508727,HC-ONC-014,prostate_met,Adenocarcinoma,Best_supportive_care,74,Male,3,25.1,8,III,0,11.2,Metachronous,1,0,0,0,0,0,0,0,1,0,0,1,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.7,1,3.24,0,0,43,None,0,0,0,0,0,0,0,0,0,0,0,None,0,1,1,8,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,3.39,1,Disease_progression,0,0,0,,193.8,,,,,
HC014-7347451685298863,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,67,Male,2,37.6,4,IV,1,0.0,Synchronous,0,0,0,0,0,1,1,0,0,1,0,0,0,0,3,Oligometastatic,1,3,0,1,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,18.7,0.0,20.7,0,8.35,0,0,84,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,9,0,0,0,Carbo_Paclitaxel_Pembro,PR,22.18,0,0,0.5,Docetaxel_mono,PD,8.28,0,0,3.06,Atezolizumab,PD,0.5,1,0,1.59,3,1.43,7.44,0,Censored,0,0,0,,,,,,,
HC014-7876684480791614,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,36,Female,0,30.2,1,III,0,7.6,Metachronous,1,0,1,0,1,0,0,0,0,0,1,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,17.9,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,14.0,1.6,0,13.46,0,0,68,None,1,0,0,0,0,0,1,0,0,0,0,None,0,0,0,6,0,0,0,Pembrolizumab_Chemo,PR,36.06,1,0,6.65,Capecitabine,PD,29.18,0,0,2.94,NA,NA,0.0,0,0,0.0,2,3.39,69.3,0,Censored,1,1,1,ER-PR-,,,,,,
HC014-7777659462584587,HC-ONC-014,renal_met,Chromophobe,Palliative_systemic,63,Female,1,27.8,2,III,0,58.6,Late_recurrence,0,0,0,1,1,0,0,1,0,1,0,0,0,0,4,Polymetastatic,0,0,0,0,1,None,0,0,1,5,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,81.9,0.0,5.9,0,13.7,0,1,83,None,1,0,0,0,0,0,0,0,0,0,1,None,0,0,1,7,0,0,0,Pembro_Lenvatinib,SD,10.55,0,1,7.88,Cabozantinib,PD,2.19,0,1,1.06,NA,NA,0.0,0,0,0.0,2,0.0,31.63,1,Disease_progression,1,1,0,,,,,1.0,Poor,
HC014-1453417644596989,HC-ONC-014,nsclc_met,Squamous_cell,Best_supportive_care,62,Male,1,24.1,3,IV,1,0.0,Synchronous,0,0,1,0,0,1,0,0,1,0,0,0,1,0,4,Polymetastatic,1,4,1,0,0,None,0,1,0,0,11.7,T790M,ALK-,Other_KRAS,HER2-,0,WT,MSS,26.5,0.0,4.6,0,5.41,0,1,30,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,1,0,1,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,7.68,0,Censored,0,0,0,,,,,,,
HC014-9622833212445847,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,49,Female,0,26.4,3,II,0,33.2,Late_recurrence,1,0,0,1,1,1,0,0,0,0,0,0,1,0,4,Polymetastatic,1,1,0,1,1,Fracture,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,8.2,10.1,0,24.73,0,0,40,None,1,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,0,0,0,0,Abemaciclib_Letrozole,PR,54.48,0,1,7.57,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,129.84,1,Intercurrent_illness,1,1,1,ER+PR+,,,,,,
HC014-7006571992889176,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,71,Female,0,25.4,4,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,12.5,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.5,0,26.67,1,1,57,None,0,0,0,0,0,0,0,1,0,0,0,None,0,0,0,4,0,0,0,FOLFOXIRI_Bev,SD,8.23,0,0,7.32,FOLFOX_Cetuximab,PR,5.22,0,0,4.34,FOLFOX_Cetuximab,PR,0.94,0,0,0.5,3,0.0,34.36,1,Disease_progression,1,1,0,,,,,,,
HC014-8682856021040500,HC-ONC-014,renal_met,Chromophobe,Oligometa_curativeintent,63,Female,1,33.8,2,III,0,10.5,Metachronous,0,0,0,0,0,1,0,1,0,0,0,0,0,0,2,Oligometastatic,1,4,0,0,0,None,0,0,1,26,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,38.0,0.0,3.7,0,7.24,0,0,87,None,1,0,0,0,0,1,0,0,0,0,0,None,0,0,0,2,0,0,0,Nivo_Cabozantinib,SD,14.19,0,1,4.26,Everolimus,PR,12.6,0,0,1.28,NA,NA,0.0,0,0,0.0,2,0.0,108.69,0,Censored,1,1,1,,,,,1.0,Intermediate,
HC014-6875085020421834,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,49,Male,1,31.2,8,III,0,42.8,Late_recurrence,0,1,0,0,1,0,0,0,0,1,0,1,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,BRCA2,MSS,0.0,0.0,0.7,0,15.58,0,0,71,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,0,4,0,0,0,Darolutamide_Docetaxel_ADT,PR,10.43,0,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,33.09,1,Disease_progression,1,1,0,,21.7,,,,,
HC014-9602744807700327,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,39,Female,1,23.5,5,III,0,24.7,Late_recurrence,0,0,0,0,1,0,1,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,7.1,11.5,0,15.02,0,0,57,None,1,1,5,1,0,0,0,0,0,0,0,Denosumab,0,0,1,3,0,0,0,Nab-Paclitaxel_Atezolizumab,PR,45.32,1,0,2.55,Capecitabine,PD,33.21,0,0,1.62,NA,NA,0.0,0,0,0.0,2,1.62,55.87,0,Censored,1,1,0,ER-PR-,,,,,,
HC014-9381189956315162,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,63,Female,1,26.2,8,IV,1,0.0,Synchronous,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,13.6,0,18.24,0,0,47,None,1,1,3,2,0,0,0,0,0,0,0,None,0,0,0,9,0,0,0,FOLFIRI_Cetuximab,PD,5.38,0,0,2.92,FOLFOX_Cetuximab,CR,12.1,0,0,0.5,FOLFOX_Cetuximab,PD,6.63,0,0,5.77,3,0.0,21.93,1,Disease_progression,1,0,0,,,,,,,
HC014-1597175233935230,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,47,Male,1,28.1,4,II,0,34.4,Late_recurrence,1,0,0,0,1,0,1,0,0,1,0,1,0,0,4,Polymetastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,6.6,1,8.7,0,0,53,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,2,0,0,0,Abiraterone_ADT,SD,1.18,0,1,0.5,Lu177-PSMA,PD,8.9,0,0,1.24,Cabazitaxel,PD,3.11,0,0,2.19,3,0.0,34.44,1,Intercurrent_illness,1,1,0,,28.3,,,,,
HC014-5036124360419721,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,56,Female,2,36.8,6,III,0,21.7,Metachronous,1,1,1,1,0,0,0,1,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,28,46.5,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.2,0,24.72,0,0,56,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,4,0,0,0,Gemcitabine_Abraxane,PR,10.02,0,0,0.71,Capecitabine,PD,2.25,0,0,0.64,Olaparib_BRCA,SD,2.95,0,1,0.85,3,0.0,6.87,0,Censored,0,0,0,,,,,,,
HC014-2675248786938149,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Best_supportive_care,46,Female,3,30.7,10,III,0,7.6,Metachronous,1,0,1,0,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,Bone_pain,1,0,0,0,29.7,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,8.3,12.9,0,15.35,1,0,48,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,0,9,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,7.07,1,Disease_progression,0,0,0,ER+PR+,,,,,,
HC014-8115839259404454,HC-ONC-014,melanoma_met,Melanoma,Best_supportive_care,86,Male,2,23.0,0,II,0,6.0,Metachronous,0,0,0,1,0,0,1,0,0,0,1,0,0,0,3,Oligometastatic,0,0,0,0,0,None,1,0,0,0,0.0,Negative,ALK-,WT,HER2-,1,WT,MSS,47.0,0.0,32.8,0,21.29,0,0,72,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,4,0,0,1,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,30.66,1,Disease_progression,1,1,0,,,,,,,0.0
HC014-5293745796226388,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,43,Female,2,21.1,1,III,0,14.5,Metachronous,0,0,0,0,1,0,1,0,1,1,1,0,0,0,5,Polymetastatic,0,0,0,0,1,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,4.7,6.7,0,23.93,0,0,20,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,1,0,1,2,0,0,0,Sacituzumab_Govitecan,PR,21.34,0,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,57.34,1,Disease_progression,1,1,0,ER-PR-,,,,,,
HC014-8638948765544288,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,60,Male,3,25.1,0,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,1,0,0,0,13.6,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,10.0,0,11.0,0,0,55,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,0,9,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,15.16,0,Censored,1,0,0,,,,,,,
HC014-1091164036073129,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,68,Male,3,31.9,6,II,0,29.4,Late_recurrence,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.2,0,17.31,0,0,39,None,0,0,0,0,0,0,0,0,0,0,0,None,1,1,0,5,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,6.69,1,Intercurrent_illness,0,0,0,,,,,,,
HC014-5757961767067993,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,49,Female,2,23.0,4,I,0,27.5,Late_recurrence,1,0,1,1,1,1,0,1,0,0,0,0,0,0,5,Polymetastatic,1,2,1,0,1,Bone_pain,0,0,1,22,9.6,Negative,ALK-,WT,HER2_1plus,0,VUS,MSS,0.0,15.7,22.6,0,11.45,0,1,72,None,1,0,0,0,0,0,0,0,0,1,0,Zoledronic_acid,0,0,0,3,0,0,0,Palbociclib_Fulvestrant,PD,110.4,0,1,3.23,Alpelisib_Fulvestrant,CR,8.6,0,0,2.61,Trastuzumab_deruxtecan,PD,0.5,0,1,1.38,6,0.0,59.36,0,Censored,1,1,0,ER+PR+,,,,,,
HC014-5535396679872107,HC-ONC-014,melanoma_met,Melanoma,Best_supportive_care,54,Male,3,33.6,6,II,0,5.9,Metachronous,0,1,1,1,0,1,0,0,0,1,0,0,0,0,4,Polymetastatic,1,5,0,0,0,None,0,0,0,0,33.0,Negative,ALK-,WT,HER2-,0,WT,MSS,85.3,0.0,44.7,0,13.13,0,1,80,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,6,0,1,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,49.09,0,Censored,1,1,0,,,,,,,0.0
HC014-6045875566562514,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,58,Female,1,23.8,1,II,0,68.7,Late_recurrence,1,1,0,1,0,1,0,1,0,1,1,0,0,0,5,Polymetastatic,1,3,0,1,0,None,0,0,1,14,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,2.4,0.0,22.7,0,19.88,1,0,48,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,9,0,1,0,Relatlimab_Nivolumab,PR,13.35,1,0,4.56,Ipilimumab_mono,SD,5.83,1,0,3.47,Nivolumab_mono,PD,3.39,1,0,5.72,4,3.7,60.2,1,Unknown,1,1,1,,,,,,,0.0
HC014-8708464008114325,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,57,Female,1,27.1,2,III,0,6.8,Metachronous,1,0,1,1,1,1,0,1,0,1,1,0,0,0,7,Polymetastatic,1,8,0,0,1,None,0,0,1,26,5.0,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,0.3,2.5,0,17.17,0,0,70,None,1,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,0,6,0,1,0,Abemaciclib_Fulvestrant,PD,20.68,0,1,1.6,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,59.13,1,Disease_progression,1,1,0,ER+PR+,,,,,,
HC014-5845103193997119,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,54,Male,1,24.6,2,III,0,45.5,Late_recurrence,1,0,0,0,1,0,1,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,7.4,0,18.26,0,0,24,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,1,8,0,0,0,Apalutamide_ADT,PR,33.31,0,0,1.71,Olaparib,PD,1.85,0,1,0.5,Pembrolizumab,PD,3.87,1,0,2.27,3,5.35,16.79,1,Disease_progression,1,0,0,,349.0,,,,,
HC014-5601753580714255,HC-ONC-014,renal_met,Clear_cell,Oligometa_curativeintent,73,Female,1,25.9,2,III,0,8.7,Metachronous,1,1,0,1,0,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,4.3,0.0,1.2,0,47.24,0,1,84,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,3,0,0,0,Pembro_Axitinib,SD,39.61,0,0,1.05,Sunitinib,PR,9.51,0,1,0.5,NA,NA,0.0,0,0,0.0,2,0.0,44.1,1,Disease_progression,1,1,0,,,,,0.0,Favorable,
HC014-1786058335646051,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,51,Female,1,16.0,0,III,0,12.3,Metachronous,0,0,0,1,0,1,1,1,0,1,1,0,0,0,6,Polymetastatic,1,3,0,1,0,None,0,0,1,13,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,90.1,0.0,13.7,0,12.51,0,0,61,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,3,0,0,0,Relatlimab_Nivolumab,PR,14.24,1,0,2.2,Vemurafenib,PD,6.51,0,0,2.46,Ipilimumab_mono,PD,1.33,1,0,2.58,3,7.53,18.65,1,Disease_progression,1,0,0,,,,,,,0.0
HC014-6165857873372398,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,50,Male,1,29.2,5,III,0,2.7,Metachronous,1,0,1,1,1,0,0,0,0,1,1,0,0,0,5,Polymetastatic,0,0,0,0,1,Fracture,0,0,0,0,10.2,Negative,ALK-,WT,HER2-,0,WT,MSS,88.2,0.0,14.4,0,29.18,0,0,58,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,5,0,0,0,Nivolumab_Ipilimumab,PR,39.45,1,0,2.7,Nivolumab_mono,SD,5.7,1,0,0.5,Ipilimumab_mono,SD,1.01,1,0,0.5,5,1.18,67.99,1,Intercurrent_illness,1,1,1,,,,,,,0.0
HC014-7715631705536130,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,61,Male,0,23.8,2,II,0,39.5,Late_recurrence,1,0,1,0,1,0,0,0,1,1,0,1,0,0,5,Polymetastatic,0,0,0,0,1,None,0,0,0,0,25.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,14.8,0,5.0,0,0,83,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,0,2,0,0,0,Abiraterone_ADT,PR,2.6,0,1,2.44,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,24.69,1,Disease_progression,1,1,0,,1.7,,,,,
HC014-8262306800379242,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,47,Male,0,28.7,6,I,0,10.2,Metachronous,1,0,1,0,0,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,46.3,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.1,0,0.37,1,1,77,None,1,0,0,0,0,0,1,0,0,0,0,None,0,0,0,3,0,0,0,FOLFOXIRI_Bev,SD,6.58,0,0,5.15,FOLFOX_Cetuximab,CR,15.66,0,0,2.6,FOLFOX_Cetuximab,PD,1.77,0,0,1.27,4,0.0,20.63,1,Disease_progression,1,0,0,,,,,,,
HC014-5608377401171090,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,44,Female,2,29.0,7,IV,1,0.0,Synchronous,0,0,0,1,1,0,0,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_3plus,0,WT,MSS,0.0,1.3,9.7,0,5.21,0,0,72,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,8,0,0,0,Pyrotinib_Capecitabine,CR,25.66,0,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,38.63,1,Disease_progression,1,1,0,ER+PR-,,,,,,
HC014-3773142658326415,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,67,Female,1,21.0,6,II,0,27.4,Late_recurrence,1,0,0,0,1,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,1.4,3.5,0,18.76,0,0,38,None,1,0,0,0,0,0,0,0,0,0,1,None,0,0,0,3,0,0,0,Palbociclib_Fulvestrant,PD,46.44,0,1,8.4,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,22.11,1,Treatment_toxicity,1,0,0,ER+PR+,,,,,,
HC014-9965145318747464,HC-ONC-014,gastric_met,Adenocarcinoma,Palliative_systemic,81,Male,1,21.6,3,I,0,25.7,Late_recurrence,1,0,1,1,0,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,25.4,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.7,0,21.51,0,0,13,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,XELOX_Bev,PR,15.74,0,0,2.95,Trastuzumab_deruxtecan_HER2,SD,2.59,0,1,0.5,NA,NA,0.0,0,0,0.0,2,0.0,9.97,0,Censored,0,0,0,,,,,,,
HC014-3468147150028047,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,53,Male,2,26.7,0,II,0,53.7,Late_recurrence,0,1,0,0,1,0,1,0,1,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,Spinal_cord_compression,0,1,0,0,0.0,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,18.6,0.0,4.5,0,17.73,0,1,42,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,0,1,3,0,0,0,Carbo_Paclitaxel_Pembro,SD,21.05,0,0,2.79,Docetaxel_mono,SD,7.68,0,0,0.59,Pemetrexed,SD,5.79,0,0,3.82,4,0.0,17.16,0,Censored,1,0,0,,,,,,,
HC014-4063100175337489,HC-ONC-014,renal_met,Clear_cell,Oligometa_curativeintent,69,Male,0,25.9,4,I,0,8.9,Metachronous,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,10.2,0.0,5.7,0,14.95,0,0,83,None,1,1,3,2,0,0,0,0,0,0,0,None,0,0,0,3,0,0,0,Pembro_Axitinib,PR,27.95,0,0,1.61,Everolimus,PD,9.66,0,0,2.9,NA,NA,0.0,0,0,0.0,2,0.0,82.58,1,Intercurrent_illness,1,1,1,,,,,1.0,Intermediate,
HC014-2884895528736342,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,84,Male,1,30.9,0,III,0,91.4,Late_recurrence,1,1,0,0,1,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,BRCA1,MSS,0.0,0.0,3.7,0,19.12,0,0,30,None,1,1,8,2,0,0,0,0,0,0,0,Denosumab,0,0,0,2,0,0,0,Docetaxel_ADT,PD,28.74,0,0,1.39,Rucaparib,SD,23.2,0,0,4.52,Lu177-PSMA,PD,3.94,0,0,0.5,3,0.0,37.54,1,Disease_progression,1,1,0,,8.2,,,,,
HC014-4725886386298363,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,66,Female,1,24.1,5,I,0,15.1,Metachronous,1,1,1,0,1,1,0,0,0,1,0,0,0,0,4,Polymetastatic,1,2,0,1,1,None,0,0,0,0,21.3,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,3.6,3.8,0,7.84,0,1,56,None,1,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,8,0,0,0,Ribociclib_Letrozole,PD,9.29,0,1,3.51,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,77.82,1,Disease_progression,1,1,1,ER+PR+,,,,,,
HC014-8131560821650474,HC-ONC-014,gastric_met,Adenocarcinoma,Oligometa_curativeintent,76,Male,0,27.3,5,I,0,44.1,Late_recurrence,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,20.6,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.7,0,34.73,0,0,57,None,1,1,3,3,0,0,0,0,0,0,0,None,0,0,0,3,0,0,0,Nivo_Chemo,SD,3.33,0,0,2.59,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,13.57,1,Unknown,1,0,0,,,,,,,
HC014-7431761450611241,HC-ONC-014,nsclc_met,Adenocarcinoma,Oligometa_curativeintent,66,Male,1,19.3,2,IV,1,0.0,Synchronous,0,0,0,0,1,0,0,1,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,Spinal_cord_compression,0,0,1,13,0.0,L858R,ALK-,G12C,HER2-,0,WT,MSS,3.8,0.0,1.8,0,1.43,0,0,83,None,1,1,5,2,0,0,0,0,0,0,0,Denosumab,0,0,0,6,0,0,0,Afatinib,PR,11.7,0,0,0.55,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,65.3,1,Disease_progression,1,1,1,,,,,,,
HC014-8912021061129745,HC-ONC-014,renal_met,Clear_cell,Palliative_systemic,61,Female,1,33.2,2,I,0,1.2,Metachronous,0,1,0,1,1,0,1,0,0,1,0,0,0,0,4,Polymetastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,12.0,0.0,2.9,0,10.47,0,1,53,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,1,8,0,0,0,Nivo_Cabozantinib,PR,20.56,0,1,0.5,Axitinib,SD,5.88,0,0,1.09,Lenvatinib_Everolimus,SD,5.45,0,1,4.67,3,0.0,13.7,1,Disease_progression,1,0,0,,,,,0.0,Favorable,
HC014-3592738656420768,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,64,Female,1,26.7,7,III,0,28.5,Late_recurrence,0,1,0,0,1,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,5.6,6.8,0,30.96,0,0,13,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,1,6,0,0,0,Nab-Paclitaxel_Atezolizumab,SD,39.0,1,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,80.07,0,Censored,1,1,1,ER-PR-,,,,,,
HC014-1421713204004396,HC-ONC-014,renal_met,Clear_cell,Oligometa_curativeintent,62,Male,0,27.2,3,II,0,46.6,Late_recurrence,1,0,1,0,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,32.4,Negative,ALK-,WT,HER2-,0,WT,MSS,9.7,0.0,2.7,0,8.6,1,0,22,None,1,1,5,1,0,0,0,1,0,0,1,Denosumab,0,0,1,3,0,0,0,Pembro_Lenvatinib,PR,60.4,0,1,5.93,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,73.82,1,Disease_progression,1,1,1,,,,,0.0,Poor,
HC014-3639461440676001,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Best_supportive_care,69,Female,2,26.6,2,III,0,68.5,Late_recurrence,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,9.9,1.7,0,27.12,0,0,48,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,61.11,1,Disease_progression,1,1,1,ER+PR+,,,,,,
HC014-5035219815956128,HC-ONC-014,nsclc_met,Squamous_cell,Maintenance,90,Female,2,24.8,11,IV,1,0.0,Synchronous,0,0,1,1,0,0,0,0,1,0,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,1,0,0,22.9,Exon19del,ALK-,Other_KRAS,HER2-,0,WT,MSS,52.0,0.0,1.3,0,9.36,0,0,34,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,5,0,0,0,Erlotinib,PR,28.14,0,0,5.79,Docetaxel_Nintedanib,PD,1.38,0,0,1.34,Pemetrexed,PD,0.5,0,0,3.11,3,0.0,75.84,1,Disease_progression,1,1,1,,,,,,,
HC014-2972050066761711,HC-ONC-014,renal_met,Clear_cell,Oligometa_curativeintent,44,Female,0,19.6,5,III,0,6.6,Metachronous,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,13.9,0.0,2.9,0,15.92,1,0,16,None,1,1,12,2,0,0,0,0,0,0,0,None,0,0,0,1,0,0,0,Pazopanib,PD,6.25,0,1,2.79,Axitinib,PR,1.19,0,0,0.84,Everolimus,CR,4.46,0,0,1.32,3,0.0,113.57,1,Disease_progression,1,1,1,,,,,1.0,Intermediate,
HC014-1496820098872640,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,75,Female,0,27.6,1,IV,1,0.0,Synchronous,0,0,1,0,0,0,1,1,0,0,0,1,1,0,5,Polymetastatic,0,0,0,0,0,None,0,0,1,27,21.3,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,18.9,0,28.2,0,0,38,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,2,0,0,0,Gemcitabine_mono,PD,4.84,0,0,0.85,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,31.31,1,Disease_progression,1,1,0,,,,,,,
HC014-2310244228920122,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,81,Female,1,22.9,2,II,0,9.3,Metachronous,0,0,1,0,1,0,0,0,0,0,0,1,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,28.9,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,3.6,15.4,0,19.32,0,1,28,None,1,0,0,0,0,0,1,1,0,0,0,Denosumab,0,0,1,6,0,0,0,Abemaciclib_Fulvestrant,PR,9.15,0,1,1.64,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,38.72,1,Disease_progression,1,1,0,ER+PR-,,,,,,
HC014-3651589952089061,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,36,Male,1,31.5,4,IV,1,0.0,Synchronous,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,6.8,1,3.26,0,1,83,None,1,1,5,2,0,0,0,0,0,0,0,None,0,0,0,5,0,0,0,Apalutamide_ADT,PR,50.27,0,0,2.91,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,89.32,1,Disease_progression,1,1,1,,2483.9,,,,,
HC014-8055564221850056,HC-ONC-014,renal_met,Clear_cell,Palliative_systemic,61,Female,1,19.3,1,III,0,7.3,Metachronous,1,0,0,1,1,0,0,0,0,0,1,0,0,0,3,Oligometastatic,0,0,0,0,1,Fracture,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,59.4,0.0,1.8,0,20.61,0,0,58,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,1,8,0,0,0,Pembro_Axitinib,PR,13.71,0,0,4.26,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,96.0,0,Censored,1,1,1,,,,,1.0,Intermediate,
HC014-7827408074316334,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,63,Female,2,30.1,4,III,0,46.6,Late_recurrence,0,1,1,0,0,1,1,0,1,1,0,0,0,0,5,Polymetastatic,1,6,0,0,0,None,0,0,0,0,33.9,Negative,ALK-,WT,HER2_0,0,BRCA1,MSS,0.0,14.8,4.7,0,10.25,0,0,15,None,1,0,0,0,0,0,0,0,0,0,0,None,1,0,0,4,0,1,0,Sacituzumab_Govitecan,PR,5.4,0,0,10.14,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,22.8,0,Censored,1,0,0,ER-PR-,,,,,,
HC014-7370427737528538,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Best_supportive_care,55,Female,4,32.6,3,III,0,9.8,Metachronous,0,0,0,0,0,0,1,1,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,7,0.0,Negative,ALK-,WT,HER2_3plus,0,WT,MSS,0.0,10.9,3.1,0,19.62,0,0,71,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,10,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,7.51,1,Disease_progression,0,0,0,ER+PR+,,,,,,
HC014-2565888031626413,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,78,Male,2,36.1,4,IV,1,0.0,Synchronous,0,0,1,1,0,0,0,1,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,21,31.9,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.3,0,26.17,0,1,31,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,7,0,0,0,Gemcitabine_mono,PD,8.91,0,0,1.2,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,23.31,1,Disease_progression,1,0,0,,,,,,,
HC014-3804023245545647,HC-ONC-014,nsclc_met,Adenocarcinoma,Best_supportive_care,67,Female,3,19.5,0,IV,1,0.0,Synchronous,0,0,1,0,1,0,0,0,0,1,0,1,0,0,4,Polymetastatic,0,0,0,0,1,Hypercalcemia,0,0,0,0,20.3,Exon20ins,ALK-,WT,HER2-,0,WT,MSI-H,31.8,0.0,2.2,0,23.89,1,0,61,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,1,0,9,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,4.51,1,Unknown,0,0,0,,,,,,,
HC014-3158294898734016,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,66,Male,2,30.5,4,I,0,52.5,Late_recurrence,1,1,0,0,1,0,0,0,1,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,4.2,0,0.71,0,1,75,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,0,5,0,0,0,Abiraterone_ADT,PR,2.86,0,1,4.04,Rucaparib,PD,2.67,0,0,2.29,Olaparib,PD,1.9,0,1,0.5,4,0.0,61.61,0,Censored,1,1,1,,38.5,,,,,
HC014-9946814227904044,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,61,Female,1,29.2,3,IV,1,0.0,Synchronous,0,0,0,0,1,0,0,1,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,1,6,0.0,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,8.9,1.4,0,9.47,0,0,32,None,1,1,3,1,0,0,0,0,0,0,1,None,0,0,1,1,0,0,0,Palbociclib_Letrozole,PR,68.71,0,1,0.77,Elacestrant,PD,7.91,0,0,4.76,Eribulin,PD,5.76,0,0,1.33,3,0.0,87.07,1,Unknown,1,1,1,ER+PR+,,,,,,
HC014-1003752252127935,HC-ONC-014,gastric_met,Adenocarcinoma,Best_supportive_care,55,Male,2,20.0,0,IV,1,0.0,Synchronous,0,0,1,1,0,0,0,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,1,0,0,0,30.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,4.7,0,2.76,0,0,25,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,3,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,31.0,1,Disease_progression,1,1,0,,,,,,,
HC014-6134842132165667,HC-ONC-014,nsclc_met,Adenocarcinoma,Oligometa_curativeintent,58,Female,1,26.3,5,II,0,3.7,Metachronous,1,0,0,0,0,1,0,1,0,0,0,0,0,0,2,Oligometastatic,1,4,0,0,0,None,0,0,1,14,0.0,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,27.5,0.0,14.1,0,24.92,0,0,14,None,1,0,0,0,0,0,1,0,0,0,0,None,0,0,0,5,0,1,0,Nivo_Ipi,PR,16.45,0,0,1.81,Docetaxel_Nintedanib,PD,5.61,0,0,0.58,NA,NA,0.0,0,0,0.0,2,0.0,14.87,1,Disease_progression,1,0,0,,,,,,,
HC014-9438060888159357,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Best_supportive_care,50,Female,2,23.5,3,I,0,80.9,Late_recurrence,1,1,0,1,1,0,0,0,1,0,1,1,0,0,5,Polymetastatic,0,0,0,0,1,None,1,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,2.5,1.3,0,14.46,0,0,46,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,0,2,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,2.24,1,Treatment_toxicity,0,0,0,ER-PR-,,,,,,
HC014-5496178405225950,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,57,Male,2,21.1,5,III,0,13.2,Metachronous,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,87.2,0.0,13.4,0,3.17,0,0,31,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,6,0,0,0,Pembrolizumab_mono,PR,18.9,1,0,1.44,Atezolizumab,PD,4.91,1,0,5.49,Pemetrexed,PD,0.94,0,0,2.78,6,0.7,55.11,1,Disease_progression,1,1,0,,,,,,,
HC014-4496819774106538,HC-ONC-014,prostate_met,Adenocarcinoma,Maintenance,59,Male,2,31.9,3,III,0,14.7,Metachronous,1,1,0,0,1,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,0.5,0,10.05,0,0,38,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,4,0,0,0,Docetaxel_ADT,SD,5.9,0,0,2.7,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,91.48,0,Censored,1,1,1,,685.1,,,,,
HC014-1110210992117402,HC-ONC-014,gastric_met,Adenocarcinoma,Palliative_systemic,57,Male,1,17.8,7,IV,1,0.0,Synchronous,0,0,0,0,0,1,0,1,0,0,0,0,0,0,2,Oligometastatic,1,4,0,0,0,None,0,0,1,6,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.4,0,20.8,0,1,87,None,1,0,0,0,0,1,0,0,0,0,0,None,0,0,0,5,1,1,0,Pembro_FP,CR,2.72,0,0,0.5,Irinotecan,SD,9.01,0,0,4.32,Ramucirumab_Paclitaxel,PD,1.6,0,0,1.79,3,0.0,13.04,1,Disease_progression,1,0,0,,,,,,,
HC014-8386622077824824,HC-ONC-014,bladder_met,Urothelial_carcinoma,Oligometa_curativeintent,47,Female,0,36.5,2,IV,1,0.0,Synchronous,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,4.6,0,9.01,0,1,38,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,0,0,0,0,GemCis,PR,0.5,0,0,2.04,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,9.66,1,Disease_progression,0,0,0,,,,,,,
HC014-2814305597761268,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,73,Male,0,27.4,4,I,0,14.5,Metachronous,0,0,0,1,1,0,0,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,Bone_pain,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.4,0,7.52,0,0,67,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,0,0,0,0,0,Abiraterone_ADT,PR,20.06,0,1,6.44,Cabazitaxel,SD,7.07,0,0,5.0,Docetaxel,PD,2.33,0,0,2.38,3,0.0,45.11,1,Disease_progression,1,1,0,,1.1,,,,,
HC014-6673000483707678,HC-ONC-014,nsclc_met,Large_cell,Best_supportive_care,60,Female,2,22.2,4,II,0,55.9,Late_recurrence,1,1,0,0,1,1,0,0,0,0,0,0,0,0,2,Oligometastatic,1,1,0,1,1,Spinal_cord_compression,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,44.4,0.0,6.0,0,29.51,1,1,32,None,1,0,0,0,1,0,0,0,0,0,0,Zoledronic_acid,1,0,1,10,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,17.53,1,Disease_progression,1,0,0,,,,,,,
HC014-6246897632906986,HC-ONC-014,nsclc_met,Squamous_cell,Palliative_systemic,70,Female,1,26.7,3,III,0,28.4,Late_recurrence,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,79.6,0.0,11.3,0,20.04,1,0,13,None,1,1,5,1,0,0,0,0,0,0,0,None,0,0,0,1,0,0,0,Pembrolizumab_mono,SD,3.51,1,0,6.33,Docetaxel_Ramucirumab,PD,8.89,0,0,0.54,NA,NA,0.0,0,0,0.0,2,0.0,10.85,1,Unknown,0,0,0,,,,,,,
HC014-4757862123356430,HC-ONC-014,nsclc_met,Adenocarcinoma,Best_supportive_care,68,Female,4,19.4,5,II,0,6.7,Metachronous,1,0,1,1,1,0,1,0,0,1,0,1,0,0,6,Polymetastatic,0,0,0,0,1,None,1,0,0,0,11.6,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,68.2,0.0,14.3,0,13.58,0,0,68,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,1,0,10,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,8.88,1,Disease_progression,0,0,0,,,,,,,
HC014-9886061472648902,HC-ONC-014,renal_met,Chromophobe,Palliative_systemic,47,Female,1,23.1,5,II,0,115.2,Late_recurrence,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,7.8,0.0,5.3,0,22.37,0,0,61,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,1,0,0,0,Pazopanib,PR,22.93,0,1,5.07,Lenvatinib_Everolimus,SD,6.1,0,1,6.28,Everolimus,SD,1.63,0,0,3.96,4,0.0,18.48,0,Censored,1,0,0,,,,,1.0,Intermediate,
HC014-6387971252119152,HC-ONC-014,ovarian_met,High_grade_serous,Best_supportive_care,57,Female,2,29.0,0,III,0,4.8,Metachronous,1,0,1,0,0,1,1,1,0,0,0,0,0,0,4,Polymetastatic,1,3,0,1,0,None,1,0,1,25,36.4,Negative,ALK-,WT,HER2-,0,VUS,MSS,0.0,0.0,8.1,0,10.67,1,1,17,None,1,0,0,0,1,0,0,0,0,0,0,None,1,0,0,10,1,1,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,49.28,1,Intercurrent_illness,1,1,0,,,HRD+,844.0,,,
HC014-3460089731409102,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,47,Female,2,25.1,3,II,0,72.0,Late_recurrence,1,0,0,0,1,0,1,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,Fracture,0,0,0,0,0.0,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,1.3,3.8,0,3.29,0,0,82,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,1,0,1,8,0,0,0,Palbociclib_Fulvestrant,PD,57.04,0,1,2.62,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,60.63,1,Disease_progression,1,1,1,ER+PR+,,,,,,
HC014-3617528953114255,HC-ONC-014,gastric_met,Adenocarcinoma,Palliative_systemic,78,Male,1,36.3,2,IV,1,0.0,Synchronous,0,0,0,1,0,0,0,1,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,15,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,19.8,0,32.69,0,0,17,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,1,0,0,0,EOX,PD,3.36,0,0,0.5,Trastuzumab_deruxtecan_HER2,SD,3.21,0,1,7.2,Paclitaxel_mono,PR,3.32,0,0,5.99,4,0.0,14.24,1,Disease_progression,1,0,0,,,,,,,
HC014-6928684214008033,HC-ONC-014,renal_met,Clear_cell,Palliative_systemic,45,Female,0,32.5,5,II,0,11.7,Metachronous,1,0,1,1,1,1,1,0,0,0,0,0,0,0,5,Polymetastatic,1,5,0,0,1,Spinal_cord_compression,0,0,0,0,33.3,Negative,ALK-,WT,HER2-,0,WT,MSS,11.4,0.0,11.8,0,20.86,0,0,49,None,1,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,6,0,1,0,Pembro_Lenvatinib,SD,18.71,0,1,2.12,Everolimus,PR,3.15,0,0,1.99,Cabozantinib,PR,2.58,0,1,3.59,5,21.81,69.19,1,Disease_progression,1,1,1,,,,,0.0,Favorable,
HC014-5394267012531694,HC-ONC-014,melanoma_met,Melanoma,Maintenance,59,Female,1,28.7,6,IV,1,0.0,Synchronous,0,0,1,0,0,1,0,1,1,1,0,0,0,0,5,Polymetastatic,1,2,0,1,0,None,0,1,1,24,28.8,Negative,ALK-,WT,HER2-,0,WT,MSS,23.3,0.0,32.3,0,5.19,0,0,71,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,2,0,1,0,Nivolumab_Ipilimumab,SD,20.26,1,0,4.32,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,65.58,1,Disease_progression,1,1,1,,,,,,,0.0
HC014-6302424199682200,HC-ONC-014,prostate_met,Adenocarcinoma,Best_supportive_care,72,Male,2,21.4,4,II,0,10.8,Metachronous,0,0,1,1,1,0,0,0,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,1,0,0,0,10.1,Negative,ALK-,WT,HER2-,0,BRCA2,MSS,0.0,0.0,2.0,0,24.83,0,1,12,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,1,0,1,2,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,26.89,0,Censored,1,1,0,,16.3,,,,,
HC014-1345752421921402,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,55,Male,0,19.2,2,II,0,59.0,Late_recurrence,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,Spinal_cord_compression,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,BRCA2,MSS,0.0,0.0,1.4,0,10.3,0,0,58,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,0,5,0,0,0,Enzalutamide_ADT,SD,17.93,0,1,0.5,Olaparib,PR,14.96,0,1,1.98,Docetaxel,PD,5.55,0,0,1.22,6,0.62,57.04,1,Intercurrent_illness,1,1,0,,56.7,,,,,
HC014-6561875088293830,HC-ONC-014,sarcoma_met,Leiomyosarcoma,Best_supportive_care,49,Male,3,17.5,6,II,0,33.0,Late_recurrence,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.9,0,17.55,0,0,24,None,0,0,0,0,0,0,0,0,0,0,0,None,0,1,0,9,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,25.15,1,Disease_progression,1,1,0,,,,,,,
HC014-5579867566810227,HC-ONC-014,renal_met,Clear_cell,Palliative_systemic,75,Female,1,32.7,0,III,0,70.3,Late_recurrence,1,1,0,1,0,0,1,1,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,31,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,31.8,0.0,1.3,0,12.45,0,0,13,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,5,0,0,0,Nivo_Cabozantinib,PR,14.22,0,1,6.99,Sunitinib,PD,23.32,0,1,6.36,NA,NA,0.0,0,0,0.0,2,0.0,53.08,1,Disease_progression,1,1,0,,,,,1.0,Intermediate,
HC014-6198804519175392,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,64,Female,1,31.0,3,II,0,12.2,Metachronous,0,0,0,0,1,1,1,0,0,0,0,0,0,1,4,Polymetastatic,1,3,0,1,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_1plus,0,BRCA2,MSS,0.0,6.4,5.9,0,3.98,0,0,63,None,1,0,0,0,1,0,0,0,0,0,0,Zoledronic_acid,0,0,0,7,0,1,0,Abemaciclib_Fulvestrant,PR,6.69,0,1,0.5,Elacestrant,PD,40.0,0,0,6.62,Pembrolizumab_mono,SD,5.78,1,0,4.07,3,7.31,65.0,0,Censored,1,1,1,ER+PR+,,,,,,
HC014-2591639812963528,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,70,Female,2,36.2,6,II,0,50.0,Late_recurrence,0,0,1,1,0,0,0,0,1,1,0,0,0,0,4,Polymetastatic,0,0,0,0,0,None,0,1,0,0,13.2,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,7.0,0,9.12,1,0,17,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,4,0,0,0,FOLFOXIRI_Bev,PR,18.65,0,0,0.75,FOLFOX_Bev,SD,6.21,0,0,0.9,NA,NA,0.0,0,0,0.0,2,0.0,13.94,1,Disease_progression,1,0,0,,,,,,,
HC014-6298900296581962,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Maintenance,51,Female,1,17.7,4,III,0,6.0,Metachronous,0,0,1,1,1,0,1,0,0,1,0,0,0,0,5,Polymetastatic,0,0,0,0,1,None,0,0,0,0,12.6,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,5.9,19.1,0,3.4,0,0,38,None,1,0,0,0,0,0,0,0,0,0,1,None,0,0,1,2,0,0,0,Palbociclib_Fulvestrant,SD,34.07,0,1,1.42,Everolimus_Exemestane,PR,8.86,0,0,0.56,Fulvestrant_mono,PD,6.56,0,0,1.86,3,0.0,76.89,0,Censored,1,1,1,ER+PR+,,,,,,
HC014-7100779278745908,HC-ONC-014,renal_met,Clear_cell,Palliative_systemic,79,Male,0,19.8,1,III,0,11.1,Metachronous,1,0,0,0,1,1,0,0,0,1,0,0,0,0,3,Oligometastatic,1,7,0,0,1,Bone_pain,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,19.6,0.0,6.0,0,7.62,0,1,49,None,1,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,4,0,0,0,Avelumab_Axitinib,SD,21.08,1,0,9.34,Lenvatinib_Everolimus,PD,5.74,0,1,2.02,NA,NA,0.0,0,0,0.0,2,0.0,63.03,1,Disease_progression,1,1,1,,,,,0.0,Intermediate,
HC014-9380371019198172,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,77,Female,3,25.1,5,III,0,65.8,Late_recurrence,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,11.2,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,7.8,0,14.7,1,0,60,None,0,0,0,0,0,0,0,0,0,0,0,None,0,1,1,10,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,30.03,1,Disease_progression,1,1,0,,,,,,,
HC014-5760972380056241,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,51,Female,0,21.4,5,II,0,1.0,Metachronous,0,0,0,1,1,0,0,1,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,1,30,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,7.0,2.3,0,5.37,0,0,66,None,1,1,5,1,0,0,0,0,0,0,1,Zoledronic_acid,0,0,1,0,0,0,0,Nab-Paclitaxel_Atezolizumab,PD,49.67,1,0,3.11,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,28.62,1,Disease_progression,1,1,0,ER-PR-,,,,,,
HC014-4432509616312716,HC-ONC-014,nsclc_met,Adenocarcinoma,Best_supportive_care,66,Female,3,34.9,3,III,0,83.4,Late_recurrence,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,43.7,0.0,0.9,0,3.27,1,0,77,None,0,0,0,0,0,0,0,0,0,0,0,None,1,1,1,10,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,22.39,1,Unknown,1,0,0,,,,,,,
HC014-1566286353094427,HC-ONC-014,nsclc_met,NOS,Palliative_systemic,80,Female,1,24.5,2,III,0,18.4,Metachronous,1,1,0,1,0,0,1,0,0,0,0,1,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,L858R,ALK-,WT,HER2-,0,WT,MSS,10.7,0.0,3.9,0,0.6,0,0,38,None,1,0,0,0,0,0,1,0,0,0,0,None,0,0,0,2,0,0,0,Afatinib,PD,2.29,0,0,0.5,Pemetrexed,PD,2.96,0,0,4.26,NA,NA,0.0,0,0,0.0,2,0.0,81.06,1,Disease_progression,1,1,1,,,,,,,
HC014-5132112553571927,HC-ONC-014,bladder_met,Urothelial_carcinoma,Palliative_systemic,62,Female,1,25.9,2,IV,1,0.0,Synchronous,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.4,0,6.83,0,1,71,None,1,1,3,2,0,0,0,0,0,0,0,None,0,0,0,8,0,0,0,Pembrolizumab_mono_cisplatin_unfit,PR,5.19,1,0,11.54,Vinflunine,PD,5.33,0,0,2.14,NA,NA,0.0,0,0,0.0,2,9.62,5.49,0,Censored,0,0,0,,,,,,,
HC014-9059870798311813,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,67,Female,1,21.2,4,III,0,10.3,Metachronous,1,1,1,0,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,27.2,Negative,ALK-,WT,HER2_3plus,0,WT,MSS,0.0,3.5,4.7,0,3.85,0,0,23,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,0,1,5,0,0,0,THP_Taxane,PR,20.31,0,0,4.57,Trastuzumab_Capecitabine,SD,1.16,0,1,1.19,Everolimus_Exemestane,PD,2.55,0,0,4.7,3,0.0,89.08,1,Disease_progression,1,1,1,ER-PR-,,,,,,
HC014-8130282373156748,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Best_supportive_care,46,Female,3,26.2,0,III,0,20.2,Metachronous,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,8.8,3.7,0,30.16,1,0,10,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,1,0,10,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,9.67,1,Disease_progression,0,0,0,ER-PR-,,,,,,
HC014-7998693445162427,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,55,Female,1,28.6,2,II,0,61.8,Late_recurrence,1,0,0,0,1,0,1,0,1,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,Hypercalcemia,0,0,0,0,0.0,Negative,ALK-,WT,HER2_1plus,0,BRCA2,MSS,0.0,4.3,3.3,0,15.8,0,0,42,None,1,1,3,1,0,0,0,0,0,0,1,None,0,0,1,3,0,0,0,Ribociclib_Letrozole,SD,57.29,0,1,16.12,Capivasertib_Fulvestrant,SD,11.84,0,0,1.36,Eribulin,PD,0.77,0,0,2.03,4,0.0,23.83,1,Disease_progression,1,0,0,ER+PR+,,,,,,
HC014-5827047727486085,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,52,Male,4,30.9,3,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,1,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,1,0,0,12.4,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.3,0,13.5,0,0,40,None,0,0,0,0,0,0,0,0,0,0,0,None,1,1,0,4,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,17.45,1,Disease_progression,1,0,0,,,,,,,
HC014-3900898524957297,HC-ONC-014,melanoma_met,Melanoma,Oligometa_curativeintent,70,Female,0,20.4,2,III,0,53.8,Late_recurrence,1,1,1,0,0,1,0,0,0,0,0,1,0,0,3,Oligometastatic,1,1,0,1,0,None,0,0,0,0,23.7,Negative,ALK-,WT,HER2-,1,WT,MSS,43.4,0.0,19.8,0,0.79,1,0,71,None,1,1,3,1,1,0,0,1,0,0,0,None,0,0,0,2,0,1,0,Vemurafenib_Cobimetinib,SD,24.78,0,0,0.5,Pembrolizumab_mono,SD,2.2,1,0,0.67,NA,NA,0.0,0,0,0.0,2,0.0,147.02,1,Disease_progression,1,1,1,,,,,,,0.0
HC014-4016451243958195,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,64,Male,0,24.1,1,II,0,20.9,Metachronous,0,0,0,0,1,0,0,0,0,1,0,1,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,0.9,1,9.5,0,0,14,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,0,1,1,0,0,0,Apalutamide_ADT,PR,14.25,0,0,1.95,Pembrolizumab,SD,6.54,1,0,4.58,NA,NA,0.0,0,0,0.0,2,13.03,22.36,1,Disease_progression,1,0,0,,70.0,,,,,
HC014-9663288656634143,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,56,Male,2,24.5,5,II,0,3.5,Metachronous,1,0,0,0,1,0,0,0,1,0,0,0,0,1,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,12.6,0,20.6,0,0,36,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,1,0,1,5,0,0,0,Docetaxel_ADT,PR,48.53,0,0,0.5,Abiraterone_Pred,CR,3.93,0,1,0.74,Olaparib,PD,13.24,0,1,4.36,3,0.0,14.45,1,Treatment_toxicity,1,0,0,,1.4,,,,,
HC014-3874929755831074,HC-ONC-014,nsclc_met,Squamous_cell,Best_supportive_care,48,Male,3,24.8,3,II,0,2.2,Metachronous,0,0,1,0,0,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,42.6,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,3.8,0.0,6.5,0,5.76,1,0,67,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,10,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,18.2,1,Disease_progression,1,0,0,,,,,,,
HC014-7058488860712329,HC-ONC-014,nsclc_met,NOS,Palliative_systemic,65,Male,1,17.9,3,II,0,73.7,Late_recurrence,1,0,0,0,0,0,0,0,1,1,0,1,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK+,WT,HER2-,0,WT,MSS,34.7,0.0,0.5,0,32.69,0,1,67,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,3,0,0,0,Brigatinib,SD,17.09,0,1,2.37,Docetaxel_Ramucirumab,SD,3.91,0,0,3.72,Docetaxel_Nintedanib,PD,1.54,0,0,2.87,3,0.0,10.23,1,Disease_progression,0,0,0,,,,,,,
HC014-2253792948773774,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,45,Female,0,27.7,3,I,0,6.9,Metachronous,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,1,14,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,0.9,2.3,0,29.75,0,0,58,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,6,0,0,0,Sacituzumab_Govitecan,SD,11.3,0,0,2.1,Eribulin,SD,12.5,0,0,6.2,NA,NA,0.0,0,0,0.0,2,0.0,44.3,0,Censored,1,1,0,ER-PR-,,,,,,
HC014-4283080676129792,HC-ONC-014,sclc_met,Small_cell_carcinoma,Palliative_systemic,41,Male,1,35.1,1,IV,1,0.0,Synchronous,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,Oligometastatic,1,2,0,1,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.4,0,3.68,1,0,27,None,1,0,0,0,1,0,0,0,0,0,0,None,0,0,0,1,0,1,0,EC,PD,5.25,0,0,0.77,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,18.93,1,Intercurrent_illness,1,0,0,,,,,,,
HC014-2121464488999429,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,53,Male,0,20.6,0,III,0,57.2,Late_recurrence,1,0,0,1,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.2,0,33.36,0,1,39,None,1,1,8,3,0,0,0,0,0,0,1,Denosumab,0,0,0,5,0,0,0,Docetaxel_ADT,SD,0.71,0,0,1.62,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,33.16,1,Treatment_toxicity,1,1,0,,238.3,,,,,
HC014-8134006908109809,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,66,Female,1,32.8,5,II,0,113.1,Late_recurrence,1,1,1,0,1,0,0,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,16.2,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,0.7,5.7,0,24.78,0,0,68,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,0,0,8,0,0,0,Sacituzumab_Govitecan,PR,33.39,0,0,8.28,Eribulin,PD,1.91,0,0,0.91,Trastuzumab_deruxtecan,SD,1.02,0,1,1.1,5,0.0,53.42,1,Disease_progression,1,1,0,ER-PR-,,,,,,
HC014-4596697690664670,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,69,Male,0,25.1,3,III,0,34.8,Late_recurrence,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,Spinal_cord_compression,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.3,0,20.24,1,0,51,None,1,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,0,2,0,0,0,Abiraterone_ADT,SD,6.08,0,1,5.02,Rucaparib,PR,8.17,0,0,5.19,Cabazitaxel,PD,4.87,0,0,0.5,3,0.0,77.68,1,Treatment_toxicity,1,1,1,,25.8,,,,,
HC014-2855382282154194,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,42,Male,2,24.5,2,II,0,28.8,Late_recurrence,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,24.9,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,8.1,0,12.87,0,1,86,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,10,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,19.29,0,Censored,1,0,0,,,,,,,
HC014-6745689559284994,HC-ONC-014,sarcoma_met,Synovial_sarcoma,Palliative_systemic,46,Male,1,26.0,8,III,0,9.9,Metachronous,0,0,1,1,1,0,0,0,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,39.9,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.1,0,16.98,0,0,39,None,1,1,12,3,0,0,0,1,0,0,1,Zoledronic_acid,0,0,1,6,0,0,0,Gemcitabine_Docetaxel,SD,1.01,0,0,7.2,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,16.22,1,Unknown,1,0,0,,,,,,,
HC014-7070242916846463,HC-ONC-014,nsclc_met,Squamous_cell,Palliative_systemic,50,Female,0,31.3,1,I,0,2.1,Metachronous,1,0,0,0,0,0,1,1,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,5,0.0,Negative,ALK-,G12C,HER2-,0,WT,MSS,84.9,0.0,16.2,0,14.11,0,1,60,None,1,1,8,3,0,0,0,0,0,0,0,None,0,0,0,1,0,0,0,Pembrolizumab_mono,PR,19.5,1,0,4.27,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,16.56,80.75,0,Censored,1,1,1,,,,,,,
HC014-6697860694703198,HC-ONC-014,melanoma_met,Melanoma,Best_supportive_care,90,Male,1,26.9,4,III,0,22.6,Metachronous,0,0,0,0,1,1,0,0,0,0,1,0,0,1,4,Polymetastatic,1,4,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,1,WT,MSS,31.8,0.0,19.3,0,31.05,0,0,81,None,1,0,0,0,0,1,0,0,0,0,1,Zoledronic_acid,0,0,0,8,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,16.62,0,Censored,1,0,0,,,,,,,0.0
HC014-1983405282023694,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,77,Female,1,24.9,4,IV,1,0.0,Synchronous,0,0,0,0,1,1,0,0,1,1,0,0,0,0,4,Polymetastatic,1,3,0,1,1,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,8.4,0,9.89,0,0,44,None,1,0,0,0,1,0,0,0,0,0,0,Denosumab,0,0,1,6,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,23.33,1,Disease_progression,1,0,0,,,,,,,
HC014-3685959781828871,HC-ONC-014,ovarian_met,High_grade_serous,Oligometa_curativeintent,60,Female,0,35.1,0,IV,1,0.0,Synchronous,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,1,11,0.0,Negative,ALK-,WT,HER2-,0,BRCA1,MSS,0.0,0.0,9.3,0,5.97,0,0,86,None,1,0,0,0,0,0,1,0,0,0,0,None,0,0,0,8,0,0,0,Carbo_PLD,SD,17.11,0,0,3.01,Olaparib,SD,13.87,0,1,0.5,NA,NA,0.0,0,0,0.0,2,0.0,80.07,1,Disease_progression,1,1,1,,,HRD+,124.5,,,
HC014-1523502021909694,HC-ONC-014,nsclc_met,Squamous_cell,Palliative_systemic,69,Male,1,25.2,5,IV,1,0.0,Synchronous,0,0,0,0,1,0,0,0,0,0,0,0,0,1,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Exon19del,ALK-,WT,HER2-,0,WT,MSS,23.9,0.0,11.2,0,13.35,0,0,75,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,1,1,0,0,0,Dacomitinib,PR,23.53,0,0,3.97,Osimertinib,PD,4.29,0,1,5.54,NA,NA,0.0,0,0,0.0,2,0.0,84.74,1,Disease_progression,1,1,1,,,,,,,
HC014-6909740315340293,HC-ONC-014,renal_met,Papillary,Palliative_systemic,46,Male,2,20.1,1,I,0,22.8,Metachronous,1,0,0,0,0,0,1,0,0,0,1,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,28.7,0.0,10.4,0,4.58,1,0,81,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,6,0,0,0,Pembro_Lenvatinib,PD,34.75,0,1,0.61,Cabozantinib,SD,3.19,0,1,4.49,NA,NA,0.0,0,0,0.0,2,0.0,52.7,1,Disease_progression,1,1,0,,,,,0.0,Intermediate,
HC014-6157410188752863,HC-ONC-014,renal_met,Sarcomatoid,Palliative_systemic,58,Male,2,18.1,4,III,0,1.0,Metachronous,0,0,0,1,0,1,0,0,0,0,0,0,1,1,4,Polymetastatic,1,4,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,43.6,0.0,2.2,0,2.54,1,1,65,None,1,0,0,0,0,0,0,0,0,0,0,None,1,0,1,2,0,1,0,Nivo_Cabozantinib,PR,29.85,0,1,6.63,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,84.47,1,Disease_progression,1,1,1,,,,,0.0,Poor,
HC014-5582645045757295,HC-ONC-014,pancreatic_met,Adenocarcinoma,Best_supportive_care,58,Male,3,36.4,4,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,14.6,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,10.0,0,17.38,1,0,37,None,0,0,0,0,0,0,0,0,0,0,0,None,0,1,1,8,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,8.1,0,Censored,0,0,0,,,,,,,
HC014-8555238542910395,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,50,Male,1,42.3,9,III,0,21.6,Metachronous,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,8.1,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.9,0,13.34,0,0,67,None,0,0,0,0,0,0,0,1,0,0,0,None,0,0,0,2,0,0,0,FOLFOX_Bev,SD,5.2,0,0,1.01,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,35.18,1,Disease_progression,1,1,0,,,,,,,
HC014-5883727196645279,HC-ONC-014,bladder_met,Urothelial_carcinoma,Palliative_systemic,40,Male,0,21.8,1,II,0,4.9,Metachronous,1,0,0,0,0,1,0,0,0,0,0,0,0,1,2,Oligometastatic,1,3,0,1,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.2,0,4.22,0,0,35,None,1,1,8,2,0,0,0,0,0,0,0,None,0,0,0,2,0,1,0,Pembrolizumab_mono_cisplatin_unfit,PR,1.95,1,0,1.5,Erdafitinib_FGFR,PR,3.14,0,0,0.5,NA,NA,0.0,0,0,0.0,2,3.32,38.27,1,Unknown,1,1,0,,,,,,,
HC014-7142235406175552,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,59,Female,2,25.3,3,III,0,33.7,Late_recurrence,1,1,1,1,1,1,0,0,0,0,1,1,0,0,6,Polymetastatic,1,5,0,0,1,None,0,0,0,0,13.9,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,3.6,5.4,0,8.95,0,1,29,None,1,0,0,0,0,1,0,0,0,0,0,Denosumab,0,0,0,4,0,0,0,Abemaciclib_Fulvestrant,CR,3.21,0,1,2.31,Alpelisib_Fulvestrant,PD,6.28,0,0,0.87,Lapatinib_Capecitabine,SD,1.83,0,0,1.58,3,0.0,40.59,1,Disease_progression,1,1,0,ER+PR+,,,,,,
HC014-7655473372944641,HC-ONC-014,melanoma_met,Melanoma,Best_supportive_care,67,Female,4,29.1,4,III,0,97.4,Late_recurrence,1,1,0,1,1,1,0,0,0,0,1,0,0,0,4,Polymetastatic,1,3,1,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,22.0,0.0,26.7,0,13.17,1,1,13,None,1,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,1,1,6,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,18.62,1,Disease_progression,1,0,0,,,,,,,0.0
HC014-2739503474829040,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,71,Male,1,24.0,3,II,0,91.2,Late_recurrence,1,1,0,0,1,0,0,0,1,0,0,1,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,9.4,0,17.64,0,0,54,None,1,0,0,0,0,0,0,0,0,0,1,None,0,0,1,9,0,0,0,Docetaxel_ADT,PR,39.79,0,0,2.6,Rucaparib,SD,15.01,0,0,3.92,NA,NA,0.0,0,0,0.0,2,0.0,42.71,1,Disease_progression,1,1,0,,43.4,,,,,
HC014-3077580832404612,HC-ONC-014,sarcoma_met,Synovial_sarcoma,Oligometa_curativeintent,51,Female,1,24.1,3,III,0,74.8,Late_recurrence,1,0,1,1,0,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,18.2,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.5,0,12.3,0,1,11,None,1,1,8,3,0,0,0,0,0,0,0,None,0,0,0,8,0,0,0,Pazopanib,SD,3.62,0,1,0.95,Eribulin,PD,4.43,0,0,1.23,NA,NA,0.0,0,0,0.0,2,0.0,18.3,0,Censored,1,0,0,,,,,,,
HC014-7804437710820363,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,42,Male,0,29.7,4,IV,1,0.0,Synchronous,0,0,1,0,0,0,1,0,0,0,0,0,1,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,21.2,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.2,0,11.29,0,1,87,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,3,0,0,0,NALIRIFOX,SD,7.9,0,0,2.35,Gemcitabine_Cisplatin,PR,4.32,0,0,3.22,NA,NA,0.0,0,0,0.0,2,0.0,30.29,1,Disease_progression,1,1,0,,,,,,,
HC014-5630589832462645,HC-ONC-014,prostate_met,Adenocarcinoma,Maintenance,51,Male,2,29.7,5,I,0,23.9,Metachronous,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,Spinal_cord_compression,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,11.8,0,2.03,0,0,36,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,9,0,0,0,Enzalutamide_ADT,PR,8.92,0,1,1.35,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,19.47,1,Disease_progression,1,0,0,,11.0,,,,,
HC014-6709812692172897,HC-ONC-014,sclc_met,Small_cell_carcinoma,Best_supportive_care,63,Male,3,26.0,4,IV,1,0.0,Synchronous,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,Oligometastatic,1,3,0,1,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,13.1,0,19.71,0,0,44,None,1,0,0,0,0,0,0,0,0,0,0,None,1,1,1,5,0,1,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,14.09,0,Censored,1,0,0,,,,,,,
HC014-7751144580312373,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,74,Male,1,23.6,6,III,0,31.4,Late_recurrence,0,0,1,0,0,0,1,1,0,1,0,0,0,0,4,Polymetastatic,0,0,0,0,0,None,0,0,1,26,13.2,Negative,ALK-,Other_KRAS,HER2_3plus,0,WT,MSS,0.0,0.0,4.6,0,28.41,0,0,42,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,FOLFOXIRI_Bev,SD,7.04,0,0,2.07,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,14.11,0,Censored,1,0,0,,,,,,,
HC014-4405639507804451,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,45,Female,0,24.5,5,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,1,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,9,12.3,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,7.1,0,0.69,0,0,22,None,1,1,5,3,0,0,0,0,0,0,0,None,0,0,0,6,0,0,0,FOLFIRINOX,PD,2.05,0,0,0.5,Capecitabine,SD,3.09,0,0,6.01,Gemcitabine_Cisplatin,SD,3.02,0,0,3.66,3,0.0,12.13,1,Disease_progression,1,0,0,,,,,,,
HC014-1938972654957829,HC-ONC-014,bladder_met,Urothelial_carcinoma,Palliative_systemic,74,Male,1,27.7,5,II,0,34.0,Late_recurrence,0,1,0,0,1,1,0,0,1,0,0,0,0,0,3,Oligometastatic,1,3,0,1,1,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.0,0,21.04,0,0,75,None,1,1,8,3,1,0,0,0,0,0,0,Denosumab,0,0,1,2,0,1,0,GemCis,PR,12.08,0,0,0.5,Vinflunine,PD,6.85,0,0,0.5,NA,NA,0.0,0,0,0.0,2,0.0,6.8,1,Disease_progression,0,0,0,,,,,,,
HC014-2456785810029503,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,52,Female,1,31.2,5,IV,1,0.0,Synchronous,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,2.6,8.0,0,5.42,1,0,71,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,6,0,0,0,Abemaciclib_Letrozole,SD,6.15,0,1,0.84,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,9.5,0,Censored,0,0,0,ER+PR+,,,,,,
HC014-4271988655722698,HC-ONC-014,ovarian_met,Clear_cell,Best_supportive_care,62,Female,3,22.2,3,II,0,20.0,Metachronous,0,0,0,1,0,0,0,1,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,26,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.2,0,20.95,1,1,39,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,9,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,33.4,0,Censored,1,1,0,,,HRD+,1.4,,,
HC014-8225419341735710,HC-ONC-014,ovarian_met,Clear_cell,Best_supportive_care,56,Female,2,19.5,6,III,0,9.3,Metachronous,1,0,0,0,0,0,0,1,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,19,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.1,0,11.25,0,0,29,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,3,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,39.14,0,Censored,1,1,0,,,HRD-,311.0,,,
HC014-4327801143093023,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,61,Male,1,20.8,3,II,0,88.1,Late_recurrence,1,0,1,0,0,0,0,1,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,19,54.1,Negative,ALK-,WT,HER2-,0,WT,pMMR,0.0,0.0,3.1,0,4.2,0,0,66,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,2,0,0,0,FOLFOXIRI_Bev,PD,13.74,0,0,2.59,FOLFOX_Cetuximab,SD,7.89,0,0,0.55,NA,NA,0.0,0,0,0.0,2,0.0,51.21,1,Disease_progression,1,1,0,,,,,,,
HC014-9590203264128337,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,70,Female,0,24.4,2,III,0,17.6,Metachronous,0,0,0,0,1,1,0,0,0,1,1,0,0,1,5,Polymetastatic,1,2,0,1,1,Spinal_cord_compression,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,14.0,2.2,0,7.12,0,1,73,None,1,0,0,0,1,0,0,0,0,0,0,Denosumab,0,0,0,3,0,1,0,Nab-Paclitaxel_Atezolizumab,CR,47.48,1,0,1.41,Vinorelbine,SD,6.92,0,0,0.5,Elacestrant,SD,3.4,0,0,2.57,4,4.56,79.06,1,Disease_progression,1,1,1,ER-PR-,,,,,,
HC014-7723720800379591,HC-ONC-014,melanoma_met,Melanoma,Oligometa_curativeintent,52,Female,0,34.5,5,III,0,7.0,Metachronous,0,1,0,1,0,0,0,0,0,0,1,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,1,WT,MSS,73.1,0.0,31.4,0,1.69,0,0,20,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,2,0,0,0,Nivolumab_Ipilimumab,PR,25.1,1,0,0.73,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,7.78,15.07,0,Censored,1,0,0,,,,,,,0.0
HC014-5404621984311391,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,51,Male,2,20.8,4,III,0,41.4,Late_recurrence,0,0,0,0,1,1,0,0,0,0,0,1,0,0,3,Oligometastatic,1,1,0,1,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,BRCA2,MSS,0.0,0.0,15.7,0,1.38,0,0,26,None,1,0,0,0,1,0,0,0,0,0,1,Denosumab,1,0,1,6,0,1,0,Docetaxel_ADT,CR,10.27,0,0,0.5,Abiraterone_Pred,PD,7.69,0,1,3.1,NA,NA,0.0,0,0,0.0,2,0.0,41.42,1,Intercurrent_illness,1,1,0,,109.0,,,,,
HC014-4906778233033110,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,60,Female,0,28.3,2,III,0,6.9,Metachronous,1,0,0,1,1,1,0,1,0,1,0,0,0,0,5,Polymetastatic,1,6,0,0,1,None,0,0,1,6,0.0,Negative,ALK-,WT,HER2_0,0,VUS,MSS,0.0,4.7,2.6,0,5.81,1,1,14,None,1,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,0,7,0,1,0,Pembrolizumab_Chemo,PD,70.99,1,0,0.74,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,101.17,0,Censored,1,1,1,ER-PR-,,,,,,
HC014-3529675223563429,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,57,Female,2,24.2,6,I,0,29.4,Late_recurrence,0,1,1,1,0,1,0,0,0,1,0,0,0,0,4,Polymetastatic,1,3,0,1,0,None,0,0,0,0,27.7,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,20.4,18.8,0,1.04,0,0,16,None,1,0,0,0,1,0,0,0,0,0,0,None,1,0,1,10,0,0,0,Abemaciclib_Fulvestrant,PR,26.54,0,1,5.1,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,41.54,1,Intercurrent_illness,1,1,0,ER+PR+,,,,,,
HC014-3389724729042139,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,50,Female,1,32.7,3,IV,1,0.0,Synchronous,0,0,0,1,0,0,1,0,0,0,0,1,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,1.3,2.3,0,0.47,0,0,62,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,1,0,0,0,Palbociclib_Letrozole,PR,17.0,0,1,4.43,Alpelisib_Fulvestrant,PR,18.69,0,0,3.99,NA,NA,0.0,0,0,0.0,2,0.0,25.77,0,Censored,1,1,0,ER+PR-,,,,,,
HC014-2971386638509450,HC-ONC-014,nsclc_met,NOS,Palliative_systemic,66,Female,1,27.9,3,IV,1,0.0,Synchronous,0,0,0,0,0,1,1,0,0,1,0,0,0,0,3,Oligometastatic,1,3,0,1,0,None,0,0,0,0,0.0,Exon19del,ALK-,WT,HER2-,0,WT,MSS,48.7,0.0,5.1,0,14.98,0,0,73,None,1,1,8,1,1,0,0,0,0,0,0,None,0,0,0,6,0,0,0,Gefitinib,PR,18.36,0,0,0.98,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,23.14,0,Censored,1,0,0,,,,,,,
HC014-6311755643049617,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,72,Male,1,22.7,6,III,0,31.5,Late_recurrence,1,1,0,0,1,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,1,Hypercalcemia,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,8.2,0,21.2,0,1,88,None,1,1,12,3,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,9,0,0,0,Enzalutamide_ADT,SD,6.66,0,1,2.29,Rucaparib,SD,9.27,0,0,2.4,NA,NA,0.0,0,0,0.0,2,0.0,93.96,1,Intercurrent_illness,1,1,1,,1.9,,,,,
HC014-1851795210607225,HC-ONC-014,sclc_met,Small_cell_carcinoma,Palliative_systemic,50,Female,1,25.8,0,IV,1,0.0,Synchronous,0,0,0,0,1,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,Fracture,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.8,0,29.3,0,1,57,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,0,0,3,0,0,0,Durvalumab_EP,PR,14.41,1,0,3.42,Lurbinectedin,CR,9.87,0,0,1.89,Pembrolizumab,PD,5.99,1,0,0.56,4,7.82,10.95,1,Disease_progression,0,0,0,,,,,,,
HC014-5375763213272385,HC-ONC-014,sarcoma_met,Synovial_sarcoma,Oligometa_curativeintent,68,Female,1,30.7,3,III,0,12.2,Metachronous,0,0,0,1,1,0,1,0,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,Bone_pain,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.7,0,9.92,0,0,51,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,0,1,5,0,0,0,Gemcitabine_Docetaxel,SD,7.26,0,0,8.26,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,19.6,1,Treatment_toxicity,1,0,0,,,,,,,
HC014-1030260576082409,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,62,Male,2,23.6,0,III,0,23.4,Metachronous,1,0,1,1,0,1,0,1,0,1,1,0,1,0,7,Polymetastatic,1,3,0,1,0,None,0,0,1,14,26.9,Negative,ALK-,WT,HER2-,0,WT,MSS,17.5,0.0,4.0,0,1.53,0,0,46,None,1,0,0,0,0,0,0,0,0,0,0,None,1,0,1,9,0,0,0,Pembrolizumab_mono,PD,3.09,1,0,2.61,Vemurafenib,PD,5.66,0,0,28.68,Nivolumab_mono,SD,1.58,1,0,2.87,3,0.0,91.47,0,Censored,1,1,1,,,,,,,0.0
HC014-3252260986511220,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,63,Female,1,35.1,2,IV,1,0.0,Synchronous,0,0,1,1,0,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,29.6,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,4.1,0,12.93,1,0,16,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,CAPOX_Bev,PR,3.02,0,0,3.03,FOLFOX_Bev,PD,5.93,0,0,0.5,NA,NA,0.0,0,0,0.0,2,0.0,70.99,1,Disease_progression,1,1,1,,,,,,,
HC014-2261694921720843,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,74,Male,3,22.8,3,III,0,26.5,Late_recurrence,1,0,1,0,0,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,1,1,0,0,11.7,Negative,ALK-,Other_KRAS,HER2-,1,WT,MSS,0.0,0.0,5.0,0,15.14,0,0,71,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,8,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,4.77,1,Disease_progression,0,0,0,,,,,,,
HC014-7281127516094266,HC-ONC-014,melanoma_met,Melanoma,Oligometa_curativeintent,77,Male,0,31.2,3,III,0,16.6,Metachronous,1,0,0,1,0,1,0,0,0,0,0,0,0,0,2,Oligometastatic,1,3,0,1,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,3.8,0.0,30.5,0,14.09,0,0,40,None,1,1,12,1,1,0,0,0,0,0,0,None,0,0,0,7,0,0,0,Nivolumab_Ipilimumab,CR,6.76,1,0,1.46,Pembrolizumab_mono,SD,6.96,1,0,1.28,NA,NA,0.0,0,0,0.0,2,0.5,88.41,1,Disease_progression,1,1,1,,,,,,,1.0
HC014-4443233559056723,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,34,Female,1,24.9,5,III,0,39.1,Late_recurrence,0,0,0,0,1,0,1,0,1,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,5.7,5.6,0,12.67,1,1,48,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,0,1,0,0,0,Abemaciclib_Fulvestrant,SD,9.27,0,1,0.59,Capivasertib_Fulvestrant,PD,28.14,0,0,4.35,Trastuzumab_Capecitabine,PR,2.92,0,1,0.52,4,0.0,94.47,1,Disease_progression,1,1,1,ER+PR+,,,,,,
HC014-7447844029124614,HC-ONC-014,melanoma_met,Melanoma,Best_supportive_care,75,Female,2,25.9,12,IV,1,0.0,Synchronous,0,0,1,1,1,1,0,0,0,1,1,0,0,0,6,Polymetastatic,1,4,0,0,1,None,1,0,0,0,18.4,Negative,ALK-,WT,HER2-,0,WT,MSS,51.4,0.0,24.5,0,11.76,1,0,62,None,1,0,0,0,0,1,0,0,0,0,1,None,0,0,0,4,0,1,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,106.23,0,Censored,1,1,1,,,,,,,0.0
HC014-2935351746039096,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,53,Male,1,23.6,11,II,0,7.1,Metachronous,1,0,0,0,1,0,0,0,0,1,1,1,0,1,5,Polymetastatic,0,0,0,0,1,Spinal_cord_compression,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.4,0,6.41,0,0,39,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,0,1,2,0,0,0,Darolutamide_Docetaxel_ADT,PR,8.46,0,0,5.55,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,53.37,1,Disease_progression,1,1,0,,76.5,,,,,
HC014-9693604321780089,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,62,Male,1,25.9,2,I,0,52.9,Late_recurrence,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,6.6,0,7.86,1,0,75,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,2,0,0,0,Darolutamide_Docetaxel_ADT,PR,7.92,0,0,3.65,Docetaxel,PR,4.51,0,0,0.84,Abiraterone_Pred,PD,1.34,0,1,6.26,3,0.0,41.8,0,Censored,1,1,0,,71.4,,,,,
HC014-6789618105160158,HC-ONC-014,renal_met,Sarcomatoid,Palliative_systemic,77,Male,1,22.8,2,II,0,9.3,Metachronous,0,0,1,1,0,0,0,1,0,1,0,0,0,0,4,Polymetastatic,0,0,0,0,0,None,0,0,1,18,8.7,Negative,ALK-,WT,HER2-,0,WT,MSS,2.3,0.0,5.6,0,5.66,0,1,18,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,5,0,0,0,Pazopanib,SD,7.85,0,1,1.94,Nivolumab_mono,SD,1.3,1,0,3.25,Axitinib,SD,4.69,0,0,2.66,3,0.0,60.74,1,Disease_progression,1,1,1,,,,,1.0,Intermediate,
HC014-2606897788169399,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,76,Female,1,23.4,3,III,0,78.3,Late_recurrence,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,22.6,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,4.0,13.9,0,8.89,1,0,85,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,Nab-Paclitaxel_Atezolizumab,PD,15.77,1,0,2.55,Capecitabine,SD,15.39,0,0,1.65,Trastuzumab_Capecitabine,SD,3.42,0,1,2.84,3,0.0,10.54,1,Disease_progression,0,0,0,ER-PR-,,,,,,
HC014-4749545077520305,HC-ONC-014,melanoma_met,Melanoma,Best_supportive_care,57,Male,3,27.8,4,I,0,1.8,Metachronous,0,1,0,0,0,1,1,1,0,0,1,0,0,0,4,Polymetastatic,1,7,0,0,0,None,0,0,1,8,0.0,Negative,ALK-,WT,HER2-,1,WT,MSS,37.9,0.0,16.9,0,6.59,1,1,83,None,1,0,0,0,0,0,0,0,0,0,0,None,1,1,1,6,0,1,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,107.43,0,Censored,1,1,1,,,,,,,0.0
HC014-6841210651532645,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,53,Male,1,20.0,5,III,0,28.0,Late_recurrence,1,0,0,1,0,0,0,1,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,20,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.4,0,2.2,0,0,55,None,1,1,5,2,0,0,0,0,0,0,0,None,0,0,0,2,0,0,0,FOLFIRI_Cetuximab,SD,12.78,0,0,4.2,FOLFOX_Cetuximab,SD,2.9,0,0,7.04,NA,NA,0.0,0,0,0.0,2,0.0,23.1,0,Censored,1,0,0,,,,,,,
HC014-1927294322236645,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,57,Female,1,29.6,7,III,0,32.1,Late_recurrence,0,1,1,1,0,0,0,0,0,1,1,1,0,0,5,Polymetastatic,0,0,0,0,0,None,0,0,0,0,24.7,Negative,ALK-,WT,HER2-,1,WT,MSS,17.2,0.0,15.5,0,15.03,1,0,57,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,5,0,0,0,Nivolumab_mono,PD,19.01,1,0,0.91,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,113.95,1,Disease_progression,1,1,1,,,,,,,1.0
HC014-9113590520764635,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,45,Female,1,25.6,6,II,0,43.0,Late_recurrence,1,0,1,0,0,0,0,1,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,24,20.5,Negative,ALK-,WT,HER2_1plus,0,BRCA1,MSS,0.0,12.7,2.4,0,1.76,0,0,60,None,1,0,0,0,0,0,1,0,0,0,0,None,0,0,0,7,0,0,0,Palbociclib_Letrozole,SD,65.48,0,1,5.14,Alpelisib_Fulvestrant,PR,0.5,0,0,3.63,Fulvestrant_mono,PD,4.86,0,0,0.77,3,0.0,144.18,1,Disease_progression,1,1,1,ER+PR+,,,,,,
HC014-8606977070152185,HC-ONC-014,hcc_met,Hepatocellular_carcinoma,Palliative_systemic,57,Female,2,25.6,3,II,0,21.0,Metachronous,1,0,1,1,0,0,1,1,0,0,0,0,0,0,4,Polymetastatic,0,0,0,0,0,None,0,0,1,29,20.8,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.5,0,2.12,0,0,58,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,5,0,0,0,Lenvatinib,PD,7.9,0,1,5.91,Ramucirumab,SD,4.37,0,0,2.5,Regorafenib,CR,2.69,0,1,0.89,3,0.0,3.1,1,Disease_progression,0,0,0,,,,,,,
HC014-9653213840350933,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,56,Female,1,34.0,0,IV,1,0.0,Synchronous,0,0,0,1,0,0,0,1,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,6,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,12.6,0,17.41,1,0,10,None,1,1,3,2,0,0,0,0,0,0,0,None,0,0,0,3,0,0,0,FOLFIRINOX,SD,3.66,0,0,1.51,FOLFOX,PD,4.36,0,0,1.07,Capecitabine,PD,2.62,0,0,11.15,4,0.0,3.47,0,Censored,0,0,0,,,,,,,
HC014-6886137869567756,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,71,Female,0,29.8,1,III,0,13.9,Metachronous,0,1,1,0,1,1,0,1,0,1,0,0,0,0,5,Polymetastatic,1,4,1,0,1,None,0,0,1,7,35.9,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,6.0,5.2,0,5.75,0,1,13,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,1,1,0,1,0,Carboplatin_Gemcitabine,PR,2.33,0,0,0.62,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,25.43,1,Disease_progression,1,1,0,ER-PR-,,,,,,
HC014-4782742298909272,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,58,Female,1,24.8,5,II,0,16.9,Metachronous,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,4.4,0,25.3,1,1,40,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,FOLFOXIRI_Bev,CR,7.38,0,0,0.5,FOLFOX_Bev,PD,10.99,0,0,5.84,NA,NA,0.0,0,0,0.0,2,0.0,21.05,0,Censored,1,0,0,,,,,,,
HC014-3790414397663168,HC-ONC-014,hcc_met,Hepatocellular_carcinoma,Palliative_systemic,73,Male,0,16.0,2,III,0,37.4,Late_recurrence,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,1,14,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,6.4,0,19.6,0,1,58,None,1,1,8,1,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,Atezolizumab_Bevacizumab,PR,20.26,1,0,6.26,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,8.32,72.83,1,Disease_progression,1,1,1,,,,,,,
HC014-8800531366652019,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,45,Female,0,20.2,0,III,0,25.2,Late_recurrence,0,0,0,0,0,0,0,0,0,1,1,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,0.0,1.2,0,19.02,0,1,35,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,5,0,0,0,Palbociclib_Fulvestrant,PD,45.46,0,1,5.18,Alpelisib_Fulvestrant,PD,12.42,0,0,0.64,Lapatinib_Capecitabine,PR,3.96,0,0,0.5,4,0.0,8.63,1,Disease_progression,0,0,0,ER+PR+,,,,,,
HC014-8460317177070488,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,49,Male,1,29.1,1,II,0,1.0,Metachronous,0,0,1,0,1,0,1,0,0,1,1,0,0,0,5,Polymetastatic,0,0,0,0,1,None,0,0,0,0,44.9,Negative,ALK-,WT,HER2-,1,WT,MSS,39.8,0.0,24.3,0,5.3,0,0,66,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,1,1,0,0,0,Nivolumab_Ipilimumab,SD,14.0,1,0,1.27,Vemurafenib,PD,10.89,0,0,0.7,NA,NA,0.0,0,0,0.0,2,0.0,89.93,0,Censored,1,1,1,,,,,,,0.0
HC014-4744009404305898,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,48,Female,1,25.3,2,I,0,40.6,Late_recurrence,1,0,0,1,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,BRCA1,MSS,0.0,1.3,9.6,0,39.14,0,1,83,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,2,0,0,0,Palbociclib_Letrozole,CR,38.52,0,1,1.66,Elacestrant,SD,15.42,0,0,0.65,Trastuzumab_deruxtecan,PR,4.81,0,1,0.5,4,10.9,90.57,0,Censored,1,1,1,ER+PR+,,,,,,
HC014-9943397059012651,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,58,Female,1,24.2,11,IV,1,0.0,Synchronous,0,0,0,0,1,0,0,1,0,0,1,0,0,1,4,Polymetastatic,0,0,0,0,1,Hypercalcemia,0,0,1,18,0.0,Negative,ALK-,WT,HER2_0,0,BRCA2,MSS,0.0,6.4,2.7,0,3.53,0,0,21,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,1,8,0,0,0,Pembrolizumab_Chemo,SD,32.89,1,0,2.61,Vinorelbine,SD,0.5,0,0,0.7,Pembrolizumab_mono,PD,9.81,1,0,1.04,3,0.0,92.94,1,Disease_progression,1,1,1,ER-PR-,,,,,,
HC014-1857539317387425,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,63,Male,2,23.4,3,II,0,7.6,Metachronous,1,0,0,0,1,0,1,0,1,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,Bone_pain,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,51.5,0.0,3.4,0,17.11,0,0,12,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,0,8,0,0,0,Pembrolizumab_mono,PR,21.93,1,0,2.34,Docetaxel_Nintedanib,SD,0.84,0,0,3.12,Docetaxel_mono,PD,0.5,0,0,4.3,4,10.25,13.38,1,Disease_progression,1,0,0,,,,,,,
HC014-1817051589897967,HC-ONC-014,hcc_met,Hepatocellular_carcinoma,Best_supportive_care,49,Female,2,26.2,8,IV,1,0.0,Synchronous,0,0,0,1,0,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,1,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,4.8,0,10.98,0,0,21,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,3,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,13.95,0,Censored,1,0,0,,,,,,,
HC014-8891441405555795,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,81,Male,1,26.6,3,IV,1,0.0,Synchronous,0,0,0,0,1,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,1,Spinal_cord_compression,0,0,0,0,0.0,Exon20ins,ALK-,Other_KRAS,HER2-,0,WT,MSS,23.4,0.0,2.8,0,12.08,0,0,50,None,1,1,12,2,0,0,0,0,0,0,1,Zoledronic_acid,0,0,0,9,0,0,0,Erlotinib,SD,23.49,0,0,12.59,Osimertinib,SD,6.01,0,1,13.24,NA,NA,0.0,0,0,0.0,2,0.0,28.36,1,Disease_progression,1,1,0,,,,,,,
HC014-9962819792105826,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,57,Female,1,29.2,5,III,0,34.7,Late_recurrence,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,9.2,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,2.7,0,12.01,0,1,84,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,5,0,0,0,FOLFOXIRI_Bev,PD,2.04,0,0,0.58,FOLFOX_Bev,PD,16.41,0,0,0.5,FOLFOX_Bev,PD,5.76,0,0,2.17,3,0.0,11.17,0,Censored,0,0,0,,,,,,,
HC014-8086020757525386,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,39,Female,1,27.2,2,III,0,10.6,Metachronous,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,41.9,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,6.8,0,10.75,0,1,40,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,2,0,0,0,FOLFIRI_Cetuximab,PR,15.18,0,0,4.23,FOLFOX_Cetuximab,SD,3.84,0,0,0.5,NA,NA,0.0,0,0,0.0,2,0.0,31.03,1,Disease_progression,1,1,0,,,,,,,
HC014-1071602340261741,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,78,Male,0,16.0,4,IV,1,0.0,Synchronous,0,0,0,0,1,0,0,1,1,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,1,9,0.0,Exon19del,ALK-,Other_KRAS,HER2-,0,WT,MSS,58.0,0.0,3.5,0,17.92,1,0,40,None,1,1,12,2,0,0,0,0,0,0,0,Zoledronic_acid,0,0,0,2,0,0,0,Dacomitinib,PD,13.68,0,0,3.07,Docetaxel_mono,SD,15.58,0,0,4.87,Osimertinib,SD,1.86,0,1,10.94,4,0.0,38.52,1,Intercurrent_illness,1,1,0,,,,,,,
HC014-1527044286206795,HC-ONC-014,renal_met,Clear_cell,Maintenance,66,Female,2,29.0,5,III,0,24.7,Late_recurrence,1,0,0,0,0,0,1,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,16.4,0.0,1.4,0,6.24,0,1,39,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,5,0,0,0,Nivo_Cabozantinib,PR,2.52,0,1,0.84,Nivolumab_mono,SD,5.84,1,0,3.7,NA,NA,0.0,0,0,0.0,2,8.83,6.32,1,Disease_progression,0,0,0,,,,,1.0,Poor,
HC014-7230979874643626,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,79,Female,1,29.6,7,III,0,42.9,Late_recurrence,1,0,0,1,1,0,0,1,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,1,10,0.0,Negative,ALK-,WT,HER2_0,0,VUS,MSS,0.0,6.6,7.6,0,8.66,0,1,39,None,1,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,1,9,0,0,0,Ribociclib_Letrozole,SD,21.11,0,1,14.2,Elacestrant,PD,19.15,0,0,1.01,NA,NA,0.0,0,0,0.0,2,0.0,156.68,1,Disease_progression,1,1,1,ER+PR-,,,,,,
HC014-4892840908911823,HC-ONC-014,nsclc_met,Large_cell,Palliative_systemic,64,Male,1,27.5,7,I,0,53.1,Late_recurrence,0,0,1,0,0,1,0,1,0,1,0,0,0,0,4,Polymetastatic,1,7,0,0,0,None,0,0,1,17,6.7,Negative,ALK-,G12C,HER2-,0,WT,MSS,75.5,0.0,5.4,0,10.09,1,0,71,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,5,0,1,0,Cemiplimab_mono,PD,3.79,1,0,3.47,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,14.27,1,Disease_progression,1,0,0,,,,,,,
HC014-6097597136065538,HC-ONC-014,ovarian_met,Mucinous,Palliative_systemic,56,Female,1,19.0,1,II,0,24.2,Late_recurrence,0,0,0,1,0,0,0,1,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,28,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.7,0,11.92,0,1,36,None,1,1,5,1,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,Carbo_PLD,CR,26.48,0,0,2.89,Niraparib,PD,8.51,0,1,1.57,Olaparib,PD,10.84,0,1,7.49,3,0.0,0.5,1,Disease_progression,0,0,0,,,HRD-,1257.1,,,
HC014-6592342697441920,HC-ONC-014,ovarian_met,Clear_cell,Palliative_systemic,58,Female,1,25.9,8,III,0,8.3,Metachronous,1,0,0,1,1,0,0,1,1,0,0,0,0,0,4,Polymetastatic,0,0,0,0,1,None,0,1,1,8,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,26.3,0,8.94,0,0,26,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,9,0,0,0,Carbo_PLD,PR,7.94,0,0,2.09,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,43.68,1,Intercurrent_illness,1,1,0,,,HRD-,976.8,,,
HC014-2299817578855183,HC-ONC-014,melanoma_met,Melanoma,Best_supportive_care,64,Female,3,31.4,2,II,0,37.6,Late_recurrence,1,1,1,1,0,1,0,0,0,1,0,0,0,0,4,Polymetastatic,1,5,0,0,0,None,0,0,0,0,13.8,Negative,ALK-,WT,HER2-,1,WT,MSS,64.2,0.0,17.8,0,8.84,0,0,11,None,1,0,0,0,0,1,0,0,0,0,0,None,1,0,1,3,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,2.61,1,Treatment_toxicity,0,0,0,,,,,,,0.0
HC014-8544594315940254,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,45,Female,2,26.1,2,III,0,37.8,Late_recurrence,0,0,1,0,1,0,0,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,Bone_pain,0,0,0,0,31.9,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,0.5,1.9,0,5.76,0,1,88,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,1,0,1,6,0,0,0,Abemaciclib_Letrozole,PD,8.65,0,1,1.32,Alpelisib_Fulvestrant,PD,9.12,0,0,0.5,Capivasertib_Fulvestrant,PD,9.56,0,0,0.85,6,0.0,73.94,1,Intercurrent_illness,1,1,1,ER+PR+,,,,,,
HC014-4805231328014662,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,61,Female,1,33.0,6,II,0,1.0,Metachronous,1,0,1,1,0,1,0,1,0,1,0,0,0,0,5,Polymetastatic,1,9,0,0,0,None,0,0,1,21,5.0,Negative,ALK-,WT,HER2_0,0,BRCA1,MSS,0.0,17.7,1.4,0,22.04,0,0,30,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,1,0,1,0,Palbociclib_Fulvestrant,PR,6.69,0,1,0.81,Fulvestrant_mono,PR,3.12,0,0,0.66,Alpelisib_Fulvestrant,PR,3.87,0,0,9.17,4,0.0,34.42,1,Disease_progression,1,1,0,ER+PR+,,,,,,
HC014-3684726306275954,HC-ONC-014,prostate_met,Adenocarcinoma,Best_supportive_care,53,Male,2,30.9,3,III,0,58.5,Late_recurrence,1,0,1,0,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,1,0,0,0,18.3,Negative,ALK-,WT,HER2-,0,BRCA2,MSS,0.0,0.0,4.7,0,14.32,0,0,67,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,1,0,1,7,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,46.16,0,Censored,1,1,0,,81.1,,,,,
HC014-1945291390456898,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,68,Male,2,34.0,3,IV,1,0.0,Synchronous,0,0,1,0,1,0,1,0,1,0,0,0,0,0,4,Polymetastatic,0,0,0,0,1,Spinal_cord_compression,0,0,0,0,7.7,Exon20ins,ALK-,Other_KRAS,HER2-,0,WT,MSS,15.5,0.0,13.3,0,8.06,1,1,48,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,0,9,0,0,0,Gefitinib,CR,15.02,0,0,3.29,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,9.1,0,Censored,0,0,0,,,,,,,
HC014-2633791416323355,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,68,Female,1,22.2,2,I,0,20.3,Metachronous,1,0,1,1,1,0,0,0,1,1,0,0,0,0,5,Polymetastatic,0,0,0,0,1,Hypercalcemia,0,0,0,0,11.1,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,1.2,3.4,0,4.78,0,0,38,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,1,8,0,0,0,Sacituzumab_Govitecan,PR,66.39,0,0,4.92,Pembrolizumab_mono,PD,3.18,1,0,0.5,Tucatinib_Tras_Cape,PR,2.12,0,0,0.95,3,6.73,45.11,1,Disease_progression,1,1,0,ER-PR-,,,,,,
HC014-7842977963261954,HC-ONC-014,nsclc_met,Large_cell,Palliative_systemic,72,Female,0,25.7,2,III,0,12.0,Metachronous,1,0,0,0,0,0,0,0,0,1,0,1,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Exon19del,ALK-,G12C,HER2-,0,WT,MSS,61.8,0.0,7.3,0,16.53,0,0,58,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,8,0,0,0,Dacomitinib,PD,51.73,0,0,3.76,Docetaxel_Nintedanib,SD,15.93,0,0,2.19,NA,NA,0.0,0,0,0.0,2,0.0,7.3,1,Unknown,0,0,0,,,,,,,
HC014-4183766128835466,HC-ONC-014,nsclc_met,Large_cell,Oligometa_curativeintent,60,Male,0,16.0,3,IV,1,0.0,Synchronous,0,0,1,0,1,0,0,0,0,0,0,0,0,1,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,5.0,Negative,ALK-,WT,HER2-,0,WT,MSS,32.1,0.0,14.0,0,28.07,1,1,29,None,1,1,5,1,0,0,0,0,0,0,0,Denosumab,0,0,0,3,0,0,0,Carbo_Paclitaxel_Pembro,CR,9.3,0,0,0.6,Pemetrexed,PD,7.95,0,0,1.24,Docetaxel_mono,PD,2.28,0,0,1.19,3,0.0,13.36,0,Censored,1,0,0,,,,,,,
HC014-2382756993935323,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,71,Male,2,32.2,2,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,1,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,18,23.8,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.9,0,5.71,1,1,48,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,0,10,0,0,0,Gemcitabine_mono,PR,11.99,0,0,1.75,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,5.0,1,Disease_progression,0,0,0,,,,,,,
HC014-6381309480577267,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,49,Male,2,21.9,4,III,0,5.1,Metachronous,1,0,0,0,1,0,1,0,1,0,0,0,0,1,4,Polymetastatic,0,0,0,0,1,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,73.1,0.0,8.3,0,9.88,0,0,64,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,1,0,1,3,0,0,0,Cemiplimab_mono,PD,5.02,1,0,0.5,Atezolizumab,PD,7.35,1,0,1.37,Docetaxel_Nintedanib,SD,3.19,0,0,1.28,3,0.0,33.0,0,Censored,1,1,0,,,,,,,
HC014-6016035932450143,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,63,Male,0,17.0,1,III,0,51.5,Late_recurrence,0,1,1,1,0,1,1,0,0,0,1,0,0,0,5,Polymetastatic,1,1,0,1,0,None,0,0,0,0,23.9,Negative,ALK-,WT,HER2-,1,WT,MSS,34.6,0.0,36.0,0,7.64,0,0,20,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,6,0,0,0,Encorafenib_Binimetinib,CR,5.61,0,0,5.15,Pembrolizumab_mono,PD,3.51,1,0,0.5,Dabrafenib,SD,2.37,0,1,0.5,3,5.12,122.75,1,Disease_progression,1,1,1,,,,,,,0.0
HC014-9965855634349909,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,55,Female,3,30.3,1,III,0,2.0,Metachronous,0,0,1,0,0,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,28.8,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,3.2,0,23.43,1,0,78,None,0,0,0,0,0,0,0,0,0,0,0,None,0,1,0,10,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,8.67,1,Disease_progression,0,0,0,,,,,,,
HC014-3239187213430024,HC-ONC-014,gastric_met,Adenocarcinoma,Palliative_systemic,73,Female,0,29.2,4,III,0,35.0,Late_recurrence,0,0,1,1,0,0,0,0,0,1,0,1,0,0,4,Polymetastatic,0,0,0,0,0,None,0,0,0,0,46.2,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.3,0,17.17,1,0,34,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,XELOX_Bev,PR,11.62,0,0,4.15,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,28.6,1,Disease_progression,1,1,0,,,,,,,
HC014-6496455164226528,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,60,Female,1,28.2,7,III,0,5.5,Metachronous,1,0,1,0,0,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,1,0,0,14.8,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,14.0,1.0,0,16.51,0,1,70,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,6,0,0,0,Abemaciclib_Fulvestrant,PR,45.9,0,1,2.85,Alpelisib_Fulvestrant,PD,5.39,0,0,0.5,Trastuzumab_Capecitabine,PD,8.12,0,1,0.98,6,5.52,40.81,0,Censored,1,1,0,ER+PR+,,,,,,
HC014-5828624713482891,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,59,Male,0,30.2,4,II,0,14.5,Metachronous,1,0,0,0,1,0,0,1,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,1,28,0.0,Negative,ALK-,WT,HER2-,0,BRCA2,MSS,0.0,0.0,7.4,0,7.33,0,1,82,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,1,6,0,0,0,Apalutamide_ADT,SD,19.16,0,0,11.87,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,54.67,1,Disease_progression,1,1,0,,2736.0,,,,,
HC014-4860108750711026,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,76,Male,2,23.3,0,III,0,8.4,Metachronous,1,0,0,1,1,0,0,1,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,1,18,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.4,1,3.7,0,1,44,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,1,0,1,7,0,0,0,Darolutamide_Docetaxel_ADT,SD,29.58,0,0,5.31,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,66.52,1,Unknown,1,1,1,,316.2,,,,,
HC014-1868504346224135,HC-ONC-014,melanoma_met,Melanoma,Oligometa_curativeintent,86,Male,1,30.7,2,III,0,1.4,Metachronous,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,62.6,0.0,21.9,0,36.8,0,0,89,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,Relatlimab_Nivolumab,PR,8.53,1,0,5.02,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.58,180.0,0,Censored,1,1,1,,,,,,,0.0
HC014-4424928313788388,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,49,Female,1,18.9,8,III,0,1.0,Metachronous,1,0,1,1,0,1,0,0,0,1,1,0,0,0,5,Polymetastatic,1,5,0,0,0,None,0,0,0,0,32.3,Negative,ALK-,WT,HER2-,0,WT,MSS,67.6,0.0,23.7,0,10.45,0,0,40,None,1,0,0,0,0,1,0,0,0,0,0,None,0,0,0,9,0,0,0,Nivolumab_Ipilimumab,PR,12.47,1,0,3.08,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,10.01,39.41,1,Disease_progression,1,1,0,,,,,,,0.0
HC014-3204633249739065,HC-ONC-014,renal_met,Chromophobe,Palliative_systemic,67,Female,1,30.3,5,II,0,16.3,Metachronous,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,Bone_pain,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,49.8,0.0,10.2,0,3.08,1,1,67,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,0,6,0,0,0,Sunitinib,SD,28.09,0,1,5.16,Lenvatinib_Everolimus,SD,8.07,0,1,2.02,Everolimus,PD,2.52,0,0,1.23,6,0.0,66.44,1,Disease_progression,1,1,1,,,,,1.0,Favorable,
HC014-7395070374091222,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,76,Male,0,29.7,4,III,0,8.3,Metachronous,0,1,1,1,0,0,0,1,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,10,15.8,Negative,ALK-,WT,HER2-,1,WT,MSS,0.0,0.0,10.1,0,12.9,0,1,83,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,8,0,0,0,FOLFOXIRI_Bev,PR,1.91,0,0,4.66,FOLFOX_Cetuximab,PR,9.76,0,0,2.2,FOLFOX_Cetuximab,SD,0.53,0,0,3.48,4,0.0,36.9,1,Unknown,1,1,0,,,,,,,
HC014-2649910390570156,HC-ONC-014,gastric_met,Adenocarcinoma,Palliative_systemic,71,Female,0,20.6,3,IV,1,0.0,Synchronous,0,0,0,0,0,0,1,1,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,5,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,4.0,0,22.31,0,1,51,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,7,1,0,0,XELOX_Bev,PD,3.1,0,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,44.12,1,Unknown,1,1,0,,,,,,,
HC014-5237800242451304,HC-ONC-014,nsclc_met,Squamous_cell,Palliative_systemic,86,Female,1,26.1,0,II,0,27.4,Late_recurrence,1,0,0,0,1,0,1,0,1,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,18.3,0.0,1.7,0,14.83,0,1,49,None,1,1,5,3,0,0,0,0,0,0,1,Denosumab,0,0,1,8,0,0,0,Nivo_Chemo,SD,17.56,0,0,5.9,Atezolizumab,CR,7.11,1,0,3.54,Docetaxel_Nintedanib,SD,3.24,0,0,1.07,3,6.11,47.14,1,Intercurrent_illness,1,1,0,,,,,,,
HC014-4146740171859165,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,42,Female,0,33.0,3,III,0,28.7,Late_recurrence,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,Oligometastatic,1,3,0,1,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,11.2,4.6,0,20.2,0,0,83,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,5,0,0,0,Abemaciclib_Fulvestrant,PD,10.7,0,1,2.36,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,93.93,1,Intercurrent_illness,1,1,1,ER+PR+,,,,,,
HC014-1941478075150114,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,60,Male,2,16.6,2,III,0,6.4,Metachronous,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,1,8,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,8.1,0,14.59,0,0,73,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,6,0,0,0,FOLFIRI_Bev,PR,27.49,0,0,2.0,FOLFOX_Cetuximab,SD,2.74,0,0,2.03,FOLFOX_Cetuximab,PD,2.74,0,0,3.06,3,0.0,9.42,1,Disease_progression,0,0,0,,,,,,,
HC014-6162337217070842,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,64,Female,1,25.7,3,I,0,19.1,Metachronous,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,5.0,Negative,ALK-,WT,HER2_2plus_FISH+,0,WT,MSS,0.0,9.4,3.4,0,21.11,0,0,54,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,Trastuzumab_Pertuzumab_Docetaxel,PD,13.29,0,1,7.43,Trastuzumab_deruxtecan,PD,2.9,0,1,1.53,NA,NA,0.0,0,0,0.0,2,0.0,114.91,0,Censored,1,1,1,ER+PR+,,,,,,
HC014-6629303666953808,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,34,Female,0,19.7,3,III,0,4.1,Metachronous,1,0,0,0,1,0,0,0,0,0,1,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,9.6,1.1,0,11.52,0,0,21,None,1,1,8,3,0,0,0,0,0,0,0,Zoledronic_acid,0,0,0,8,0,0,0,Ribociclib_Letrozole,SD,49.49,0,1,8.77,Fulvestrant_mono,PD,5.52,0,0,2.35,Lapatinib_Capecitabine,SD,2.08,0,0,4.33,4,0.0,29.11,1,Disease_progression,1,1,0,ER+PR+,,,,,,
HC014-1907407715084716,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,57,Female,1,33.4,4,III,0,20.7,Metachronous,1,0,1,1,1,1,0,0,0,0,0,0,0,0,4,Polymetastatic,1,3,0,1,1,Fracture,0,0,0,0,63.3,Negative,ALK-,WT,HER2_3plus,0,WT,MSS,0.0,0.7,3.5,0,1.96,0,0,59,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,0,1,3,0,0,0,Trastuzumab_Pertuzumab_Docetaxel,PR,14.28,0,1,10.29,Lapatinib_Capecitabine,PR,0.72,0,0,4.4,NA,NA,0.0,0,0,0.0,2,0.0,145.64,1,Intercurrent_illness,1,1,1,ER-PR-,,,,,,
HC014-1251410319950867,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,69,Male,1,30.5,3,III,0,76.1,Late_recurrence,1,0,0,0,0,0,1,0,1,0,0,1,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,29.5,0.0,8.3,0,25.6,0,1,44,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,Atezo_Carbo_Pem_Bev,PR,22.98,0,0,2.96,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,23.68,0,Censored,1,0,0,,,,,,,
HC014-7982886607382249,HC-ONC-014,crc_met,Adenocarcinoma,Maintenance,69,Male,1,28.9,3,IV,1,0.0,Synchronous,0,0,1,1,0,0,0,1,1,0,0,0,0,0,4,Polymetastatic,0,0,0,0,0,None,0,0,1,28,6.2,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,2.2,0,7.16,1,1,70,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,6,0,0,0,FOLFIRI_Bev,PD,5.48,0,0,0.51,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,8.13,1,Disease_progression,0,0,0,,,,,,,
HC014-4356629932986497,HC-ONC-014,crc_met,Adenocarcinoma,Maintenance,68,Female,2,23.0,2,IV,1,0.0,Synchronous,0,0,1,1,0,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,35.2,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.9,0,5.73,0,0,53,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,0,4,0,0,0,FOLFOX_Cetuximab,PD,23.28,0,0,7.83,FOLFOX_Cetuximab,PD,3.09,0,0,3.68,FOLFOX_Cetuximab,PD,0.55,0,0,0.97,3,0.0,45.91,1,Disease_progression,1,1,0,,,,,,,
HC014-3433857010028368,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,61,Female,2,21.3,4,II,0,6.3,Metachronous,0,0,1,0,0,0,0,1,1,0,0,0,1,0,4,Polymetastatic,0,0,0,0,0,None,0,1,1,30,5.0,Negative,ALK-,WT,HER2-,0,WT,MSS,28.6,0.0,20.0,0,10.35,0,1,63,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,0,7,0,0,0,Nivolumab_Ipilimumab,SD,17.79,1,0,1.21,Dabrafenib,PD,2.15,0,1,1.54,NA,NA,0.0,0,0,0.0,2,0.0,102.92,0,Censored,1,1,1,,,,,,,0.0
HC014-1617094178788838,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,66,Male,1,23.8,3,III,0,138.7,Late_recurrence,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,Bone_pain,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,BRCA1,MSS,0.0,0.0,8.6,0,8.4,0,0,45,None,1,0,0,0,0,0,1,0,0,0,0,Zoledronic_acid,0,0,1,7,0,0,0,Darolutamide_Docetaxel_ADT,PR,2.94,0,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,78.89,0,Censored,1,1,1,,532.3,,,,,
HC014-6328839803097533,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,48,Female,1,22.6,5,II,0,47.9,Late_recurrence,1,1,0,1,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,4.9,2.0,0,2.48,0,1,57,None,1,1,5,2,0,0,0,0,0,0,1,Zoledronic_acid,0,0,0,7,0,0,0,Abemaciclib_Fulvestrant,PR,2.94,0,1,1.4,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,100.42,1,Intercurrent_illness,1,1,1,ER+PR+,,,,,,
HC014-1621960220018870,HC-ONC-014,gastric_met,Adenocarcinoma,Oligometa_curativeintent,64,Male,1,20.2,7,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,12.9,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,4.4,0,8.48,0,1,37,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,8,0,0,0,Nivo_Chemo,PD,5.27,0,0,0.5,Trastuzumab_deruxtecan_HER2,PD,8.17,0,1,3.31,Paclitaxel_mono,CR,2.21,0,0,1.33,3,0.0,19.91,1,Disease_progression,1,0,0,,,,,,,
HC014-1516555530598884,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Best_supportive_care,50,Female,3,31.8,4,III,0,61.0,Late_recurrence,1,1,0,1,1,0,0,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,Hypercalcemia,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,18.3,11.3,0,28.6,1,1,19,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,1,0,10,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,68.8,1,Disease_progression,1,1,1,ER-PR-,,,,,,
HC014-3902866063844940,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,79,Female,0,26.1,7,I,0,24.1,Late_recurrence,1,0,1,0,1,1,0,0,1,1,0,0,0,0,5,Polymetastatic,1,6,0,0,1,None,0,0,0,0,23.2,Negative,ALK-,WT,HER2-,0,WT,MSS,11.0,0.0,3.9,0,36.59,0,0,88,None,1,0,0,0,0,1,0,0,0,0,0,Zoledronic_acid,0,0,0,6,0,1,0,Carbo_Paclitaxel_Pembro,PD,6.87,0,0,3.52,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,48.64,1,Disease_progression,1,1,0,,,,,,,
HC014-1052146178228138,HC-ONC-014,bladder_met,Urothelial_carcinoma,Palliative_systemic,74,Female,1,35.3,5,IV,1,0.0,Synchronous,0,0,0,0,0,0,1,0,0,0,1,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.3,0,17.48,0,0,56,None,1,0,0,0,0,0,1,0,0,0,0,None,0,0,0,7,0,0,0,GemCis,CR,9.97,0,0,3.15,Pembrolizumab_mono,PD,9.52,1,0,1.55,Vinflunine,PD,1.89,0,0,8.43,3,2.9,15.94,1,Disease_progression,1,0,0,,,,,,,
HC014-6055659149360618,HC-ONC-014,nsclc_met,Large_cell,Oligometa_curativeintent,73,Female,0,28.0,2,I,0,35.0,Late_recurrence,1,0,0,1,0,1,0,0,1,0,0,0,0,0,3,Oligometastatic,1,4,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,84.9,0.0,7.4,0,16.65,0,0,72,None,1,1,8,3,0,1,0,0,0,0,0,None,0,0,0,8,0,1,0,Cemiplimab_mono,PR,37.81,1,0,0.57,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,14.3,180.0,1,Disease_progression,1,1,1,,,,,,,
HC014-5493437462379217,HC-ONC-014,nsclc_met,Squamous_cell,Palliative_systemic,63,Female,1,20.4,4,III,0,10.3,Metachronous,0,1,0,0,1,0,0,0,1,0,0,1,0,0,3,Oligometastatic,0,0,0,0,1,Fracture,0,1,0,0,0.0,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,39.5,0.0,9.8,0,12.24,0,1,64,None,1,1,5,2,0,0,0,0,0,0,0,Denosumab,0,0,1,3,0,0,0,Nivo_Chemo,SD,1.99,0,0,6.73,Docetaxel_Ramucirumab,PD,1.43,0,0,0.5,NA,NA,0.0,0,0,0.0,2,0.0,20.67,0,Censored,1,0,0,,,,,,,
HC014-3992586947600718,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,50,Female,0,25.4,1,III,0,11.6,Metachronous,1,0,1,1,0,0,0,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,13.2,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,1.9,0,4.11,0,0,54,None,1,0,0,0,0,0,1,1,0,0,0,None,0,0,0,3,0,0,0,FOLFOX_Bev,PD,5.88,0,0,12.17,FOLFOX_Bev,SD,0.89,0,0,0.5,FOLFOX_Bev,PD,10.54,0,0,1.86,3,0.0,2.07,1,Disease_progression,0,0,0,,,,,,,
HC014-2101688020735404,HC-ONC-014,sarcoma_met,Synovial_sarcoma,Palliative_systemic,43,Male,1,23.4,5,III,0,27.5,Late_recurrence,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.1,0,10.25,1,1,55,None,1,1,3,3,0,0,0,0,0,0,0,None,0,0,0,5,0,0,0,Pazopanib,PR,21.11,0,1,0.54,Dacarbazine,PR,1.54,0,0,1.14,NA,NA,0.0,0,0,0.0,2,0.0,25.16,0,Censored,1,1,0,,,,,,,
HC014-4835247148662473,HC-ONC-014,renal_met,Sarcomatoid,Best_supportive_care,34,Male,4,24.5,6,III,0,25.8,Late_recurrence,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,40.7,0.0,3.3,0,19.64,0,1,15,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,0,9,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,10.8,0,Censored,0,0,0,,,,,1.0,Intermediate,
HC014-5237414641320872,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,58,Male,1,19.0,2,I,0,24.3,Late_recurrence,0,0,0,1,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.2,1,6.76,0,0,52,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,3,0,0,0,Docetaxel_ADT,PR,9.19,0,0,7.87,Rucaparib,PD,4.22,0,0,2.3,NA,NA,0.0,0,0,0.0,2,0.0,43.37,1,Disease_progression,1,1,0,,23.4,,,,,
HC014-5466208715026198,HC-ONC-014,ovarian_met,High_grade_serous,Best_supportive_care,47,Female,3,26.9,3,III,0,2.1,Metachronous,1,0,1,0,0,0,0,1,1,1,0,0,0,0,4,Polymetastatic,0,0,0,0,0,None,0,1,1,24,22.8,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,8.5,0,2.15,0,0,80,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,7,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,11.8,1,Intercurrent_illness,0,0,0,,,HRD+,126.6,,,
HC014-1938343644510934,HC-ONC-014,gastric_met,Adenocarcinoma,Best_supportive_care,43,Female,3,27.4,4,IV,1,0.0,Synchronous,0,0,1,0,0,0,1,1,0,1,0,0,0,0,4,Polymetastatic,0,0,0,0,0,None,0,0,1,6,42.8,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,25.5,0,11.64,1,0,29,None,0,0,0,0,0,0,0,0,0,0,0,None,1,1,1,10,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,1.81,1,Disease_progression,0,0,0,,,,,,,
HC014-8627528672285843,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,64,Female,0,33.6,4,II,0,87.5,Late_recurrence,0,0,1,0,0,0,0,1,0,0,1,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,30,50.7,Negative,ALK-,WT,HER2-,1,WT,MSS,2.6,0.0,31.2,0,13.47,0,0,52,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,0,0,0,0,Pembrolizumab_mono,PD,7.42,1,0,3.41,Dabrafenib,PR,10.92,0,1,3.41,Ipilimumab_mono,PR,2.13,1,0,4.3,3,5.8,180.0,1,Disease_progression,1,1,1,,,,,,,0.0
HC014-5526790466806164,HC-ONC-014,nsclc_met,Squamous_cell,Palliative_systemic,62,Male,1,28.8,4,II,0,1.0,Metachronous,1,0,1,0,0,0,1,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,15.3,Negative,ALK-,WT,HER2-,0,WT,MSS,42.5,0.0,4.1,0,7.44,0,0,22,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,1,0,0,0,Nivo_Chemo,PR,6.79,0,0,6.88,Docetaxel_Ramucirumab,PD,5.08,0,0,0.96,Osimertinib,PD,7.02,0,1,0.51,4,0.0,62.6,1,Disease_progression,1,1,1,,,,,,,
HC014-8155052690454534,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,64,Male,0,23.0,0,III,0,72.9,Late_recurrence,1,0,1,0,0,1,0,1,0,0,0,0,0,0,3,Oligometastatic,1,3,0,1,0,None,0,0,1,27,12.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,7.5,0,19.38,0,0,31,None,1,0,0,0,1,0,0,1,0,0,0,None,0,0,0,4,0,1,0,FOLFOX_Bev,SD,15.23,0,0,3.86,FOLFOX_Cetuximab,SD,1.48,0,0,0.56,NA,NA,0.0,0,0,0.0,2,0.0,57.63,0,Censored,1,1,0,,,,,,,
HC014-6480300450220707,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,56,Male,1,28.2,2,IV,1,0.0,Synchronous,0,0,1,1,0,1,0,1,1,0,0,0,0,0,5,Polymetastatic,1,3,0,1,0,None,0,1,1,28,34.2,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.9,0,25.46,0,1,63,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,6,0,0,0,FOLFIRINOX,SD,7.09,0,0,1.79,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,24.81,1,Disease_progression,1,1,0,,,,,,,
HC014-5698048268984039,HC-ONC-014,sclc_met,Small_cell_carcinoma,Maintenance,66,Male,2,32.3,8,IV,1,0.0,Synchronous,0,0,1,0,0,1,0,0,1,1,0,0,0,0,4,Polymetastatic,1,3,0,1,0,None,0,1,0,0,23.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.8,0,7.28,1,1,53,None,1,0,0,0,1,0,0,0,0,0,0,None,1,0,1,8,0,0,0,EP,SD,3.55,0,0,0.5,Lurbinectedin,PD,0.55,0,0,0.92,NA,NA,0.0,0,0,0.0,2,0.0,8.62,0,Censored,0,0,0,,,,,,,
HC014-9973520461574751,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,42,Female,2,32.1,3,II,0,39.2,Late_recurrence,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,Spinal_cord_compression,0,0,0,0,0.0,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,3.5,10.2,0,18.69,0,0,32,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,1,0,0,9,0,0,0,Sacituzumab_Govitecan,PD,41.83,0,0,2.65,Vinorelbine,PD,13.14,0,0,5.24,Everolimus_Exemestane,PD,4.27,0,0,1.55,3,0.0,6.52,1,Disease_progression,0,0,0,ER-PR-,,,,,,
HC014-4612556121557211,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,62,Male,1,28.8,8,III,0,3.0,Metachronous,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.4,0,13.89,0,0,58,None,1,1,5,2,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,3,0,0,0,Darolutamide_Docetaxel_ADT,PR,4.42,0,0,0.5,Olaparib,CR,19.15,0,1,0.8,Cabazitaxel,PD,5.22,0,0,1.19,4,0.0,34.97,1,Treatment_toxicity,1,1,0,,861.3,,,,,
HC014-3983684692081526,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,56,Male,0,18.9,2,I,0,53.9,Late_recurrence,0,0,1,0,0,0,0,1,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,26,16.6,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.4,0,11.56,1,0,28,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,FOLFOX_Cetuximab,SD,2.21,0,0,5.1,FOLFOX_Cetuximab,SD,17.27,0,0,1.07,FOLFOX_Cetuximab,PD,4.12,0,0,1.62,4,0.0,59.57,1,Unknown,1,1,0,,,,,,,
HC014-7339030412698225,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,43,Male,2,26.5,1,II,0,1.0,Metachronous,0,0,1,0,1,1,0,0,0,0,1,0,0,0,4,Polymetastatic,1,1,0,1,1,None,0,0,0,0,32.6,Negative,ALK-,WT,HER2-,0,WT,MSS,66.9,0.0,14.3,0,3.23,1,0,53,None,1,0,0,0,1,0,0,0,0,0,1,Denosumab,1,0,1,7,0,1,0,Relatlimab_Nivolumab,PD,11.72,1,0,0.8,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,69.93,1,Disease_progression,1,1,1,,,,,,,0.0
HC014-1120733648365457,HC-ONC-014,renal_met,Papillary,Best_supportive_care,51,Female,2,26.4,7,III,0,16.5,Metachronous,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,Hypercalcemia,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,11.9,0.0,4.3,0,7.22,1,0,65,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,1,0,0,2,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,79.86,1,Disease_progression,1,1,1,,,,,1.0,Intermediate,
HC014-9645136201463902,HC-ONC-014,prostate_met,Adenocarcinoma,Best_supportive_care,37,Male,2,25.7,7,I,0,65.0,Late_recurrence,1,0,1,1,1,1,0,0,1,0,0,1,0,0,6,Polymetastatic,1,5,0,0,1,Fracture,1,0,0,0,20.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.0,0,20.86,0,1,81,None,1,0,0,0,0,1,0,0,0,0,0,Denosumab,1,0,1,7,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,48.83,1,Disease_progression,1,1,0,,10.4,,,,,
HC014-2750694620689325,HC-ONC-014,ovarian_met,High_grade_serous,Palliative_systemic,75,Female,1,26.9,3,III,0,7.5,Metachronous,0,0,0,1,0,0,0,1,1,1,0,0,0,0,4,Polymetastatic,0,0,0,0,0,None,0,1,1,31,0.0,Negative,ALK-,WT,HER2-,0,BRCA1,MSS,0.0,0.0,4.4,0,10.09,0,0,12,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,4,1,0,0,Carbo_Pac_Bev,PR,17.72,0,0,0.51,Gemcitabine_Carbo,PD,17.68,0,0,0.5,NA,NA,0.0,0,0,0.0,2,0.0,31.83,1,Disease_progression,1,1,0,,,HRD-,493.2,,,
HC014-8292356247298946,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,54,Male,1,20.7,4,III,0,1.0,Metachronous,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,6.4,0,10.72,0,0,57,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,5,0,0,0,Docetaxel_ADT,PR,16.14,0,0,1.25,Cabazitaxel,PR,9.34,0,0,0.5,Enzalutamide,PD,1.69,0,1,0.61,5,14.7,96.28,1,Disease_progression,1,1,1,,98.1,,,,,
HC014-4734610323588024,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,34,Female,0,23.1,4,I,0,10.5,Metachronous,1,0,1,1,1,0,0,0,0,1,0,0,1,0,5,Polymetastatic,0,0,0,0,1,None,0,0,0,0,21.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,13.2,4.2,0,14.59,0,0,61,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,0,0,0,0,0,Abemaciclib_Letrozole,PD,20.26,0,1,5.32,Alpelisib_Fulvestrant,PD,23.11,0,0,3.16,NA,NA,0.0,0,0,0.0,2,0.0,31.16,0,Censored,1,1,0,ER+PR+,,,,,,
HC014-2306081187975742,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,61,Male,1,32.2,2,III,0,27.6,Late_recurrence,0,0,0,0,0,1,0,0,0,0,1,0,0,0,2,Oligometastatic,1,4,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,20.9,0.0,16.2,0,9.16,1,0,37,None,1,1,5,2,0,0,0,0,0,0,0,None,0,0,0,2,0,1,0,Nivolumab_Ipilimumab,PD,3.3,1,0,1.56,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,60.22,0,Censored,1,1,1,,,,,,,1.0
HC014-1979790295972211,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,53,Male,1,28.8,2,IV,1,0.0,Synchronous,0,0,1,0,0,1,0,0,0,1,1,0,0,0,4,Polymetastatic,1,1,0,1,0,None,0,0,0,0,9.2,Negative,ALK-,WT,HER2-,0,WT,MSS,7.6,0.0,50.0,0,10.79,0,0,67,None,1,0,0,0,1,0,0,0,0,0,0,None,0,0,0,8,0,0,0,Relatlimab_Nivolumab,SD,3.39,1,0,11.98,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,133.35,1,Disease_progression,1,1,1,,,,,,,1.0
HC014-2382915595383963,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,59,Male,1,21.6,2,II,0,75.5,Late_recurrence,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,8.6,0,28.89,0,0,31,None,1,0,0,0,0,0,1,0,0,0,0,None,0,0,0,3,0,0,0,CAPOX_Bev,SD,1.51,0,0,9.27,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,9.05,0,Censored,0,0,0,,,,,,,
HC014-4921666768166304,HC-ONC-014,melanoma_met,Melanoma,Best_supportive_care,90,Male,3,28.2,5,IV,1,0.0,Synchronous,0,0,0,1,0,1,0,0,0,1,1,0,0,0,4,Polymetastatic,1,3,0,1,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,1,WT,MSS,63.4,0.0,41.0,0,18.57,0,0,72,None,1,0,0,0,0,0,0,0,0,0,0,None,1,1,1,5,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,15.8,0,Censored,1,0,0,,,,,,,0.0
HC014-4424654712066415,HC-ONC-014,prostate_met,Adenocarcinoma,Best_supportive_care,77,Male,3,31.2,0,III,0,28.9,Late_recurrence,1,1,0,1,1,0,0,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,BRCA2,MSS,0.0,0.0,0.5,0,7.51,0,1,78,None,1,0,0,0,0,0,0,0,0,0,1,None,0,0,1,6,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,9.47,1,Disease_progression,0,0,0,,1260.9,,,,,
HC014-5271315535809971,HC-ONC-014,nsclc_met,Squamous_cell,Best_supportive_care,68,Male,4,19.8,2,III,0,4.8,Metachronous,1,0,0,0,1,1,0,0,1,0,0,0,0,0,3,Oligometastatic,1,6,0,0,1,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,1.1,0.0,4.6,0,2.77,1,0,40,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,0,0,5,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,4.13,1,Disease_progression,0,0,0,,,,,,,
HC014-2513367212872085,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,60,Male,1,20.7,1,III,0,4.0,Metachronous,1,1,0,1,1,0,1,1,0,1,0,1,0,0,6,Polymetastatic,0,0,0,0,1,Bone_pain,0,0,1,30,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.8,1,17.53,0,1,26,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,1,7,0,0,0,Darolutamide_Docetaxel_ADT,PR,0.5,0,0,6.52,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,49.11,1,Disease_progression,1,1,0,,23.2,,,,,
HC014-6102258224346038,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,80,Female,0,29.5,6,II,0,1.7,Metachronous,1,0,1,1,0,0,0,0,1,1,1,0,0,0,5,Polymetastatic,0,0,0,0,0,None,0,0,0,0,23.7,Negative,ALK-,WT,HER2_2plus_FISH+,0,BRCA1,MSS,0.0,4.6,8.0,0,47.99,0,0,14,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,2,0,0,0,THP_Pertuzumab_Tras_Taxane,SD,27.25,0,1,3.14,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,69.68,0,Censored,1,1,1,ER-PR-,,,,,,
HC014-3726957918358375,HC-ONC-014,ovarian_met,High_grade_serous,Palliative_systemic,45,Female,1,28.3,2,III,0,3.4,Metachronous,1,0,1,1,0,0,0,1,1,1,0,0,0,0,5,Polymetastatic,0,0,0,0,0,None,0,1,1,7,19.3,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.4,0,37.89,1,0,66,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,8,0,0,0,Carbo_Pac,PD,7.43,0,0,4.41,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,37.59,1,Disease_progression,1,1,0,,,HRD-,411.8,,,
HC014-2970989070412247,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,65,Male,1,23.1,4,II,0,29.3,Late_recurrence,1,0,1,0,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,23.7,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.4,0,10.13,0,0,58,None,1,1,5,1,0,0,0,1,0,0,1,Denosumab,0,0,1,1,0,0,0,Docetaxel_ADT,PR,10.04,0,0,7.74,Enzalutamide,PR,6.43,0,1,1.9,Pembrolizumab,SD,4.17,1,0,0.5,3,23.18,21.28,0,Censored,1,0,0,,13.8,,,,,
HC014-9807647187126796,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,72,Male,2,27.8,7,III,0,21.3,Metachronous,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,Fracture,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.2,0,17.28,1,0,66,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,0,8,0,0,0,Abiraterone_ADT,PR,13.54,0,1,0.56,Abiraterone_Pred,PR,5.73,0,1,7.29,Pembrolizumab,PR,3.78,1,0,4.45,4,1.01,9.8,0,Censored,0,0,0,,54.1,,,,,
HC014-9712966629207640,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,29,Male,0,26.7,5,I,0,32.8,Late_recurrence,1,0,0,0,1,0,1,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,VUS,MSS,0.0,0.0,4.6,1,4.17,0,1,12,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,0,8,0,0,0,Enzalutamide_ADT,PR,25.43,0,1,2.26,Rucaparib,SD,6.82,0,0,3.17,NA,NA,0.0,0,0,0.0,2,0.0,19.98,1,Intercurrent_illness,1,0,0,,48.8,,,,,
HC014-3204274911952904,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,87,Female,1,30.0,0,II,0,9.6,Metachronous,1,1,1,0,1,0,0,0,0,1,1,0,0,0,4,Polymetastatic,0,0,0,0,1,Fracture,0,0,0,0,17.0,Negative,ALK-,WT,HER2_3plus,0,VUS,MSS,0.0,1.0,3.3,0,0.42,1,1,10,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,8,0,0,0,Pyrotinib_Capecitabine,PD,7.25,0,0,0.92,Tucatinib_Tras_Cape,PD,10.39,0,0,0.62,Lapatinib_Capecitabine,PR,3.59,0,0,1.93,3,0.0,4.07,1,Unknown,0,0,0,ER+PR+,,,,,,
HC014-5378894139877330,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,60,Male,0,21.9,2,IV,1,0.0,Synchronous,0,0,1,1,0,0,0,0,0,0,0,0,1,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,5.1,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.5,0,33.96,0,0,27,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,6,1,0,0,Gemcitabine_mono,PR,2.48,0,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,14.3,1,Disease_progression,1,0,0,,,,,,,
HC014-6710883417676609,HC-ONC-014,pancreatic_met,Adenocarcinoma,Best_supportive_care,50,Male,3,17.1,3,III,0,52.4,Late_recurrence,0,1,0,0,0,0,1,1,0,0,0,1,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,17,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,9.5,0,10.83,0,0,40,None,0,0,0,0,0,0,0,0,0,0,0,None,0,1,0,6,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,2.27,0,Censored,0,0,0,,,,,,,
HC014-5358242003605742,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,43,Female,2,17.1,4,I,0,8.7,Metachronous,1,0,1,1,0,0,0,0,0,0,1,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,19.5,Negative,ALK-,WT,HER2-,0,WT,MSS,45.0,0.0,18.3,0,23.87,0,0,21,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,Nivolumab_Ipilimumab,PR,32.25,1,0,3.98,Pembrolizumab_mono,PD,9.15,1,0,2.02,Ipilimumab_mono,CR,1.81,1,0,0.75,5,4.59,106.33,0,Censored,1,1,1,,,,,,,0.0
HC014-4767166399964513,HC-ONC-014,ovarian_met,Mucinous,Oligometa_curativeintent,57,Female,0,25.9,6,III,0,24.3,Late_recurrence,0,1,0,0,0,0,0,1,1,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,1,1,13,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.5,0,2.41,0,0,22,None,1,1,3,3,0,0,0,0,0,0,0,None,0,0,0,0,1,0,0,Carbo_Pac_Bev,SD,28.79,0,0,2.97,Gemcitabine_Carbo,PR,5.33,0,0,7.17,Niraparib,PD,0.85,0,1,1.57,3,0.0,98.25,1,Unknown,1,1,1,,,HRD+,2998.0,,,
HC014-3217328283550956,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,48,Male,1,29.8,7,III,0,42.6,Late_recurrence,1,1,1,0,0,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,34.5,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,0.5,0,29.94,0,0,68,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,1,0,0,0,Docetaxel_ADT,PR,7.7,0,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,9.73,0,Censored,0,0,0,,50.2,,,,,
HC014-4743592785063934,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,66,Female,2,34.2,8,IV,1,0.0,Synchronous,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,56.9,0.0,20.7,0,15.32,1,0,26,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,0,2,0,0,0,Nivolumab_Ipilimumab,CR,21.33,1,0,1.3,Nivolumab_mono,PR,5.42,1,0,0.5,Vemurafenib,PD,2.96,0,0,0.5,3,10.29,32.19,1,Disease_progression,1,1,0,,,,,,,0.0
HC014-5611343166662979,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,47,Male,1,24.6,5,III,0,11.4,Metachronous,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,7.4,0,21.56,0,1,41,None,1,1,5,1,0,0,0,0,0,0,0,None,0,0,1,5,0,0,0,CAPOX_Bev,PR,13.27,0,0,1.41,FOLFOX_Bev,PD,6.03,0,0,1.9,FOLFOX_Bev,PR,11.4,0,0,1.18,5,0.0,15.34,1,Disease_progression,1,0,0,,,,,,,
HC014-9295322768264142,HC-ONC-014,nsclc_met,Squamous_cell,Best_supportive_care,77,Female,3,21.5,3,III,0,1.0,Metachronous,1,0,0,0,0,0,1,0,0,0,0,1,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,49.0,0.0,8.8,0,6.12,0,0,35,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,8,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,35.31,0,Censored,1,1,0,,,,,,,
HC014-7987635876988435,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,71,Male,2,39.3,0,II,0,36.0,Late_recurrence,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,1,WT,MSS,33.5,0.0,21.4,0,12.84,1,1,39,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,0,10,0,0,0,Vemurafenib_Cobimetinib,SD,0.79,0,0,2.65,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,102.77,0,Censored,1,1,1,,,,,,,0.0
HC014-4097676956404816,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,72,Female,1,20.0,3,IV,1,0.0,Synchronous,0,0,1,1,0,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,18.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,9.2,0,8.83,0,0,23,None,1,1,12,1,0,0,0,0,0,0,0,None,0,0,0,5,0,0,0,NALIRIFOX,PD,9.98,0,0,1.31,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,29.88,1,Disease_progression,1,1,0,,,,,,,
HC014-5028229789395922,HC-ONC-014,bladder_met,Urothelial_carcinoma,Palliative_systemic,56,Male,2,25.3,5,II,0,34.9,Late_recurrence,1,0,0,0,0,0,0,1,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,24,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.3,0,24.07,0,1,34,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,3,0,0,0,EV_Pembrolizumab,PR,4.89,1,0,6.12,Docetaxel,PD,4.1,0,0,0.95,Erdafitinib_FGFR,SD,0.82,0,0,8.49,4,1.0,15.43,1,Disease_progression,1,0,0,,,,,,,
HC014-6870895799524649,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,54,Female,1,27.8,6,III,0,73.6,Late_recurrence,0,0,1,0,1,0,0,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,23.7,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,21.5,0,38.05,0,1,48,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,0,9,0,0,0,CAPOX_Bev,PD,21.13,0,0,1.01,FOLFOX_Bev,PD,7.89,0,0,4.11,FOLFOX_Bev,PD,1.84,0,0,1.35,3,0.0,30.33,0,Censored,1,1,0,,,,,,,
HC014-7309545818677326,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,65,Female,1,28.5,5,I,0,15.9,Metachronous,0,0,1,0,0,1,0,0,0,0,0,0,0,0,2,Oligometastatic,1,2,0,1,0,None,0,0,0,0,43.5,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,0.6,2.5,0,37.13,0,0,66,None,1,1,12,2,0,0,0,1,0,0,0,None,0,0,0,4,0,1,0,Palbociclib_Fulvestrant,PR,15.95,0,1,2.03,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,109.2,0,Censored,1,1,1,ER+PR+,,,,,,
HC014-6150221082470874,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,74,Female,1,28.1,4,IV,1,0.0,Synchronous,0,0,1,1,0,0,1,0,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,26.6,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,9.9,0,11.98,0,0,70,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,6,1,0,0,Gemcitabine_Abraxane,PR,1.39,0,0,6.36,Olaparib_BRCA,SD,8.73,0,1,0.55,NA,NA,0.0,0,0,0.0,2,0.0,23.26,1,Disease_progression,1,0,0,,,,,,,
HC014-4454733919074166,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,71,Male,0,31.2,2,III,0,56.5,Late_recurrence,1,0,1,0,1,0,1,0,1,0,0,1,0,0,5,Polymetastatic,0,0,0,0,1,None,0,0,0,0,15.8,Negative,ALK-,G12C,HER2-,0,WT,MSS,0.3,0.0,2.8,0,10.58,1,0,42,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,7,0,0,0,Nivo_Chemo,PD,8.66,0,0,3.26,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,14.44,1,Disease_progression,1,0,0,,,,,,,
HC014-3938864157356674,HC-ONC-014,nsclc_met,Adenocarcinoma,Oligometa_curativeintent,52,Male,1,30.2,3,I,0,49.8,Late_recurrence,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Exon19del,ALK-,WT,HER2-,0,WT,MSS,24.4,0.0,12.7,0,22.96,0,0,60,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,8,0,0,0,Dacomitinib,SD,16.47,0,0,1.95,Docetaxel_Nintedanib,CR,5.82,0,0,6.89,NA,NA,0.0,0,0,0.0,2,0.0,20.31,1,Disease_progression,1,0,0,,,,,,,
HC014-8489742264904495,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,55,Female,1,30.2,6,III,0,2.6,Metachronous,0,0,0,0,0,0,0,0,1,1,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,1,0,0,0.0,Exon20ins,ALK-,Other_KRAS,HER2-,0,WT,MSS,30.5,0.0,12.0,0,18.21,0,0,53,None,1,1,3,3,0,0,0,0,0,0,0,None,0,0,0,6,0,0,0,Afatinib,PR,42.81,0,0,3.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,27.54,0,Censored,1,1,0,,,,,,,
HC014-5922110215421915,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,52,Male,1,25.9,10,III,0,16.4,Metachronous,0,0,0,0,1,0,0,0,0,1,0,0,0,1,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.4,1,22.65,0,0,89,None,1,1,12,2,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,2,0,0,0,Darolutamide_Docetaxel_ADT,PD,7.95,0,0,4.03,Lu177-PSMA,PR,16.98,0,0,4.5,Cabazitaxel,PD,3.2,0,0,0.5,6,17.23,78.42,1,Intercurrent_illness,1,1,1,,11.4,,,,,
HC014-5701638888406608,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,57,Male,2,26.1,3,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,31.2,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,13.5,0,24.57,0,0,17,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,3,0,0,0,Gemcitabine_mono,PR,21.79,0,0,10.02,Gemcitabine_Cisplatin,PD,2.17,0,0,7.81,NA,NA,0.0,0,0,0.0,2,0.0,7.65,1,Disease_progression,0,0,0,,,,,,,
HC014-6400638578381786,HC-ONC-014,prostate_met,Adenocarcinoma,Best_supportive_care,59,Male,2,21.3,3,III,0,14.2,Metachronous,1,0,0,0,1,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.8,0,9.96,0,0,41,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,1,0,0,5,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,30.66,1,Disease_progression,1,1,0,,73.9,,,,,
HC014-1187319976395154,HC-ONC-014,nsclc_met,Squamous_cell,Oligometa_curativeintent,71,Female,1,28.2,1,IV,1,0.0,Synchronous,0,0,0,0,0,0,0,0,1,1,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,40.6,0.0,2.9,0,5.15,0,0,57,None,1,0,0,0,0,0,1,0,0,0,0,None,0,0,0,1,0,0,0,Atezo_Carbo_Pem_Bev,PR,36.49,0,0,1.44,Atezolizumab,SD,11.56,1,0,0.5,Docetaxel_Nintedanib,PD,0.5,0,0,0.5,3,20.25,16.39,0,Censored,1,0,0,,,,,,,
HC014-2449471684798875,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,60,Female,1,30.6,2,II,0,15.2,Metachronous,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,1,18,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,15.5,0,2.58,0,0,86,None,1,1,12,2,0,0,0,0,0,0,0,None,0,0,0,2,0,0,0,FOLFOX_Bev,SD,11.49,0,0,7.24,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,9.12,1,Disease_progression,0,0,0,,,,,,,
HC014-4015142965955834,HC-ONC-014,renal_met,Clear_cell,Maintenance,51,Male,0,29.8,3,III,0,13.0,Metachronous,1,0,0,1,1,0,1,1,0,0,0,0,0,0,4,Polymetastatic,0,0,0,0,1,Spinal_cord_compression,0,0,1,26,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,13.9,0.0,4.6,0,11.0,0,0,71,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,0,6,0,0,0,Avelumab_Axitinib,SD,20.74,1,0,6.19,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,21.48,1,Unknown,1,0,0,,,,,0.0,Favorable,
HC014-2744429066114861,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,66,Female,1,24.9,7,II,0,3.5,Metachronous,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_2plus_FISH+,0,WT,MSS,0.0,2.6,3.0,0,17.13,1,0,35,None,1,0,0,0,0,0,1,0,0,0,0,None,0,0,0,9,0,0,0,THP_Pertuzumab_Tras_Taxane,PD,51.0,0,1,0.6,Tucatinib_Tras_Cape,PR,13.53,0,0,0.82,Capecitabine,PD,0.5,0,0,5.43,3,0.0,126.38,0,Censored,1,1,1,ER+PR+,,,,,,
HC014-6782762170312517,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,64,Female,1,34.4,7,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,1,0,0,0,0,1,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,9,18.1,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,6.5,0,23.36,1,1,27,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,FOLFOX_Bev,SD,9.93,0,0,2.65,FOLFOX_Cetuximab,PD,10.88,0,0,0.5,NA,NA,0.0,0,0,0.0,2,0.0,36.58,1,Treatment_toxicity,1,1,0,,,,,,,
HC014-5321596293970400,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,66,Female,2,23.0,1,IV,1,0.0,Synchronous,0,0,1,0,1,1,1,0,1,0,0,0,0,0,5,Polymetastatic,1,3,0,1,1,None,0,1,0,0,5.0,Exon19del,ALK-,WT,HER2-,0,WT,MSS,67.7,0.0,28.2,0,25.2,1,0,44,None,1,0,0,0,1,0,0,0,0,0,0,Zoledronic_acid,0,0,1,6,0,1,0,Erlotinib,PR,47.73,0,0,3.66,Osimertinib,PD,0.83,0,1,1.84,Docetaxel_Nintedanib,PD,0.86,0,0,3.45,4,0.0,24.91,1,Disease_progression,1,1,0,,,,,,,
HC014-8389615182863172,HC-ONC-014,bladder_met,Urothelial_carcinoma,Palliative_systemic,67,Female,1,25.0,9,III,0,3.1,Metachronous,1,0,0,1,0,0,1,0,0,0,0,1,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,4.3,0,36.0,0,0,69,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,5,0,0,0,GemCis,PR,1.67,0,0,2.02,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,1.9,1,Treatment_toxicity,0,0,0,,,,,,,
HC014-9201424630240753,HC-ONC-014,nsclc_met,Squamous_cell,Maintenance,61,Female,0,28.6,5,II,0,25.3,Late_recurrence,0,0,1,1,1,1,0,1,0,1,0,0,0,0,6,Polymetastatic,1,5,1,0,1,None,0,0,1,12,11.2,Negative,ALK-,G12C,HER2-,0,WT,MSS,20.1,0.0,17.4,0,10.09,0,1,88,None,1,0,0,0,0,0,0,0,0,0,1,None,0,0,1,5,0,1,0,Pembro_Carbo_Pem,PR,8.74,0,0,1.77,Docetaxel_mono,SD,16.34,0,0,6.23,NA,NA,0.0,0,0,0.0,2,0.0,17.9,1,Intercurrent_illness,1,0,0,,,,,,,
HC014-5724093649405052,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,52,Female,0,23.7,6,II,0,10.6,Metachronous,0,0,0,0,1,0,0,0,0,1,1,0,0,0,3,Oligometastatic,0,0,0,0,1,Spinal_cord_compression,0,0,0,0,0.0,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,4.9,17.5,0,13.29,0,0,76,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,1,1,0,0,0,Palbociclib_Fulvestrant,PD,84.3,0,1,0.5,Fulvestrant_mono,SD,17.4,0,0,1.28,Pembrolizumab_mono,PD,3.54,1,0,3.92,4,0.0,80.77,1,Disease_progression,1,1,1,ER+PR+,,,,,,
HC014-3973190629185646,HC-ONC-014,nsclc_met,Large_cell,Oligometa_curativeintent,42,Male,0,28.7,0,III,0,12.1,Metachronous,0,0,0,0,1,0,1,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,28.0,0.0,6.2,0,3.55,0,1,65,None,1,1,5,2,0,0,0,0,0,0,0,Denosumab,0,0,0,4,0,0,0,Carbo_Paclitaxel_Pembro,SD,38.6,0,0,5.63,Atezolizumab,PD,3.76,1,0,0.54,NA,NA,0.0,0,0,0.0,2,0.0,19.54,0,Censored,1,0,0,,,,,,,
HC014-1359433545624108,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Best_supportive_care,57,Female,0,25.5,5,III,0,109.0,Late_recurrence,1,0,1,0,0,0,0,0,0,1,1,0,1,0,4,Polymetastatic,0,0,0,0,0,None,0,0,0,0,9.9,Negative,ALK-,WT,HER2_3plus,0,WT,MSS,0.0,1.3,13.4,0,2.24,1,0,31,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,2,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,46.32,1,Disease_progression,1,1,0,ER+PR+,,,,,,
HC014-2194092542908780,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,59,Female,0,30.1,3,II,0,28.1,Late_recurrence,1,0,1,0,0,0,0,1,0,0,0,0,1,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,5,19.1,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,18.7,2.5,0,13.08,0,0,34,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,Ribociclib_Letrozole,SD,1.62,0,1,3.81,Everolimus_Exemestane,PD,5.26,0,0,2.86,NA,NA,0.0,0,0,0.0,2,0.0,39.23,0,Censored,1,1,0,ER+PR+,,,,,,
HC014-7584739046403912,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,53,Male,2,23.9,5,III,0,6.7,Metachronous,1,0,0,0,0,0,0,0,0,1,0,1,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,G12C,HER2-,0,WT,MSI-H,68.2,0.0,7.9,0,4.06,0,0,27,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,Pembrolizumab_mono,CR,35.17,1,0,0.72,Docetaxel_mono,PD,1.24,0,0,0.64,NA,NA,0.0,0,0,0.0,2,6.87,13.55,1,Disease_progression,1,0,0,,,,,,,
HC014-1111925402904065,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,61,Female,1,21.0,2,II,0,30.6,Late_recurrence,1,0,1,1,1,0,0,0,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,5.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,10.4,7.1,0,16.08,0,0,84,None,1,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,1,8,0,0,0,Palbociclib_Fulvestrant,SD,23.44,0,1,0.84,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,59.98,0,Censored,1,1,0,ER+PR+,,,,,,
HC014-7133760582180601,HC-ONC-014,melanoma_met,Melanoma,Best_supportive_care,52,Male,2,26.4,2,II,0,13.1,Metachronous,1,0,0,0,0,1,1,0,0,0,1,0,0,0,3,Oligometastatic,1,4,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,1,WT,MSS,5.4,0.0,12.6,0,2.72,0,1,17,None,1,0,0,0,0,1,0,0,0,0,0,None,1,0,1,8,0,1,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,35.26,0,Censored,1,1,0,,,,,,,1.0
HC014-8529945026210028,HC-ONC-014,nsclc_met,NOS,Palliative_systemic,56,Male,1,19.7,4,IV,1,0.0,Synchronous,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,13.0,0.0,4.5,0,18.11,0,0,14,None,1,1,8,3,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,Nivo_Chemo,PR,10.62,0,0,3.7,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,9.03,1,Disease_progression,0,0,0,,,,,,,
HC014-7035711046071378,HC-ONC-014,gastric_met,Adenocarcinoma,Best_supportive_care,56,Female,3,26.5,2,IV,1,0.0,Synchronous,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,8.1,0,2.01,1,1,47,None,0,0,0,0,0,0,0,0,0,0,0,None,0,1,0,5,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,6.09,1,Disease_progression,0,0,0,,,,,,,
HC014-4962115288288402,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,42,Male,1,24.9,6,III,0,22.7,Metachronous,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,35.4,Negative,ALK-,Other_KRAS,HER2-,1,WT,MSS,0.0,0.0,1.8,0,17.76,1,0,63,None,1,1,5,2,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,FOLFOX_Bev,SD,13.28,0,0,1.11,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,28.4,1,Disease_progression,1,1,0,,,,,,,
HC014-1879571651428938,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,64,Female,2,28.5,4,III,0,10.8,Metachronous,1,0,1,0,1,0,0,0,0,1,0,1,1,1,6,Polymetastatic,0,0,0,0,1,None,0,0,0,0,33.8,Negative,ALK-,WT,HER2_2plus_FISH+,0,WT,MSS,0.0,22.9,7.5,0,12.8,0,0,74,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,1,0,1,8,0,0,0,Pyrotinib_Capecitabine,PD,60.34,0,0,0.5,Lapatinib_Capecitabine,PD,7.63,0,0,0.5,NA,NA,0.0,0,0,0.0,2,0.0,38.55,1,Treatment_toxicity,1,1,0,ER+PR+,,,,,,
HC014-5020790474195102,HC-ONC-014,gastric_met,Adenocarcinoma,Palliative_systemic,87,Female,0,27.6,1,IV,1,0.0,Synchronous,0,0,0,0,0,0,0,1,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,23,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.6,0,7.09,0,1,58,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,3,0,0,0,Nivo_Chemo,PR,19.89,0,0,2.59,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,12.87,0,Censored,1,0,0,,,,,,,
HC014-9874345990509004,HC-ONC-014,nsclc_met,Adenocarcinoma,Oligometa_curativeintent,61,Female,1,30.4,3,III,0,2.5,Metachronous,1,0,0,0,1,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Exon19del,ALK-,WT,HER2-,0,WT,MSS,33.3,0.0,4.5,0,24.57,0,1,53,None,1,1,3,3,0,0,0,0,0,0,1,Zoledronic_acid,0,0,0,8,0,0,0,Gefitinib,CR,18.41,0,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,48.13,1,Disease_progression,1,1,0,,,,,,,
HC014-2512761858864744,HC-ONC-014,nsclc_met,NOS,Oligometa_curativeintent,78,Male,0,37.6,5,IV,1,0.0,Synchronous,0,0,0,0,1,1,0,0,0,0,0,0,0,0,2,Oligometastatic,1,1,0,1,1,None,0,0,0,0,0.0,T790M,ALK-,WT,HER2-,0,WT,MSS,62.5,0.0,7.7,0,32.07,0,0,66,None,1,1,5,2,1,0,0,0,0,0,1,Zoledronic_acid,0,0,1,0,0,0,0,Erlotinib,PD,25.45,0,0,0.5,Pemetrexed,SD,0.68,0,0,0.84,Docetaxel_Ramucirumab,PD,3.26,0,0,7.62,4,0.0,2.38,1,Disease_progression,0,0,0,,,,,,,
HC014-3341397799269681,HC-ONC-014,nsclc_met,Adenocarcinoma,Oligometa_curativeintent,67,Female,0,32.0,5,III,0,16.3,Metachronous,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,63.8,0.0,12.5,0,15.23,1,0,27,None,1,1,5,2,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,Cemiplimab_mono,SD,31.94,1,0,15.67,Atezolizumab,PD,3.67,1,0,1.8,Osimertinib,SD,6.95,0,1,3.23,4,0.0,69.93,1,Disease_progression,1,1,1,,,,,,,
HC014-8886356357360109,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,61,Female,1,28.5,3,III,0,1.9,Metachronous,0,0,1,0,0,1,0,0,0,0,0,0,0,0,2,Oligometastatic,1,1,0,1,0,None,0,0,0,0,18.3,Negative,ALK-,WT,HER2_3plus,0,WT,MSS,0.0,2.9,4.6,0,13.22,0,0,14,None,1,1,12,1,1,0,0,0,0,0,0,None,0,0,0,9,0,0,0,Pyrotinib_Capecitabine,PD,32.17,0,0,9.66,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,65.01,1,Disease_progression,1,1,1,ER+PR+,,,,,,
HC014-9456777706076203,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,79,Female,1,39.5,7,III,0,23.0,Metachronous,1,0,1,0,0,0,0,1,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,22,21.2,Negative,ALK-,WT,HER2_1plus,0,VUS,MSS,0.0,16.8,3.1,0,16.98,0,1,18,None,1,1,5,3,0,0,0,0,0,0,0,None,0,0,0,6,0,0,0,Palbociclib_Letrozole,PR,16.37,0,1,5.23,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,41.9,1,Intercurrent_illness,1,1,0,ER+PR+,,,,,,
HC014-3338809471548192,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,52,Female,0,33.9,1,IV,1,0.0,Synchronous,0,0,1,0,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,Hypercalcemia,0,0,0,0,41.5,Negative,ALK-,WT,HER2-,0,WT,MSS,17.4,0.0,11.3,0,14.72,0,0,11,None,1,1,3,1,0,0,0,1,0,0,1,Denosumab,0,0,1,6,0,0,0,Nivo_Ipi,SD,23.92,0,0,5.1,Atezolizumab,CR,18.22,1,0,2.7,NA,NA,0.0,0,0,0.0,2,9.13,89.35,1,Disease_progression,1,1,1,,,,,,,
HC014-9746167882739623,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,67,Male,0,31.9,2,I,0,37.9,Late_recurrence,0,1,1,0,1,0,0,0,0,0,0,0,0,1,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,20.8,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.0,0,8.42,1,0,70,None,1,1,5,1,0,0,0,0,0,0,0,None,0,0,1,7,0,0,0,Enzalutamide_ADT,PR,3.72,0,1,0.71,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,76.67,0,Censored,1,1,1,,231.4,,,,,
HC014-5602336990981343,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,69,Female,0,31.8,2,IV,1,0.0,Synchronous,0,0,0,0,0,1,1,0,1,0,0,0,1,0,4,Polymetastatic,1,1,0,1,0,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,73.5,0.0,12.7,0,26.33,0,0,57,None,1,0,0,0,1,0,0,0,0,0,0,None,0,0,0,5,0,1,0,Cemiplimab_mono,SD,17.94,1,0,0.8,Pemetrexed,PD,9.6,0,0,2.93,Docetaxel_mono,PD,2.61,0,0,0.66,3,0.0,47.59,1,Treatment_toxicity,1,1,0,,,,,,,
HC014-4153244915064376,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,45,Female,1,30.5,1,III,0,18.9,Metachronous,1,0,1,0,0,0,0,1,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,30,24.6,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.4,0,40.46,0,0,42,None,1,1,5,1,0,0,0,0,0,0,0,None,0,0,0,7,1,0,0,Gemcitabine_mono,SD,8.97,0,0,1.3,Capecitabine,SD,6.67,0,0,0.72,Gemcitabine_Cisplatin,PD,3.58,0,0,4.06,4,0.0,9.91,1,Disease_progression,0,0,0,,,,,,,
HC014-1718737208886931,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,41,Male,2,28.5,3,III,0,5.3,Metachronous,1,0,1,0,0,0,1,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,21.8,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.9,0,9.79,0,0,15,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,9,0,0,0,FOLFOX_Bev,PD,7.1,0,0,5.97,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,13.11,0,Censored,1,0,0,,,,,,,
HC014-9942919231442355,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,48,Male,2,31.9,6,IV,1,0.0,Synchronous,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,7.2,0,16.63,0,1,42,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,1,0,1,2,0,0,0,NALIRIFOX,PR,7.25,0,0,2.12,Gemcitabine_Cisplatin,PD,0.89,0,0,3.47,FOLFOX,PD,2.92,0,0,1.95,6,0.0,4.93,1,Disease_progression,0,0,0,,,,,,,
HC014-9355131154087497,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,58,Male,2,31.5,3,II,0,15.7,Metachronous,1,0,0,1,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.9,0,5.83,0,0,78,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,1,5,0,0,0,Abiraterone_ADT,CR,1.54,0,1,0.5,Docetaxel,PD,17.8,0,0,0.5,Enzalutamide,PD,2.15,0,1,1.13,3,0.0,49.44,0,Censored,1,1,0,,60.9,,,,,
HC014-5681794324595539,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,31,Female,1,23.4,3,III,0,22.7,Metachronous,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,14.5,Negative,ALK-,Other_KRAS,HER2-,1,WT,MSS,0.0,0.0,13.0,0,34.3,1,0,68,None,0,0,0,0,0,0,0,1,0,0,0,None,0,0,0,2,0,0,0,FOLFOX_Bev,PD,41.31,0,0,0.5,FOLFOX_Bev,PD,0.5,0,0,0.68,FOLFOX_Bev,PD,9.72,0,0,0.5,3,0.0,21.88,0,Censored,1,0,0,,,,,,,
HC014-2402171434660990,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,66,Male,1,28.6,3,I,0,28.9,Late_recurrence,1,1,1,0,0,0,0,0,0,0,0,1,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,13.6,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,6.4,0,8.97,0,1,29,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,5,0,0,0,Abiraterone_ADT,PR,73.6,0,1,1.22,Olaparib,PR,9.31,0,1,1.54,Rucaparib,PD,0.86,0,0,0.5,3,0.0,41.07,1,Disease_progression,1,1,0,,4.0,,,,,
HC014-5526580278329555,HC-ONC-014,pancreatic_met,Adenocarcinoma,Oligometa_curativeintent,53,Female,1,23.4,6,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,6.5,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.4,0,42.08,1,1,37,None,0,0,0,0,0,0,0,1,0,0,0,None,0,0,0,2,0,0,0,FOLFIRINOX,SD,5.4,0,0,0.95,Capecitabine,SD,8.51,0,0,2.05,NA,NA,0.0,0,0,0.0,2,0.0,0.5,1,Disease_progression,0,0,0,,,,,,,
HC014-3267419772302564,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,60,Female,2,25.0,2,III,0,13.4,Metachronous,1,0,1,0,0,1,0,0,1,0,0,0,0,1,4,Polymetastatic,1,5,0,0,0,None,0,1,0,0,13.5,Negative,ALK-,WT,HER2-,1,WT,MSS,14.8,0.0,29.7,0,16.3,0,0,63,None,1,0,0,0,0,1,0,0,0,0,0,None,1,0,1,8,0,1,0,Encorafenib_Binimetinib,PR,7.8,0,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,81.99,1,Disease_progression,1,1,1,,,,,,,1.0
HC014-7756517668673648,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,75,Female,0,18.4,3,I,0,7.0,Metachronous,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,1.4,4.0,0,26.65,0,0,51,None,1,1,12,2,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,Abemaciclib_Fulvestrant,PR,16.21,0,1,4.14,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,18.85,0,Censored,1,0,0,ER+PR+,,,,,,
HC014-6792601966372630,HC-ONC-014,renal_met,Clear_cell,Palliative_systemic,43,Female,2,23.5,3,IV,1,0.0,Synchronous,0,0,1,1,1,0,0,0,1,0,0,0,0,0,4,Polymetastatic,0,0,0,0,1,Fracture,0,1,0,0,33.9,Negative,ALK-,WT,HER2-,0,WT,MSS,49.9,0.0,7.6,0,32.53,1,0,63,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,1,0,0,2,0,0,0,Pembro_Axitinib,SD,9.32,0,0,0.74,Everolimus,SD,15.39,0,0,3.68,Lenvatinib_Everolimus,PD,4.96,0,1,0.68,5,0.0,11.88,1,Disease_progression,0,0,0,,,,,0.0,Favorable,
HC014-1085924593306488,HC-ONC-014,prostate_met,Adenocarcinoma,Best_supportive_care,55,Male,1,35.0,3,III,0,7.5,Metachronous,1,1,0,0,1,0,0,1,1,1,0,1,0,0,5,Polymetastatic,0,0,0,0,1,Fracture,0,0,1,26,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.7,0,19.32,0,1,62,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,1,7,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,32.32,1,Disease_progression,1,1,0,,27.8,,,,,
HC014-6470823758517329,HC-ONC-014,nsclc_met,Squamous_cell,Oligometa_curativeintent,88,Male,1,28.2,4,IV,1,0.0,Synchronous,0,0,0,0,0,0,0,1,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,12,0.0,Negative,ALK-,G12C,HER2-,0,WT,MSS,82.2,0.0,6.4,0,6.59,0,0,20,None,1,1,8,3,0,0,0,0,0,0,0,None,0,0,0,8,0,0,0,Pembrolizumab_mono,SD,39.89,1,0,11.19,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,22.4,1,Unknown,1,0,0,,,,,,,
HC014-5848874270326223,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,63,Male,2,19.2,5,IV,1,0.0,Synchronous,0,0,1,1,0,0,0,0,1,0,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,1,0,0,21.7,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,13.5,0,31.45,0,0,42,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,10,0,0,0,FOLFIRI_Cetuximab,PR,47.57,0,0,0.5,FOLFOX_Cetuximab,PR,2.99,0,0,0.5,FOLFOX_Cetuximab,PD,8.02,0,0,2.77,5,0.0,16.43,0,Censored,1,0,0,,,,,,,
HC014-8069958615575109,HC-ONC-014,renal_met,Clear_cell,Best_supportive_care,42,Female,3,27.2,2,I,0,12.9,Metachronous,1,0,0,1,1,0,0,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,Spinal_cord_compression,1,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,24.1,0.0,9.1,0,17.76,0,0,13,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,1,1,0,4,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,16.03,1,Intercurrent_illness,1,0,0,,,,,1.0,Intermediate,
HC014-6144797090837363,HC-ONC-014,prostate_met,Adenocarcinoma,Maintenance,61,Male,2,24.3,7,III,0,28.7,Late_recurrence,1,0,0,0,1,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,VUS,MSS,0.0,0.0,11.3,0,13.99,0,0,27,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,0,4,0,0,0,Darolutamide_Docetaxel_ADT,SD,11.63,0,0,0.5,Abiraterone_Pred,PR,20.01,0,1,8.05,NA,NA,0.0,0,0,0.0,2,0.0,44.99,1,Disease_progression,1,1,0,,122.0,,,,,
HC014-6919958677870970,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,74,Male,0,26.7,0,III,0,1.8,Metachronous,0,1,0,1,1,0,0,1,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,1,19,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.0,1,14.64,1,1,73,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,4,0,0,0,Apalutamide_ADT,SD,18.04,0,0,1.27,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,68.02,1,Disease_progression,1,1,1,,18.4,,,,,
HC014-2240826546168464,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,60,Male,1,26.4,4,III,0,11.7,Metachronous,1,1,0,0,1,1,0,1,0,0,0,0,0,0,3,Oligometastatic,1,4,0,0,1,Fracture,0,0,1,18,0.0,Negative,ALK-,WT,HER2-,0,BRCA2,MSS,0.0,0.0,4.6,1,13.74,0,0,61,None,1,0,0,0,0,1,0,0,0,0,0,Zoledronic_acid,0,0,0,6,0,1,0,Apalutamide_ADT,PR,11.82,0,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,56.84,1,Disease_progression,1,1,0,,239.3,,,,,
HC014-6873538362266325,HC-ONC-014,gastric_met,Adenocarcinoma,Oligometa_curativeintent,67,Female,1,27.4,0,III,0,16.3,Metachronous,1,1,0,0,1,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,6.7,0,35.08,0,0,64,None,1,1,5,1,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,8,0,0,0,XELOX_Bev,PR,5.81,0,0,4.95,Ramucirumab_Paclitaxel,PD,1.64,0,0,1.2,NA,NA,0.0,0,0,0.0,2,0.0,13.51,1,Disease_progression,1,0,0,,,,,,,
HC014-8283789080680939,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,57,Female,0,20.3,3,II,0,25.1,Late_recurrence,0,0,0,0,1,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,10.0,1.8,0,12.98,1,0,31,None,1,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,2,0,0,0,Abemaciclib_Fulvestrant,CR,1.96,0,1,0.5,Alpelisib_Fulvestrant,PR,31.0,0,0,0.99,Fulvestrant_mono,PD,2.1,0,0,7.32,3,0.0,172.56,0,Censored,1,1,1,ER+PR+,,,,,,
HC014-8327037064727239,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,67,Female,0,22.7,3,I,0,1.7,Metachronous,1,0,1,1,0,0,0,1,0,0,0,0,0,1,4,Polymetastatic,0,0,0,0,0,None,0,0,1,10,16.0,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,7.0,0,4.44,0,1,49,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,6,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,18.56,0,Censored,1,0,0,,,,,,,
HC014-7224100368436865,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,68,Female,2,31.7,3,III,0,26.5,Late_recurrence,0,0,0,1,0,0,1,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,VUS,MSS,0.0,2.7,1.1,0,19.83,1,0,87,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,9,0,0,0,Palbociclib_Letrozole,PR,83.12,0,1,4.29,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,6.95,0,Censored,0,0,0,ER+PR-,,,,,,
HC014-2323247066183901,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,65,Female,0,24.7,7,III,0,2.3,Metachronous,0,1,1,1,0,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,63.0,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,13.6,0,6.82,0,0,61,None,1,1,5,1,0,0,0,0,0,0,0,None,0,0,0,0,0,0,0,CAPOX_Bev,PR,6.08,0,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,61.65,1,Disease_progression,1,1,1,,,,,,,
HC014-5624936122816610,HC-ONC-014,hcc_met,Hepatocellular_carcinoma,Palliative_systemic,54,Male,2,16.0,4,III,0,22.0,Metachronous,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,5.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,26.2,0,22.03,0,0,89,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,6,0,0,0,Sorafenib,SD,21.2,0,1,0.5,Ramucirumab,PR,5.07,0,0,0.5,Pembrolizumab_mono,PR,5.23,1,0,6.27,3,1.44,26.08,0,Censored,1,1,0,,,,,,,
HC014-2906610394585063,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,56,Female,1,27.9,2,II,0,17.8,Metachronous,1,1,0,1,1,1,1,1,1,0,1,0,0,0,7,Polymetastatic,1,2,1,0,1,None,0,0,1,27,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,37.2,0.0,11.8,0,13.91,0,0,74,None,1,0,0,0,0,1,0,0,0,1,0,Zoledronic_acid,0,0,1,2,0,1,0,Nivolumab_mono,PR,20.13,1,0,7.97,Ipilimumab_mono,PD,8.3,1,0,0.57,Vemurafenib,PD,3.83,0,0,0.5,3,3.19,114.02,1,Disease_progression,1,1,1,,,,,,,0.0
HC014-8097572780913968,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,61,Male,2,27.4,2,III,0,43.2,Late_recurrence,0,0,1,0,1,0,0,1,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,1,5,15.7,Negative,ALK-,WT,HER2-,0,WT,MSS,7.4,0.0,4.6,0,3.55,0,0,12,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,1,8,0,0,0,Nivo_Ipi,SD,61.34,0,0,1.64,Docetaxel_Ramucirumab,PR,5.66,0,0,7.76,NA,NA,0.0,0,0,0.0,2,0.0,28.11,1,Disease_progression,1,1,0,,,,,,,
HC014-3636472573809930,HC-ONC-014,renal_met,Clear_cell,Palliative_systemic,60,Female,2,27.4,3,I,0,13.7,Metachronous,0,0,0,0,0,0,0,0,0,1,0,1,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,9.1,0.0,7.5,0,5.85,0,1,37,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,0,7,0,0,0,Pembro_Axitinib,SD,7.69,0,0,6.33,Nivolumab_mono,SD,22.04,1,0,1.89,Everolimus,SD,2.08,0,0,1.76,3,0.0,55.9,1,Treatment_toxicity,1,1,0,,,,,0.0,Poor,
HC014-3219250825604865,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Maintenance,54,Female,2,27.4,1,III,0,31.7,Late_recurrence,1,0,0,0,1,0,1,1,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,1,28,0.0,Negative,ALK-,WT,HER2_1plus,0,VUS,MSS,0.0,1.8,11.2,0,6.72,1,0,88,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,1,0,1,7,0,0,0,Abemaciclib_Letrozole,PD,20.82,0,1,12.72,Fulvestrant_mono,PD,13.29,0,0,4.85,Lapatinib_Capecitabine,PD,1.8,0,0,0.5,4,0.0,83.32,1,Disease_progression,1,1,1,ER+PR-,,,,,,
HC014-3596452928131253,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,61,Female,2,27.9,4,III,0,16.5,Metachronous,0,0,0,0,0,0,0,0,0,1,1,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,47.5,0.0,12.2,0,8.48,0,0,43,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,5,0,0,0,Nivolumab_mono,CR,12.93,1,0,5.29,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,7.74,15.85,1,Intercurrent_illness,1,0,0,,,,,,,0.0
HC014-5302127352837415,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,54,Female,1,19.6,4,II,0,7.5,Metachronous,0,0,0,0,1,1,1,0,0,0,0,0,0,0,3,Oligometastatic,1,2,0,1,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,7.7,2.5,0,14.58,0,0,19,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,0,3,0,1,0,Palbociclib_Letrozole,PR,13.64,0,1,5.98,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,162.31,1,Disease_progression,1,1,1,ER+PR+,,,,,,
HC014-8910108140328106,HC-ONC-014,gastric_met,Adenocarcinoma,Best_supportive_care,78,Male,3,26.2,2,IV,1,0.0,Synchronous,0,0,1,1,0,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,33.1,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,8.7,0,10.86,1,0,24,None,0,0,0,0,0,0,0,0,0,0,0,None,1,1,1,3,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,18.98,0,Censored,1,0,0,,,,,,,
HC014-8114697461743050,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,63,Male,2,22.0,3,II,0,6.0,Metachronous,1,1,1,1,1,0,1,0,0,1,0,1,0,0,6,Polymetastatic,0,0,0,0,1,None,0,0,0,0,47.3,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.5,0,12.36,0,1,76,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,0,1,9,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,18.4,1,Disease_progression,1,0,0,,,,,,,
HC014-8305435893924466,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,90,Female,2,31.0,0,II,0,16.3,Metachronous,1,0,0,1,1,0,0,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Exon19del,ALK-,WT,HER2-,0,WT,MSS,53.3,0.0,7.4,0,12.43,0,0,67,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,0,2,0,0,0,Gefitinib,PR,5.49,0,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,24.27,1,Disease_progression,1,1,0,,,,,,,
HC014-5079988285265706,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,61,Male,1,29.9,6,IV,1,0.0,Synchronous,0,0,1,1,0,1,0,1,1,0,0,0,0,0,5,Polymetastatic,1,4,0,0,0,None,0,0,1,18,6.6,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,4.0,0,4.72,0,0,40,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,1,1,0,0,Gemcitabine_mono,PR,4.91,0,0,1.52,Capecitabine,SD,0.5,0,0,3.44,FOLFOX,PD,2.31,0,0,9.78,3,0.0,13.57,1,Disease_progression,1,0,0,,,,,,,
HC014-1710193463738589,HC-ONC-014,melanoma_met,Melanoma,Best_supportive_care,72,Male,2,30.2,9,III,0,1.7,Metachronous,1,1,0,0,1,1,1,0,0,0,1,0,0,0,4,Polymetastatic,1,3,0,1,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,41.6,0.0,31.8,0,20.93,0,1,19,None,1,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,1,0,1,9,0,1,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,22.68,0,Censored,1,0,0,,,,,,,0.0
HC014-1259013843024851,HC-ONC-014,gastric_met,Adenocarcinoma,Oligometa_curativeintent,49,Female,0,25.3,3,IV,1,0.0,Synchronous,0,0,0,1,0,0,0,1,0,0,0,0,0,1,3,Oligometastatic,0,0,0,0,0,None,0,0,1,17,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,4.7,0,6.03,0,0,84,None,1,0,0,0,0,0,1,0,0,0,0,None,0,0,0,6,1,0,0,Pembro_FP,PR,12.77,0,0,2.19,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,57.16,0,Censored,1,1,0,,,,,,,
HC014-9717694838007004,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,77,Female,3,22.4,3,III,0,22.2,Metachronous,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,12.8,0,1.84,0,0,74,None,0,0,0,0,0,0,0,0,0,0,0,None,1,1,1,6,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,12.51,1,Disease_progression,1,0,0,,,,,,,
HC014-7123932447675449,HC-ONC-014,melanoma_met,Melanoma,Oligometa_curativeintent,46,Male,1,31.0,7,III,0,25.7,Late_recurrence,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,25.1,0.0,21.1,0,5.57,0,0,65,None,1,0,0,0,0,0,1,0,0,0,0,None,0,0,0,7,0,0,0,Relatlimab_Nivolumab,PR,14.39,1,0,3.0,Nivolumab_mono,PD,9.18,1,0,1.77,Vemurafenib,PR,5.04,0,0,7.39,3,2.68,49.08,1,Disease_progression,1,1,0,,,,,,,0.0
HC014-1087584282078023,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,67,Male,3,31.9,4,III,0,17.6,Metachronous,0,0,1,0,0,0,0,1,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,20,29.7,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,0.8,0,15.11,1,0,25,None,0,0,0,0,0,0,0,0,0,0,0,None,1,1,1,10,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,25.38,0,Censored,1,1,0,,,,,,,
HC014-7952779477433953,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,54,Male,1,20.8,5,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,1,0,0,44.7,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.9,0,17.61,0,0,82,None,1,1,5,1,0,0,0,0,0,0,0,None,0,0,0,5,0,0,0,Gemcitabine_mono,PD,15.66,0,0,1.63,FOLFOX,PD,1.95,0,0,1.71,NA,NA,0.0,0,0,0.0,2,0.0,28.58,0,Censored,1,1,0,,,,,,,
HC014-2547078917312532,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,59,Male,1,31.3,5,III,0,11.0,Metachronous,0,1,1,0,1,0,0,0,0,0,0,1,0,1,4,Polymetastatic,0,0,0,0,1,Bone_pain,0,0,0,0,37.3,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.9,1,31.33,0,1,74,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,0,8,0,0,0,Darolutamide_Docetaxel_ADT,SD,37.42,0,0,0.69,Olaparib,PD,2.38,0,1,2.32,Rucaparib,PR,1.99,0,0,3.57,3,0.0,15.09,1,Disease_progression,1,0,0,,854.8,,,,,
HC014-7849045335150390,HC-ONC-014,nsclc_met,Adenocarcinoma,Oligometa_curativeintent,52,Male,1,28.6,10,IV,1,0.0,Synchronous,0,0,0,0,1,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSI-H,33.2,0.0,15.7,0,15.39,0,0,37,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,5,0,0,0,Nivo_Ipi,SD,22.24,0,0,0.91,Docetaxel_mono,PD,15.27,0,0,0.61,NA,NA,0.0,0,0,0.0,2,0.0,39.74,0,Censored,1,1,0,,,,,,,
HC014-4745679869964909,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,70,Male,1,30.6,5,III,0,38.5,Late_recurrence,0,0,1,0,1,0,0,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,23.7,Negative,ALK-,WT,HER2-,0,BRCA2,MSS,0.0,0.0,6.4,0,7.23,1,0,64,None,1,0,0,0,0,0,0,1,0,0,1,Denosumab,0,0,0,1,0,0,0,Darolutamide_Docetaxel_ADT,PR,21.42,0,0,2.97,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,115.53,0,Censored,1,1,1,,32.5,,,,,
HC014-3119919115625960,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,66,Male,2,31.9,2,I,0,18.3,Metachronous,0,0,1,1,1,0,1,1,0,0,0,0,0,0,5,Polymetastatic,0,0,0,0,1,None,0,0,1,25,16.7,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,12.0,0,7.95,1,1,61,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,4,0,0,0,FOLFOXIRI_Bev,SD,11.73,0,0,0.74,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,37.71,1,Treatment_toxicity,1,1,0,,,,,,,
HC014-5201683906914054,HC-ONC-014,renal_met,Clear_cell,Palliative_systemic,83,Male,0,27.2,5,III,0,48.0,Late_recurrence,1,0,0,1,0,1,1,1,0,0,0,0,0,0,4,Polymetastatic,1,4,0,0,0,None,0,0,1,23,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,20.4,0,16.31,0,0,64,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,1,0,1,0,Nivo_Ipi,PR,5.87,0,0,0.5,Everolimus,PD,9.5,0,0,3.97,Nivolumab_mono,SD,2.8,1,0,0.5,4,20.11,82.48,1,Treatment_toxicity,1,1,1,,,,,1.0,Intermediate,
HC014-2704963865055900,HC-ONC-014,renal_met,Clear_cell,Palliative_systemic,66,Female,2,29.8,7,II,0,19.3,Metachronous,1,1,1,1,0,0,0,0,1,0,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,20.0,Negative,ALK-,WT,HER2-,0,WT,MSS,32.1,0.0,4.6,0,8.62,0,0,74,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,8,0,0,0,Sunitinib,SD,17.55,0,1,3.99,Everolimus,CR,15.96,0,0,4.78,Axitinib,PD,1.97,0,0,7.03,3,0.0,4.63,1,Disease_progression,0,0,0,,,,,1.0,Favorable,
HC014-3786168838637772,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,66,Female,0,18.9,5,II,0,19.1,Metachronous,1,0,0,0,0,0,1,1,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,30,0.0,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,8.8,5.2,0,11.55,0,0,41,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,2,0,0,0,Nab-Paclitaxel_Atezolizumab,PR,10.32,1,0,1.41,Pembrolizumab_mono,SD,1.75,1,0,3.68,NA,NA,0.0,0,0,0.0,2,14.91,106.7,1,Intercurrent_illness,1,1,1,ER-PR-,,,,,,
HC014-1595473542831617,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,45,Female,1,19.8,4,I,0,24.2,Late_recurrence,0,1,1,0,1,1,0,0,1,0,0,0,0,0,4,Polymetastatic,1,3,0,1,1,Fracture,0,1,0,0,40.7,Negative,ALK-,WT,HER2_2plus_FISH+,0,WT,MSS,0.0,13.3,19.6,0,4.57,0,0,49,None,1,0,0,0,1,0,0,0,0,0,0,Denosumab,0,0,0,1,0,0,0,Pyrotinib_Capecitabine,PR,42.5,0,0,0.84,Lapatinib_Capecitabine,PD,13.6,0,0,1.47,Tucatinib_Tras_Cape,PD,7.43,0,0,0.5,4,0.0,87.95,1,Disease_progression,1,1,1,ER+PR+,,,,,,
HC014-2714083041593793,HC-ONC-014,nsclc_met,Squamous_cell,Palliative_systemic,38,Male,2,33.1,2,IV,1,0.0,Synchronous,0,0,1,0,1,0,0,0,1,0,0,0,0,1,4,Polymetastatic,0,0,0,0,1,None,0,1,0,0,24.0,Negative,ALK-,G12C,HER2-,0,WT,MSS,20.0,0.0,5.7,0,15.67,0,1,52,None,1,0,0,0,0,0,0,0,0,0,1,None,1,0,0,6,0,0,0,Nivo_Chemo,SD,22.1,0,0,12.14,Pemetrexed,PD,15.08,0,0,2.71,Docetaxel_mono,PD,0.57,0,0,1.04,6,0.0,22.21,1,Disease_progression,1,0,0,,,,,,,
HC014-3804421834830132,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Best_supportive_care,68,Female,3,27.3,8,II,0,33.0,Late_recurrence,1,1,1,0,1,0,0,0,1,1,0,0,0,0,4,Polymetastatic,0,0,0,0,1,Hypercalcemia,0,1,0,0,18.4,Negative,ALK-,WT,HER2_1plus,0,BRCA2,MSS,0.0,16.3,9.9,0,0.62,0,0,20,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,1,0,0,4,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,10.29,1,Disease_progression,0,0,0,ER-PR-,,,,,,
HC014-5570237272600791,HC-ONC-014,hcc_met,Hepatocellular_carcinoma,Palliative_systemic,48,Male,1,23.4,1,IV,1,0.0,Synchronous,0,0,0,1,0,0,1,0,1,0,0,0,1,0,4,Polymetastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,8.2,0,36.33,1,0,41,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,9,0,0,0,Tremelimumab_Durvalumab,PR,6.99,1,0,7.55,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,5.35,33.64,0,Censored,1,1,0,,,,,,,
HC014-6377981409415185,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,57,Female,1,22.1,0,III,0,47.7,Late_recurrence,1,0,1,0,0,1,0,1,0,0,0,0,0,0,3,Oligometastatic,1,4,0,0,0,None,0,0,1,23,13.6,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,8.8,0,18.51,0,1,45,None,1,1,5,1,0,1,0,1,0,0,0,None,0,0,0,9,0,0,0,FOLFIRI_Cetuximab,SD,9.46,0,0,0.5,FOLFOX_Cetuximab,SD,11.87,0,0,7.44,NA,NA,0.0,0,0,0.0,2,0.0,1.84,0,Censored,0,0,0,,,,,,,
HC014-2803667827378175,HC-ONC-014,bladder_met,Urothelial_carcinoma,Maintenance,47,Female,1,32.5,0,I,0,7.9,Metachronous,1,0,1,1,1,0,1,0,1,1,0,0,0,0,6,Polymetastatic,0,0,0,0,1,None,0,1,0,0,7.3,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.1,0,46.0,0,1,72,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,2,0,0,0,EV_Pembrolizumab,SD,2.09,1,0,1.18,Enfortumab_Vedotin,SD,0.5,0,0,7.81,Erdafitinib_FGFR,PD,2.55,0,0,5.64,5,0.0,14.14,1,Disease_progression,1,0,0,,,,,,,
HC014-8774764945970401,HC-ONC-014,gastric_met,Adenocarcinoma,Best_supportive_care,60,Female,3,16.0,0,III,0,101.2,Late_recurrence,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,1,26,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,7.2,0,8.48,1,0,57,None,0,0,0,0,0,0,0,0,0,0,0,None,0,1,1,8,1,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,1.61,0,Censored,0,0,0,,,,,,,
HC014-4130865692895619,HC-ONC-014,nsclc_met,Squamous_cell,Palliative_systemic,44,Female,2,20.4,3,III,0,15.6,Metachronous,1,1,0,1,1,0,1,0,1,1,0,0,0,0,5,Polymetastatic,0,0,0,0,1,None,0,1,0,0,0.0,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,43.7,0.0,12.8,0,9.63,0,0,30,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,1,0,1,4,0,0,0,Nivo_Ipi,CR,27.92,0,0,2.47,Docetaxel_Nintedanib,PD,0.52,0,0,2.18,Docetaxel_mono,PD,1.79,0,0,4.14,3,0.0,10.09,0,Censored,0,0,0,,,,,,,
HC014-7627801486020021,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,55,Male,1,17.4,4,IV,1,0.0,Synchronous,0,0,0,0,1,0,1,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.2,0,17.32,0,0,81,None,1,0,0,0,0,0,1,0,0,0,1,Denosumab,0,0,0,6,0,0,0,Docetaxel_ADT,PR,23.51,0,0,3.73,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,72.86,1,Disease_progression,1,1,1,,33.5,,,,,
HC014-1897862226604114,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,65,Male,1,29.4,3,III,0,11.9,Metachronous,1,0,0,1,0,1,1,0,0,0,0,1,0,0,4,Polymetastatic,1,3,0,1,0,None,0,0,0,0,0.0,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,4.0,0.0,1.2,0,20.29,0,0,23,None,1,0,0,0,1,0,0,0,0,0,0,None,0,0,0,5,0,0,0,Atezo_Carbo_Pem_Bev,PR,4.9,0,0,1.16,Docetaxel_Nintedanib,PD,3.94,0,0,0.98,NA,NA,0.0,0,0,0.0,2,0.0,26.98,0,Censored,1,1,0,,,,,,,
HC014-9792966280489522,HC-ONC-014,crc_met,Adenocarcinoma,Maintenance,57,Female,2,34.1,4,III,0,1.5,Metachronous,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,26.1,Negative,ALK-,WT,HER2-,0,WT,MSI-H,0.0,0.0,5.8,0,6.08,1,0,20,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,9,0,0,0,FOLFOX_Bev,SD,24.24,0,0,3.82,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,7.23,1,Disease_progression,0,0,0,,,,,,,
HC014-9420935609685675,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,62,Male,0,31.4,5,IV,1,0.0,Synchronous,0,0,1,0,0,1,0,0,1,1,0,0,0,0,4,Polymetastatic,1,5,0,0,0,None,0,1,0,0,26.7,Negative,ALK-,WT,HER2-,0,WT,MSS,79.7,0.0,1.8,0,12.33,0,0,56,None,1,0,0,0,0,1,0,0,0,0,0,None,0,0,0,0,0,0,0,Cemiplimab_mono,PR,16.62,1,0,3.01,Docetaxel_Ramucirumab,PR,5.5,0,0,6.64,Pemetrexed,PD,6.24,0,0,1.74,3,1.73,39.81,0,Censored,1,1,0,,,,,,,
HC014-5701085933158041,HC-ONC-014,pancreatic_met,Adenocarcinoma,Oligometa_curativeintent,57,Male,1,20.8,3,II,0,3.7,Metachronous,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,14.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.5,0,20.62,1,0,31,None,0,0,0,0,0,0,0,1,0,0,0,None,0,0,0,9,0,0,0,Gemcitabine_Abraxane,PD,4.94,0,0,0.5,Olaparib_BRCA,PD,7.85,0,1,5.2,NA,NA,0.0,0,0,0.0,2,0.0,1.6,0,Censored,0,0,0,,,,,,,
HC014-4339525213795806,HC-ONC-014,melanoma_met,Melanoma,Oligometa_curativeintent,64,Male,1,26.2,4,III,0,38.7,Late_recurrence,1,0,0,1,0,1,0,0,0,0,0,0,0,0,2,Oligometastatic,1,3,0,1,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,1,WT,MSS,88.1,0.0,18.2,0,13.72,0,1,86,None,1,1,3,1,1,0,0,0,0,0,0,None,0,0,0,9,0,0,0,Vemurafenib_Cobimetinib,PR,8.16,0,0,3.61,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,33.15,0,Censored,1,1,0,,,,,,,1.0
HC014-3704848750786249,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,67,Female,1,21.5,0,IV,1,0.0,Synchronous,0,0,0,0,1,0,1,0,0,0,0,1,0,1,4,Polymetastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,BRCA2,MSS,0.0,37.9,8.9,0,11.45,0,1,65,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,0,7,0,0,0,Abemaciclib_Letrozole,PD,3.55,0,1,1.28,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,15.74,0,Censored,1,0,0,ER+PR+,,,,,,
HC014-7107937893737997,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,60,Male,2,19.7,2,II,0,3.1,Metachronous,1,0,0,0,1,0,0,1,1,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,1,1,23,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.0,0,9.35,0,0,80,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,0,3,0,0,0,Apalutamide_ADT,PR,4.72,0,0,1.73,Cabazitaxel,PD,8.47,0,0,1.69,NA,NA,0.0,0,0,0.0,2,0.0,14.11,0,Censored,1,0,0,,1.2,,,,,
HC014-6038685106675322,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,64,Female,0,32.7,3,II,0,11.3,Metachronous,1,0,1,0,0,0,0,1,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,8,12.2,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,5.1,8.1,0,20.18,1,1,64,None,1,1,3,2,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,Ribociclib_Letrozole,PR,37.48,0,1,0.5,Fulvestrant_mono,SD,14.17,0,0,8.06,NA,NA,0.0,0,0,0.0,2,0.0,43.32,1,Disease_progression,1,1,0,ER+PR+,,,,,,
HC014-8378696404570870,HC-ONC-014,melanoma_met,Melanoma,Oligometa_curativeintent,58,Male,0,25.1,0,III,0,18.6,Metachronous,1,0,1,0,0,0,1,0,0,0,0,1,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,16.5,Negative,ALK-,WT,HER2-,1,WT,MSS,51.7,0.0,23.4,0,13.13,0,1,56,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,0,0,0,0,Vemurafenib_Cobimetinib,SD,11.31,0,0,2.44,Pembrolizumab_mono,SD,9.42,1,0,5.46,NA,NA,0.0,0,0,0.0,2,0.0,180.0,1,Disease_progression,1,1,1,,,,,,,0.0
HC014-1146033704678613,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,62,Male,1,19.5,4,III,0,30.7,Late_recurrence,0,0,1,0,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,19.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,0.5,0,6.49,0,0,23,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,0,9,0,0,0,Enzalutamide_ADT,PD,21.13,0,1,0.5,Cabazitaxel,PR,1.79,0,0,2.63,Rucaparib,SD,4.6,0,0,1.63,3,0.0,19.87,1,Intercurrent_illness,1,0,0,,18.7,,,,,
HC014-6189552597902706,HC-ONC-014,pancreatic_met,Adenocarcinoma,Oligometa_curativeintent,53,Female,1,20.9,4,IV,1,0.0,Synchronous,0,0,1,1,0,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,40.3,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.0,0,10.24,0,1,87,None,1,1,12,3,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,FOLFIRINOX,PD,10.89,0,0,1.03,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,31.16,1,Disease_progression,1,1,0,,,,,,,
HC014-4720271609148707,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,49,Male,1,34.4,1,II,0,1.0,Metachronous,0,0,1,1,1,1,0,0,0,0,0,0,0,1,5,Polymetastatic,1,2,0,1,1,None,0,0,0,0,28.0,Negative,ALK-,WT,HER2-,0,WT,MSS,27.3,0.0,35.6,0,11.62,1,0,32,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,0,6,0,0,0,Nivolumab_Ipilimumab,SD,19.97,1,0,1.06,Pembrolizumab_mono,PD,5.1,1,0,0.69,NA,NA,0.0,0,0,0.0,2,0.0,119.78,1,Intercurrent_illness,1,1,1,,,,,,,1.0
HC014-3249166667589007,HC-ONC-014,nsclc_met,Squamous_cell,Oligometa_curativeintent,56,Male,0,29.4,4,III,0,28.0,Late_recurrence,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Exon19del,ALK-,Other_KRAS,HER2-,0,WT,MSS,52.9,0.0,18.4,0,9.96,0,0,76,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,Osimertinib,PR,16.17,0,1,11.61,Docetaxel_Ramucirumab,PD,15.83,0,0,4.48,NA,NA,0.0,0,0,0.0,2,0.0,32.73,1,Intercurrent_illness,1,1,0,,,,,,,
HC014-3520933342043649,HC-ONC-014,renal_met,Clear_cell,Palliative_systemic,67,Male,0,26.9,3,I,0,16.4,Metachronous,1,0,0,1,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,Fracture,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,9.2,0.0,5.0,0,22.24,1,1,77,None,1,1,3,1,0,0,0,0,0,0,1,Denosumab,0,0,1,3,0,0,0,Avelumab_Axitinib,PD,10.55,1,0,1.43,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,160.25,1,Disease_progression,1,1,1,,,,,1.0,Favorable,
HC014-7157261163994520,HC-ONC-014,renal_met,Clear_cell,Palliative_systemic,51,Male,1,27.3,0,I,0,21.0,Metachronous,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,21.8,0.0,2.6,0,28.48,0,1,14,None,1,0,0,0,0,0,1,0,0,0,0,None,0,0,0,6,0,0,0,Nivo_Ipi,PR,5.09,0,0,3.93,Nivolumab_mono,PD,2.05,1,0,5.6,NA,NA,0.0,0,0,0.0,2,1.48,63.46,1,Intercurrent_illness,1,1,1,,,,,1.0,Intermediate,
HC014-1771670794519001,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,52,Male,1,27.1,3,III,0,44.3,Late_recurrence,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,Fracture,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.3,0,16.27,0,0,21,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,1,4,0,0,0,Docetaxel_ADT,SD,50.11,0,0,9.8,Pembrolizumab,PD,26.75,1,0,4.33,Lu177-PSMA,PR,8.0,0,0,1.69,3,2.3,28.94,1,Intercurrent_illness,1,1,0,,35.4,,,,,
HC014-5101673110170845,HC-ONC-014,hcc_met,Hepatocellular_carcinoma,Maintenance,87,Male,2,25.9,4,IV,1,0.0,Synchronous,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.6,0,5.75,0,0,21,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,7,0,0,0,Lenvatinib,PD,1.06,0,1,2.79,Ramucirumab,PD,4.04,0,0,0.5,Nivolumab_Ipi,SD,1.74,1,0,1.74,3,0.0,16.69,1,Disease_progression,1,0,0,,,,,,,
HC014-1055726997101994,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,55,Female,1,24.0,5,III,0,28.5,Late_recurrence,1,0,1,0,0,0,0,1,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,29,28.5,Negative,ALK-,G12C,HER2-,0,WT,MSS,0.0,0.0,6.3,0,21.34,0,1,33,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,9,0,0,0,FOLFIRI_Bev,PR,14.8,0,0,0.5,FOLFOX_Bev,PR,2.92,0,0,4.27,NA,NA,0.0,0,0,0.0,2,0.0,19.35,1,Treatment_toxicity,1,0,0,,,,,,,
HC014-6833959837123684,HC-ONC-014,gastric_met,Adenocarcinoma,Palliative_systemic,80,Female,1,39.9,6,III,0,56.6,Late_recurrence,1,0,1,0,0,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,26.1,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.5,0,12.84,0,0,74,None,1,1,5,2,0,0,0,1,0,0,0,None,0,0,0,2,0,0,0,XELOX_Bev,PR,9.69,0,0,2.28,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,8.74,1,Intercurrent_illness,0,0,0,,,,,,,
HC014-8517187981781995,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,51,Male,0,32.7,4,III,0,52.9,Late_recurrence,0,1,1,1,1,0,0,1,0,0,0,0,0,0,4,Polymetastatic,0,0,0,0,1,None,0,0,1,19,17.5,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,9.2,0,24.18,0,0,23,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,1,8,0,0,0,FOLFOX_Bev,SD,16.08,0,0,5.24,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,8.83,1,Disease_progression,0,0,0,,,,,,,
HC014-6524195146256454,HC-ONC-014,hcc_met,Hepatocellular_carcinoma,Best_supportive_care,59,Female,3,36.1,7,IV,1,0.0,Synchronous,0,0,1,1,0,0,0,0,0,0,0,0,1,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,16.9,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.5,0,18.49,0,0,48,None,0,0,0,0,0,0,0,0,0,0,0,None,0,1,0,6,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,1.81,1,Disease_progression,0,0,0,,,,,,,
HC014-5104290541578033,HC-ONC-014,sarcoma_met,Liposarcoma,Oligometa_curativeintent,60,Female,1,25.6,2,II,0,11.4,Metachronous,1,0,0,1,0,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,4.7,0,1.72,0,0,80,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,3,0,0,0,Pazopanib,CR,11.44,0,1,0.5,Gemcitabine_Dacarbazine,SD,2.35,0,0,0.5,NA,NA,0.0,0,0,0.0,2,0.0,16.54,0,Censored,1,0,0,,,,,,,
HC014-6127239728920854,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,67,Female,1,29.7,4,III,0,19.9,Metachronous,1,1,1,1,0,1,0,0,1,1,0,0,0,0,5,Polymetastatic,1,7,0,0,0,None,0,1,0,0,48.1,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,21.2,3.0,0,5.88,0,0,72,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,1,0,1,0,Palbociclib_Fulvestrant,PD,22.22,0,1,4.73,Capivasertib_Fulvestrant,PR,10.41,0,0,10.65,Vinorelbine,PD,1.53,0,0,1.75,4,0.0,77.09,1,Disease_progression,1,1,1,ER+PR+,,,,,,
HC014-2451944619622158,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,60,Male,1,23.0,6,IV,1,0.0,Synchronous,0,0,1,1,0,0,0,1,0,0,0,1,0,0,4,Polymetastatic,0,0,0,0,0,None,0,0,1,25,31.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.5,0,20.53,0,1,77,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,4,0,0,0,Gemcitabine_Abraxane,PR,0.67,0,0,1.27,Olaparib_BRCA,PR,3.21,0,1,6.34,FOLFOX,PD,1.41,0,0,2.12,4,0.0,5.93,1,Disease_progression,0,0,0,,,,,,,
HC014-8185365902426768,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,64,Female,1,22.3,4,III,0,42.0,Late_recurrence,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,16.9,11.8,0,20.31,1,0,66,None,1,0,0,0,0,0,1,0,0,0,0,None,0,0,0,3,0,0,0,Ribociclib_Letrozole,PD,20.82,0,1,2.25,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,12.64,0,Censored,1,0,0,ER+PR+,,,,,,
HC014-3308006775829418,HC-ONC-014,prostate_met,Adenocarcinoma,Best_supportive_care,60,Male,4,30.6,1,III,0,6.3,Metachronous,0,0,0,0,1,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,8.7,1,5.54,0,1,80,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,7,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,10.56,1,Disease_progression,0,0,0,,398.2,,,,,
HC014-3199308005134481,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,63,Female,1,34.3,4,IV,1,0.0,Synchronous,0,0,0,0,0,1,0,1,0,0,0,0,1,0,3,Oligometastatic,1,4,0,0,0,None,0,0,1,31,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,23.0,0.0,13.5,0,13.93,1,1,36,None,1,1,3,3,0,1,0,0,0,0,0,None,0,0,0,8,0,0,0,Nivo_Chemo,PD,20.44,0,0,0.81,Docetaxel_mono,PD,9.28,0,0,8.87,NA,NA,0.0,0,0,0.0,2,0.0,26.28,1,Disease_progression,1,1,0,,,,,,,
HC014-7836057558953489,HC-ONC-014,nsclc_met,Adenocarcinoma,Best_supportive_care,31,Female,3,19.1,5,III,0,26.9,Late_recurrence,0,0,0,0,0,1,1,0,1,0,0,1,0,0,4,Polymetastatic,1,3,0,1,0,None,0,1,0,0,0.0,Exon19del,ALK-,WT,HER2-,0,WT,MSS,88.5,0.0,4.0,0,11.08,0,0,68,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,8,0,1,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,46.54,1,Intercurrent_illness,1,1,0,,,,,,,
HC014-1084621700827385,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,36,Female,0,30.5,7,III,0,12.1,Metachronous,1,0,1,1,1,1,0,0,0,0,0,0,0,0,4,Polymetastatic,1,2,0,1,1,Fracture,0,0,0,0,8.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,4.1,1.3,0,7.95,0,0,84,None,1,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,0,3,0,1,0,Pembrolizumab_Chemo,PR,17.92,1,0,13.9,Eribulin,PR,7.05,0,0,1.26,NA,NA,0.0,0,0,0.0,2,11.53,47.63,1,Intercurrent_illness,1,1,0,ER-PR-,,,,,,
HC014-1139998431052084,HC-ONC-014,sarcoma_met,Liposarcoma,Palliative_systemic,87,Male,2,34.8,4,IV,1,0.0,Synchronous,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,7.5,0,10.7,0,0,61,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,4,0,0,0,Gemcitabine_Docetaxel,PD,8.17,0,0,11.79,Trabectedin,PR,5.88,0,0,0.5,NA,NA,0.0,0,0,0.0,2,0.0,11.9,1,Disease_progression,0,0,0,,,,,,,
HC014-7250179160087227,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Maintenance,90,Female,2,27.2,2,III,0,70.2,Late_recurrence,0,0,0,1,1,0,1,1,1,1,0,0,0,0,6,Polymetastatic,0,0,0,0,1,Bone_pain,0,0,1,5,0.0,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,9.7,2.9,0,11.86,0,0,25,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,8,0,0,0,Palbociclib_Fulvestrant,PR,23.12,0,1,4.44,Alpelisib_Fulvestrant,CR,14.38,0,0,4.3,Vinorelbine,PD,1.95,0,0,3.99,5,14.09,25.9,0,Censored,1,1,0,ER+PR+,,,,,,
HC014-5470945727339041,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,63,Male,1,22.2,6,III,0,8.0,Metachronous,1,0,0,1,0,0,0,1,0,0,1,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,30,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,30.6,0.0,22.4,0,10.89,0,1,63,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,5,0,0,0,Nivolumab_mono,PD,12.01,1,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,180.0,0,Censored,1,1,1,,,,,,,1.0
HC014-4064215975806743,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,59,Male,2,28.6,6,IV,1,0.0,Synchronous,0,0,1,0,1,0,0,1,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,1,5,41.2,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.6,0,0.99,1,1,30,None,1,0,0,0,0,0,0,0,0,0,1,None,1,0,0,4,0,0,0,Apalutamide_ADT,PR,17.19,0,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,15.31,1,Unknown,1,0,0,,74.1,,,,,
HC014-6308849012952009,HC-ONC-014,ovarian_met,High_grade_serous,Palliative_systemic,28,Female,1,29.3,10,II,0,27.7,Late_recurrence,1,0,0,0,0,0,1,1,0,1,1,0,0,0,4,Polymetastatic,0,0,0,0,0,None,0,0,1,7,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.8,0,25.32,0,1,78,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,3,0,0,0,NIRAPARIB_maint,PR,3.25,0,0,0.5,Olaparib,PD,4.78,0,1,7.78,Gemcitabine_Carbo,SD,2.35,0,0,0.5,6,0.0,12.84,1,Disease_progression,1,0,0,,,Unknown,542.8,,,
HC014-2007353190379479,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,42,Female,1,29.3,5,I,0,30.1,Late_recurrence,0,0,1,0,1,0,1,0,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,Hypercalcemia,0,0,0,0,5.0,Exon19del,ALK-,Other_KRAS,HER2-,0,WT,MSS,48.7,0.0,5.7,0,7.22,0,1,81,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,4,0,0,0,Dacomitinib,PD,6.1,0,0,6.4,Docetaxel_mono,PD,0.66,0,0,8.34,NA,NA,0.0,0,0,0.0,2,0.0,32.29,1,Treatment_toxicity,1,1,0,,,,,,,
HC014-8629747479889170,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,83,Male,1,31.0,1,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,64.4,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,1.4,0,4.84,0,0,27,None,1,1,3,3,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,FOLFOX_Bev,PD,23.12,0,0,2.21,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,33.9,0,Censored,1,1,0,,,,,,,
HC014-3078505682907581,HC-ONC-014,ovarian_met,High_grade_serous,Palliative_systemic,68,Female,1,19.7,3,I,0,52.7,Late_recurrence,1,0,0,0,0,0,0,1,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,30,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.8,0,24.97,0,0,19,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,8,0,0,0,Carbo_PLD,PR,3.74,0,0,1.9,Trabectedin_PLD,PD,13.9,0,0,6.15,NA,NA,0.0,0,0,0.0,2,0.0,27.75,1,Disease_progression,1,1,0,,,HRD-,11.0,,,
HC014-2022913249188904,HC-ONC-014,nsclc_met,Squamous_cell,Best_supportive_care,60,Male,3,36.8,6,IV,1,0.0,Synchronous,0,0,1,0,1,0,0,0,0,0,0,1,0,0,3,Oligometastatic,0,0,0,0,1,Bone_pain,1,0,0,0,24.0,Negative,ALK-,G12C,HER2-,0,WT,MSS,81.7,0.0,20.7,0,26.85,0,0,74,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,1,0,1,3,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,34.01,1,Disease_progression,1,1,0,,,,,,,
HC014-7961021011949014,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Maintenance,61,Female,1,30.0,10,III,0,25.0,Late_recurrence,1,0,1,1,1,0,0,0,0,0,0,1,0,0,4,Polymetastatic,0,0,0,0,1,Bone_pain,0,0,0,0,5.0,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,3.3,1.6,0,17.68,0,0,60,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,1,1,0,0,0,Nab-Paclitaxel_Atezolizumab,SD,4.11,1,0,4.76,Capecitabine,SD,1.41,0,0,1.7,Vinorelbine,PD,5.15,0,0,7.24,5,9.04,28.62,1,Disease_progression,1,1,0,ER-PR-,,,,,,
HC014-6340699094474566,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,58,Male,0,21.7,3,II,0,28.8,Late_recurrence,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.4,0,2.13,0,1,16,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,1,7,0,0,0,Docetaxel_ADT,PR,73.6,0,0,3.64,Abiraterone_Pred,PD,0.5,0,1,0.5,NA,NA,0.0,0,0,0.0,2,0.0,32.19,1,Disease_progression,1,1,0,,84.3,,,,,
HC014-4864643360817700,HC-ONC-014,nsclc_met,Squamous_cell,Best_supportive_care,55,Female,3,22.5,2,IV,1,0.0,Synchronous,0,0,0,1,0,1,0,0,0,1,0,0,0,0,3,Oligometastatic,1,6,0,0,0,None,0,0,0,0,0.0,Exon19del,ALK-,WT,HER2-,0,WT,MSS,57.4,0.0,6.8,0,32.26,0,0,76,None,1,0,0,0,0,1,0,0,0,0,0,None,1,0,1,4,0,1,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,10.01,1,Disease_progression,0,0,0,,,,,,,
HC014-7726652759160086,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,62,Male,1,19.5,1,III,0,14.8,Metachronous,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,7.5,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,29.3,0,31.44,0,0,42,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,6,0,0,0,FOLFOX_Bev,CR,5.68,0,0,1.51,FOLFOX_Bev,PD,18.53,0,0,1.8,NA,NA,0.0,0,0,0.0,2,0.0,7.65,1,Intercurrent_illness,0,0,0,,,,,,,
HC014-3568645066078531,HC-ONC-014,nsclc_met,Adenocarcinoma,Oligometa_curativeintent,57,Female,1,31.9,10,II,0,3.1,Metachronous,1,0,0,0,0,1,0,0,0,1,0,0,0,0,2,Oligometastatic,1,7,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,3.2,0.0,2.9,0,9.19,0,1,48,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,3,0,1,0,Nivo_Ipi,PR,18.99,0,0,4.48,Atezolizumab,SD,5.15,1,0,0.87,NA,NA,0.0,0,0,0.0,2,32.4,71.06,1,Disease_progression,1,1,1,,,,,,,
HC014-1095965318513127,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,64,Female,1,31.6,3,II,0,17.1,Metachronous,0,1,1,0,1,1,0,0,0,1,0,0,0,0,4,Polymetastatic,1,7,0,0,1,None,0,0,0,0,18.8,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,7.2,4.8,0,8.38,0,0,14,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,0,1,9,0,1,0,Palbociclib_Letrozole,SD,24.15,0,1,6.98,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,10.81,1,Intercurrent_illness,0,0,0,ER+PR+,,,,,,
HC014-1269807789559259,HC-ONC-014,nsclc_met,Squamous_cell,Palliative_systemic,53,Female,2,21.9,4,III,0,28.1,Late_recurrence,1,1,0,0,0,1,1,0,1,0,0,0,0,0,3,Oligometastatic,1,2,0,1,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,54.1,0.0,11.8,0,42.82,0,0,86,None,1,0,0,0,1,0,0,0,0,0,0,None,0,0,1,3,0,0,0,Pembrolizumab_mono,PD,27.12,1,0,2.19,Pemetrexed,PD,11.61,0,0,0.5,NA,NA,0.0,0,0,0.0,2,0.0,34.54,0,Censored,1,1,0,,,,,,,
HC014-6708782142186796,HC-ONC-014,ovarian_met,High_grade_serous,Oligometa_curativeintent,72,Female,1,30.2,6,I,0,25.4,Late_recurrence,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.2,0,5.28,0,0,40,None,1,1,5,1,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,Carbo_Pac,PR,30.17,0,0,2.39,Gemcitabine_Carbo,PR,11.89,0,0,4.29,Niraparib,PD,3.27,0,1,18.68,3,0.0,68.7,1,Treatment_toxicity,1,1,1,,,HRD+,465.7,,,
HC014-5491007788676796,HC-ONC-014,pancreatic_met,Adenocarcinoma,Oligometa_curativeintent,61,Female,0,29.1,1,IV,1,0.0,Synchronous,0,0,1,0,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,40.1,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,9.7,0,11.52,0,0,23,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,0,1,6,0,0,0,Gemcitabine_Abraxane,PD,5.91,0,0,0.5,Capecitabine,PD,2.56,0,0,7.25,NA,NA,0.0,0,0,0.0,2,0.0,6.16,1,Disease_progression,0,0,0,,,,,,,
HC014-8356500001941106,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,65,Male,2,23.8,1,III,0,2.0,Metachronous,1,1,0,0,1,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,1,Fracture,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,13.6,0,5.09,0,0,56,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,1,0,0,3,0,0,0,Abiraterone_ADT,PR,25.31,0,1,2.39,Enzalutamide,SD,3.1,0,1,1.09,Lu177-PSMA,SD,10.53,0,0,0.82,3,0.0,25.84,1,Unknown,1,1,0,,363.8,,,,,
HC014-4688829300782485,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Best_supportive_care,70,Female,3,26.3,6,III,0,15.7,Metachronous,1,0,0,0,1,0,0,1,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,1,20,0.0,Negative,ALK-,WT,HER2_3plus,0,WT,MSS,0.0,2.5,7.5,0,3.33,1,0,14,None,1,0,0,0,0,0,0,0,0,0,1,None,1,1,0,5,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,64.6,0,Censored,1,1,1,ER+PR+,,,,,,
HC014-9672588185566706,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,64,Female,0,32.0,4,III,0,11.7,Metachronous,1,0,0,0,1,1,0,1,0,1,0,1,0,0,5,Polymetastatic,1,4,0,0,1,Fracture,0,0,1,10,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,12.6,2.2,0,2.77,1,0,83,None,1,0,0,0,0,1,0,0,0,0,1,Zoledronic_acid,0,0,1,4,0,0,0,Carboplatin_Gemcitabine,PD,88.61,0,0,0.5,Eribulin,PD,2.84,0,0,4.37,Tucatinib_Tras_Cape,SD,3.0,0,0,0.54,3,0.0,81.98,1,Unknown,1,1,1,ER-PR-,,,,,,
HC014-5855969447359440,HC-ONC-014,ovarian_met,High_grade_serous,Palliative_systemic,71,Female,0,34.0,2,IV,1,0.0,Synchronous,0,0,1,0,0,1,0,1,0,1,0,0,0,0,4,Polymetastatic,1,2,0,1,0,None,0,0,1,27,21.2,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,30.7,0,10.13,1,1,36,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,3,0,1,0,Carbo_Pac_Bev,PR,23.0,0,0,4.32,Bevacizumab_mono,SD,3.13,0,0,0.72,Gemcitabine_Carbo,PD,3.34,0,0,1.9,4,0.0,28.21,0,Censored,1,1,0,,,Unknown,205.0,,,
HC014-6942618937683505,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,61,Female,2,29.3,0,III,0,21.0,Metachronous,1,0,0,1,1,1,0,0,0,0,0,0,0,0,3,Oligometastatic,1,2,0,1,1,Hypercalcemia,0,0,0,0,0.0,Negative,ALK-,WT,HER2_3plus,0,VUS,MSS,0.0,4.9,3.6,0,19.98,0,1,59,None,1,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,3,0,0,0,Trastuzumab_Pertuzumab_Docetaxel,PR,54.36,0,1,3.39,Trastuzumab_Capecitabine,PR,39.48,0,1,1.26,NA,NA,0.0,0,0,0.0,2,0.0,48.21,1,Disease_progression,1,1,0,ER+PR-,,,,,,
HC014-6726794024448521,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,64,Male,1,27.6,1,III,0,17.4,Metachronous,0,0,0,1,0,0,1,0,0,0,1,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,33.2,0.0,24.8,0,23.1,0,1,27,None,1,1,5,2,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,Relatlimab_Nivolumab,PR,9.0,1,0,0.5,Nivolumab_mono,SD,3.26,1,0,6.07,NA,NA,0.0,0,0,0.0,2,6.52,180.0,1,Disease_progression,1,1,1,,,,,,,0.0
HC014-4217162148170451,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,65,Male,0,32.3,3,III,0,47.8,Late_recurrence,0,0,0,0,1,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,Fracture,0,0,0,0,0.0,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,9.0,6.2,0,24.58,0,0,73,None,1,0,0,0,0,0,1,0,0,0,0,Zoledronic_acid,0,0,1,2,0,0,0,Ribociclib_Letrozole,PR,20.52,0,1,0.52,Everolimus_Exemestane,PR,15.5,0,0,6.11,Trastuzumab_deruxtecan,PD,2.25,0,1,6.32,4,0.0,36.53,0,Censored,1,1,0,ER+PR-,,,,,,
HC014-2770306924169084,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Maintenance,52,Female,1,33.1,0,IV,1,0.0,Synchronous,0,0,1,1,1,0,0,1,0,1,0,1,0,0,6,Polymetastatic,0,0,0,0,1,None,0,0,1,16,8.1,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,0.9,10.8,0,13.96,0,1,44,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,4,0,0,0,Palbociclib_Fulvestrant,PR,55.69,0,1,2.57,Alpelisib_Fulvestrant,PR,16.14,0,0,0.5,Capivasertib_Fulvestrant,SD,2.62,0,0,2.42,3,0.0,38.56,1,Disease_progression,1,1,0,ER+PR+,,,,,,
HC014-3806510452376063,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Best_supportive_care,57,Female,2,30.3,3,III,0,5.0,Metachronous,0,1,0,1,1,0,0,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,Bone_pain,0,0,0,0,0.0,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,11.6,5.1,0,21.14,0,1,50,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,1,0,1,8,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,144.69,1,Unknown,1,1,1,ER+PR+,,,,,,
HC014-9106475847949694,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,66,Female,1,26.0,7,I,0,51.5,Late_recurrence,0,1,1,0,0,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,19.6,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,11.4,0,9.49,0,0,70,None,1,0,0,0,0,0,0,1,0,0,0,None,0,0,0,9,0,0,0,FOLFOX_Bev,PD,6.88,0,0,0.52,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,107.35,1,Unknown,1,1,1,,,,,,,
HC014-6555900628736528,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,51,Female,1,27.2,4,III,0,72.1,Late_recurrence,0,0,0,1,1,0,1,1,1,0,0,0,0,0,5,Polymetastatic,0,0,0,0,1,None,0,0,1,6,0.0,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,3.5,14.6,0,22.2,0,1,38,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,1,1,0,0,0,Nab-Paclitaxel_Atezolizumab,PR,24.52,1,0,1.45,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,18.87,88.75,0,Censored,1,1,1,ER-PR-,,,,,,
HC014-6975995845029076,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,82,Male,3,30.5,2,IV,1,0.0,Synchronous,0,0,1,1,0,0,1,1,0,1,0,0,0,0,5,Polymetastatic,0,0,0,0,0,None,0,0,1,18,58.2,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.5,0,14.21,0,0,75,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,5,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,0.86,0,Censored,0,0,0,,,,,,,
HC014-1109578248430454,HC-ONC-014,renal_met,Clear_cell,Palliative_systemic,71,Male,1,37.6,2,I,0,6.0,Metachronous,0,0,1,1,1,0,0,0,0,1,0,0,0,0,4,Polymetastatic,0,0,0,0,1,None,0,0,0,0,12.3,Negative,ALK-,WT,HER2-,0,WT,MSS,27.3,0.0,5.9,0,13.75,0,0,40,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,0,6,0,0,0,Nivo_Ipi,PR,22.64,0,0,0.5,Lenvatinib_Everolimus,PR,4.65,0,1,1.73,Cabozantinib,SD,2.12,0,1,0.5,3,0.0,33.78,1,Disease_progression,1,1,0,,,,,0.0,Intermediate,
HC014-5280325709830967,HC-ONC-014,prostate_met,Adenocarcinoma,Maintenance,73,Male,1,33.9,6,III,0,1.3,Metachronous,1,0,1,1,1,0,0,0,0,0,0,0,0,1,4,Polymetastatic,0,0,0,0,1,None,0,0,0,0,24.7,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.9,0,8.28,0,1,88,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,0,2,0,0,0,Darolutamide_Docetaxel_ADT,PD,32.83,0,0,12.42,Abiraterone_Pred,SD,2.57,0,1,0.5,Pembrolizumab,SD,5.75,1,0,4.95,4,0.0,47.69,0,Censored,1,1,0,,4.8,,,,,
HC014-1458829455653565,HC-ONC-014,nsclc_met,Adenocarcinoma,Best_supportive_care,21,Male,3,30.3,4,III,0,11.4,Metachronous,1,0,0,0,1,0,1,1,1,0,0,0,0,0,4,Polymetastatic,0,0,0,0,1,None,0,1,1,22,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,1.0,0.0,2.5,0,10.09,0,0,71,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,0,0,1,10,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,21.39,1,Disease_progression,1,0,0,,,,,,,
HC014-2800036200620814,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,55,Male,3,23.0,6,III,0,5.2,Metachronous,0,0,1,0,1,0,0,0,0,0,1,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,30.9,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,16.3,0,22.36,1,0,20,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,7,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,19.07,1,Disease_progression,1,0,0,,,,,,,
HC014-2046518461009025,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,71,Male,1,25.0,2,III,0,18.7,Metachronous,1,0,1,0,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,34.3,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,6.0,0,17.73,1,0,65,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,1,2,0,0,0,FOLFOX_Bev,PR,4.59,0,0,3.37,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,13.76,1,Intercurrent_illness,1,0,0,,,,,,,
HC014-6676118358929813,HC-ONC-014,ovarian_met,Clear_cell,Palliative_systemic,49,Female,2,31.4,3,II,0,18.8,Metachronous,1,0,0,0,0,0,0,1,1,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,1,1,18,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.1,0,27.77,0,0,86,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,2,0,0,0,NIRAPARIB_maint,SD,23.36,0,0,0.5,Trabectedin_PLD,PD,10.85,0,0,11.35,Niraparib,SD,10.19,0,1,0.5,3,0.0,23.75,1,Disease_progression,1,0,0,,,HRD-,61.0,,,
HC014-4902230678666969,HC-ONC-014,melanoma_met,Melanoma,Best_supportive_care,50,Female,3,24.0,4,II,0,15.3,Metachronous,1,0,0,0,0,0,0,0,0,1,1,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,1,WT,MSS,16.3,0.0,26.6,0,1.11,0,0,69,None,0,0,0,0,0,0,0,0,0,0,0,None,1,1,1,4,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,27.0,1,Unknown,1,1,0,,,,,,,0.0
HC014-7954856558555057,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,62,Male,1,34.6,3,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,1,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,24,9.4,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,6.0,0,1.6,0,0,66,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,6,0,0,0,Gemcitabine_Abraxane,PD,2.07,0,0,8.57,Olaparib_BRCA,PD,5.28,0,1,2.23,NA,NA,0.0,0,0,0.0,2,0.0,7.56,0,Censored,0,0,0,,,,,,,
HC014-9634287145930286,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,35,Female,0,31.5,4,I,0,143.4,Late_recurrence,1,1,1,0,1,1,0,0,1,1,0,0,0,0,5,Polymetastatic,1,1,0,1,1,None,0,1,0,0,5.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,0.8,1.6,0,12.12,0,0,62,None,1,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,5,0,1,0,Ribociclib_Letrozole,PD,32.09,0,1,1.03,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,21.21,1,Disease_progression,1,0,0,ER+PR+,,,,,,
HC014-5002026646590074,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,33,Female,0,27.8,4,III,0,20.2,Metachronous,0,0,0,1,0,0,0,1,0,0,1,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,20,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,5.7,0.0,46.4,0,19.74,0,0,54,None,1,1,12,2,0,0,0,0,0,0,0,None,0,0,0,1,0,0,0,Relatlimab_Nivolumab,PR,38.91,1,0,2.73,Nivolumab_mono,SD,1.93,1,0,0.87,Pembrolizumab_mono,SD,4.53,1,0,0.5,3,0.17,180.0,0,Censored,1,1,1,,,,,,,0.0
HC014-6825846086969910,HC-ONC-014,gastric_met,Adenocarcinoma,Oligometa_curativeintent,74,Male,1,20.4,4,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,38.5,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.5,0,9.03,0,0,44,None,1,1,12,1,0,0,0,0,0,0,0,None,0,0,0,5,1,0,0,ECF,PR,15.08,0,0,0.5,Paclitaxel_mono,SD,5.81,0,0,9.22,NA,NA,0.0,0,0,0.0,2,0.0,73.49,1,Intercurrent_illness,1,1,1,,,,,,,
HC014-2859071189119925,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,54,Female,1,25.6,0,II,0,59.3,Late_recurrence,1,0,1,1,1,0,0,0,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,Spinal_cord_compression,0,0,0,0,5.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,3.0,4.5,0,13.21,0,0,56,None,0,0,0,0,0,0,0,1,0,0,0,Zoledronic_acid,0,0,1,3,0,0,0,Carboplatin_Gemcitabine,PR,42.84,0,0,6.52,Vinorelbine,SD,15.21,0,0,3.12,NA,NA,0.0,0,0,0.0,2,0.0,9.83,1,Disease_progression,0,0,0,ER-PR-,,,,,,
HC014-1531404484713687,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,73,Male,2,27.5,2,IV,1,0.0,Synchronous,0,0,1,0,1,0,0,1,0,0,0,1,0,0,4,Polymetastatic,0,0,0,0,1,Bone_pain,0,0,1,26,35.7,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,7.7,0,10.32,1,0,71,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,1,0,0,3,1,0,0,Gemcitabine_mono,PR,5.11,0,0,3.62,Capecitabine,SD,1.42,0,0,4.85,Olaparib_BRCA,SD,2.53,0,1,2.9,3,0.0,6.49,1,Disease_progression,0,0,0,,,,,,,
HC014-9791327942219772,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,59,Male,0,32.2,5,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,1,0,0,23.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.5,0,13.78,0,1,15,None,1,1,3,2,0,0,0,1,0,0,0,None,0,0,0,3,0,0,0,FOLFOXIRI_Bev,SD,1.52,0,0,7.69,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,42.88,1,Disease_progression,1,1,0,,,,,,,
HC014-6749212605395866,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Best_supportive_care,66,Female,2,27.2,0,III,0,68.0,Late_recurrence,1,0,1,0,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,Hypercalcemia,1,0,0,0,5.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,10.3,2.3,0,17.2,0,1,73,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,1,0,1,7,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,102.75,1,Treatment_toxicity,1,1,1,ER+PR-,,,,,,
HC014-1265336369606604,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,65,Male,3,27.6,2,IV,1,0.0,Synchronous,0,0,1,1,0,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,25.5,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,10.8,0,13.87,0,1,40,None,0,0,0,0,0,0,0,0,0,0,0,None,1,1,1,5,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,8.03,1,Disease_progression,0,0,0,,,,,,,
HC014-4064453842424641,HC-ONC-014,pancreatic_met,Adenocarcinoma,Best_supportive_care,65,Male,2,20.4,5,IV,1,0.0,Synchronous,0,0,1,1,0,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,47.5,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,3.2,0,19.27,0,1,34,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,0,6,1,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,18.07,1,Disease_progression,1,0,0,,,,,,,
HC014-9547964086340473,HC-ONC-014,nsclc_met,Large_cell,Palliative_systemic,69,Female,2,20.9,6,III,0,29.6,Late_recurrence,1,0,0,1,0,0,0,0,1,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,13.3,0.0,12.8,0,1.76,1,0,88,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,4,0,0,0,Nivo_Ipi,SD,3.37,0,0,1.89,Docetaxel_Ramucirumab,SD,3.04,0,0,8.94,Docetaxel_mono,PD,6.84,0,0,0.5,3,0.0,7.67,1,Disease_progression,0,0,0,,,,,,,
HC014-7344198196369492,HC-ONC-014,ovarian_met,High_grade_serous,Oligometa_curativeintent,60,Female,1,29.2,4,II,0,8.8,Metachronous,0,0,0,0,0,0,0,1,1,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,21,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.8,0,25.33,1,0,43,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,8,0,0,0,Carbo_Pac_Bev,PR,16.7,0,0,7.46,Niraparib,PD,10.81,0,1,2.78,Bevacizumab_mono,SD,0.5,0,0,0.5,3,0.0,77.16,1,Disease_progression,1,1,1,,,HRD-,13.1,,,
HC014-9414348013964613,HC-ONC-014,gastric_met,Adenocarcinoma,Palliative_systemic,59,Female,1,26.5,3,III,0,2.0,Metachronous,1,0,1,0,0,0,0,1,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,1,11,30.3,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.3,0,7.97,0,0,45,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,6,0,0,0,EOX,PD,3.27,0,0,1.0,Trastuzumab_deruxtecan_HER2,SD,2.22,0,1,5.2,Ramucirumab_Paclitaxel,PD,2.88,0,0,2.31,3,0.0,1.83,1,Disease_progression,0,0,0,,,,,,,
HC014-5396905481988751,HC-ONC-014,gastric_met,Adenocarcinoma,Oligometa_curativeintent,68,Female,1,22.7,2,IV,1,0.0,Synchronous,0,0,0,1,1,0,0,0,1,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,Spinal_cord_compression,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,12.5,0,7.08,0,0,79,None,1,0,0,0,0,0,1,0,0,0,1,Denosumab,0,0,1,6,0,0,0,EOX,SD,19.81,0,0,0.5,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,39.47,1,Unknown,1,1,0,,,,,,,
HC014-4185814008723650,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,73,Female,0,34.7,0,I,0,57.4,Late_recurrence,1,0,0,0,1,0,0,1,0,0,0,1,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,1,23,0.0,Negative,ALK-,WT,HER2_3plus,0,BRCA1,MSS,0.0,6.4,4.4,0,29.12,0,0,63,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,1,0,0,0,THP_Taxane,PR,15.3,0,0,0.63,Trastuzumab_Capecitabine,SD,6.23,0,1,1.82,NA,NA,0.0,0,0,0.0,2,0.0,61.1,1,Disease_progression,1,1,1,ER-PR-,,,,,,
HC014-7860132188860580,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,69,Female,1,22.6,5,III,0,31.0,Late_recurrence,1,0,0,0,1,0,0,1,0,0,1,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,1,22,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,7.7,10.3,0,16.18,1,1,19,None,1,1,8,2,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,1,0,0,0,Abemaciclib_Letrozole,PR,16.68,0,1,2.91,Alpelisib_Fulvestrant,PR,6.06,0,0,5.38,Trastuzumab_Capecitabine,SD,3.62,0,1,2.97,5,0.0,86.71,1,Disease_progression,1,1,1,ER+PR+,,,,,,
HC014-1173569004310558,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,57,Male,1,20.7,2,IV,1,0.0,Synchronous,0,0,0,0,1,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.0,0,26.24,1,0,52,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,6,0,0,0,Apalutamide_ADT,SD,23.29,0,0,0.84,Cabazitaxel,PR,6.96,0,0,0.5,NA,NA,0.0,0,0,0.0,2,0.0,76.3,0,Censored,1,1,1,,2.9,,,,,
HC014-4077047814649574,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Best_supportive_care,61,Female,1,25.8,2,I,0,1.0,Metachronous,1,0,1,1,1,0,0,0,0,1,0,1,0,0,5,Polymetastatic,0,0,0,0,1,None,0,0,0,0,14.9,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,5.9,1.4,0,40.22,0,0,27,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,1,7,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,22.22,0,Censored,1,0,0,ER+PR+,,,,,,
HC014-4489796449114743,HC-ONC-014,gastric_met,Adenocarcinoma,Palliative_systemic,79,Female,1,31.1,2,IV,1,0.0,Synchronous,0,0,0,0,0,1,1,0,0,0,0,0,0,0,2,Oligometastatic,1,5,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,14.2,0,5.51,0,1,18,None,1,1,5,3,0,1,0,0,0,0,0,None,0,0,0,6,0,1,0,Nivo_Chemo,PR,9.39,0,0,1.17,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,33.96,0,Censored,1,1,0,,,,,,,
HC014-5794456607222801,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,53,Female,1,23.4,0,III,0,11.0,Metachronous,1,0,1,1,0,0,0,0,1,0,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,1,0,0,40.3,Negative,ALK-,Other_KRAS,HER2-,0,WT,MSS,0.0,0.0,4.5,0,15.87,0,1,40,None,0,0,0,0,0,0,0,1,0,0,0,None,0,0,0,3,0,0,0,FOLFOXIRI_Bev,PD,0.56,0,0,8.06,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,19.61,0,Censored,1,0,0,,,,,,,
HC014-7683933125785248,HC-ONC-014,ovarian_met,High_grade_serous,Palliative_systemic,64,Female,1,26.7,4,IV,1,0.0,Synchronous,0,0,0,1,0,0,1,1,1,0,0,0,0,0,4,Polymetastatic,0,0,0,0,0,None,0,1,1,30,0.0,Negative,ALK-,WT,HER2-,0,VUS,MSS,0.0,0.0,10.7,0,32.65,1,1,59,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,1,0,0,0,Carbo_Pac_Bev,SD,10.03,0,0,2.17,Gemcitabine_Carbo,SD,19.0,0,0,3.45,Olaparib,PR,2.11,0,1,6.13,3,0.0,4.2,1,Disease_progression,0,0,0,,,HRD+,313.7,,,
HC014-8447027275408016,HC-ONC-014,nsclc_met,Squamous_cell,Best_supportive_care,61,Male,3,32.2,1,III,0,70.4,Late_recurrence,1,1,0,0,0,0,1,1,1,1,0,0,0,0,4,Polymetastatic,0,0,0,0,0,None,0,1,1,14,0.0,Negative,ALK-,G12C,HER2-,0,WT,MSS,31.0,0.0,4.8,0,10.36,0,0,13,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,5,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,5.08,1,Disease_progression,0,0,0,,,,,,,
HC014-3094686561661459,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,65,Male,2,26.5,0,IV,1,0.0,Synchronous,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.6,0,5.81,0,1,58,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,10,0,0,0,Gemcitabine_mono,SD,14.23,0,0,4.56,Capecitabine,SD,2.23,0,0,1.71,NA,NA,0.0,0,0,0.0,2,0.0,42.47,1,Disease_progression,1,1,0,,,,,,,
HC014-3121408670333872,HC-ONC-014,gastric_met,Adenocarcinoma,Oligometa_curativeintent,54,Female,1,36.7,2,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,0,1,0,0,0,1,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,8.9,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.9,0,7.76,0,1,85,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,9,0,0,0,EOX,PD,2.33,0,0,4.12,Paclitaxel_mono,PR,0.5,0,0,2.4,Trastuzumab_deruxtecan_HER2,PD,3.36,0,1,3.93,3,0.0,13.99,1,Disease_progression,1,0,0,,,,,,,
HC014-9955599617665811,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,52,Female,2,28.2,2,II,0,35.1,Late_recurrence,1,1,0,0,1,1,0,0,0,1,0,0,0,0,3,Oligometastatic,1,5,0,0,1,None,0,0,0,0,0.0,L858R,ALK-,Other_KRAS,HER2-,0,WT,MSS,43.5,0.0,4.7,0,22.14,0,0,50,None,1,0,0,0,0,1,0,0,0,0,1,Denosumab,1,0,0,4,0,0,0,Gefitinib,PR,17.0,0,0,4.72,Docetaxel_mono,PD,1.35,0,0,0.67,NA,NA,0.0,0,0,0.0,2,0.0,13.84,1,Intercurrent_illness,1,0,0,,,,,,,
HC014-4116798339616559,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,65,Male,3,32.6,1,IV,1,0.0,Synchronous,0,0,1,1,0,0,1,0,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,32.2,Negative,ALK-,G12C,HER2-,0,WT,MSS,0.0,0.0,1.6,0,6.8,0,0,32,None,0,0,0,0,0,0,0,0,0,0,0,None,0,1,1,9,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,21.09,1,Disease_progression,1,0,0,,,,,,,
HC014-7656225285604391,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,60,Male,0,16.6,8,IV,1,0.0,Synchronous,0,0,0,0,1,1,0,0,0,0,0,0,0,1,3,Oligometastatic,1,5,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.4,0,22.4,1,1,30,None,1,1,5,3,0,1,0,0,0,0,0,None,0,0,1,4,0,0,0,Apalutamide_ADT,PR,38.91,0,0,0.5,Docetaxel,CR,5.55,0,0,2.14,Lu177-PSMA,SD,3.28,0,0,1.38,3,0.0,31.8,0,Censored,1,1,0,,49.7,,,,,
HC014-5868413254593602,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,58,Male,1,31.9,8,III,0,18.8,Metachronous,1,0,0,0,1,1,0,0,0,0,0,0,0,0,2,Oligometastatic,1,2,0,1,1,Fracture,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,6.7,0,9.6,0,1,32,None,1,1,3,1,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,2,0,1,0,Enzalutamide_ADT,SD,9.93,0,1,2.24,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,92.87,1,Disease_progression,1,1,1,,8.0,,,,,
HC014-5257104432818048,HC-ONC-014,nsclc_met,Adenocarcinoma,Best_supportive_care,65,Male,3,29.4,2,III,0,1.0,Metachronous,0,0,1,0,0,0,0,0,1,1,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,1,0,0,13.4,Negative,ALK-,WT,HER2-,0,WT,MSS,24.1,0.0,0.7,0,31.43,0,1,65,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,3,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,7.77,1,Disease_progression,0,0,0,,,,,,,
HC014-4600901571801452,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,41,Female,0,31.2,5,III,0,14.5,Metachronous,1,0,0,0,1,0,0,1,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,1,19,0.0,Negative,ALK-,WT,HER2_3plus,0,WT,MSS,0.0,0.8,1.7,0,31.92,0,1,54,None,1,1,3,2,0,0,0,0,0,0,1,Denosumab,0,0,1,4,0,0,0,Trastuzumab_Pertuzumab_Docetaxel,PR,21.77,0,1,2.44,Lapatinib_Capecitabine,PR,10.53,0,0,0.5,Fulvestrant_mono,PR,4.14,0,0,2.94,3,0.0,116.89,1,Disease_progression,1,1,1,ER-PR-,,,,,,
HC014-2309849164388335,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Best_supportive_care,49,Female,2,32.5,0,I,0,5.6,Metachronous,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,Spinal_cord_compression,0,0,0,0,0.0,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,9.4,23.5,0,1.29,0,0,85,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,1,0,1,8,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,107.45,1,Unknown,1,1,1,ER-PR-,,,,,,
HC014-1681237258431676,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Oligometa_curativeintent,53,Female,1,26.7,2,III,0,3.5,Metachronous,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,Fracture,0,0,0,0,0.0,Negative,ALK-,WT,HER2_3plus,0,WT,MSS,0.0,20.8,3.4,0,20.61,0,0,30,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,0,0,3,0,0,0,Pyrotinib_Capecitabine,PD,19.42,0,0,4.86,Trastuzumab_deruxtecan,SD,7.5,0,1,4.41,NA,NA,0.0,0,0,0.0,2,0.0,148.83,1,Treatment_toxicity,1,1,1,ER-PR-,,,,,,
HC014-3259268794379941,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,53,Male,0,25.3,6,IV,1,0.0,Synchronous,0,0,0,1,0,0,1,0,1,0,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,69.5,0.0,5.1,0,28.03,0,0,78,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,0,0,0,0,Pembrolizumab_mono,CR,13.95,1,0,8.77,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,1.08,90.15,0,Censored,1,1,1,,,,,,,
HC014-9270194090332365,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,55,Female,1,24.0,4,II,0,22.7,Metachronous,1,0,1,0,0,0,0,0,0,0,1,0,0,1,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,6.4,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,0.4,13.4,0,7.13,0,1,40,None,1,1,12,1,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,Pembrolizumab_Chemo,SD,2.58,1,0,1.09,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,152.65,0,Censored,1,1,1,ER-PR-,,,,,,
HC014-3110810334585068,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,47,Female,1,23.6,3,IV,1,0.0,Synchronous,0,0,1,0,1,1,0,0,1,0,0,0,1,0,5,Polymetastatic,1,2,0,1,1,None,0,0,0,0,9.6,Negative,ALK-,WT,HER2-,0,WT,MSS,24.6,0.0,29.5,0,8.38,1,1,28,None,1,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,0,6,0,1,0,Nivolumab_Ipilimumab,PR,10.7,1,0,0.67,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,15.99,85.6,0,Censored,1,1,1,,,,,,,0.0
HC014-2720195903072601,HC-ONC-014,nsclc_met,Large_cell,Best_supportive_care,53,Male,2,24.4,10,III,0,52.7,Late_recurrence,1,1,1,0,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,1,0,0,0,15.4,Negative,ALK-,WT,HER2-,0,WT,MSS,48.3,0.0,4.5,0,1.1,0,0,30,None,1,0,0,0,0,0,0,0,0,0,1,Zoledronic_acid,0,0,0,7,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,80.84,1,Disease_progression,1,1,1,,,,,,,
HC014-3835717552437496,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,60,Female,0,26.0,6,III,0,5.9,Metachronous,1,1,1,0,0,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,1,0,0,19.0,Negative,ALK-,G12C,HER2-,0,WT,MSS,0.0,0.0,4.2,0,24.92,0,0,42,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,8,0,0,0,FOLFIRI_Bev,PR,3.53,0,0,6.62,FOLFOX_Bev,PD,3.97,0,0,3.33,FOLFOX_Bev,SD,2.72,0,0,0.88,3,0.0,45.14,1,Disease_progression,1,1,0,,,,,,,
HC014-5040412776103817,HC-ONC-014,nsclc_met,Squamous_cell,Palliative_systemic,64,Male,1,27.1,8,III,0,13.9,Metachronous,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Exon20ins,ALK-,WT,HER2-,0,WT,MSS,54.2,0.0,5.7,0,6.1,0,1,43,None,1,1,3,3,0,0,0,0,0,0,1,Denosumab,0,0,0,9,0,0,0,Gefitinib,SD,6.19,0,0,0.76,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,16.46,1,Disease_progression,1,0,0,,,,,,,
HC014-6525565506968644,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,68,Male,2,25.8,1,III,0,31.3,Late_recurrence,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,BRCA2,MSS,0.0,0.0,4.1,1,4.02,0,1,67,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,8,0,0,0,Docetaxel_ADT,PR,7.28,0,0,1.07,Lu177-PSMA,SD,3.41,0,0,3.01,NA,NA,0.0,0,0,0.0,2,0.0,36.68,1,Disease_progression,1,1,0,,19.6,,,,,
HC014-9009050327766746,HC-ONC-014,renal_met,Clear_cell,Oligometa_curativeintent,35,Female,0,26.4,3,III,0,22.7,Metachronous,1,0,0,1,0,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,40.0,0.0,1.0,0,6.33,0,0,26,None,1,1,8,2,0,0,0,0,0,0,0,None,0,0,0,8,0,0,0,Pazopanib,SD,4.23,0,1,6.96,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,49.26,1,Disease_progression,1,1,0,,,,,0.0,Favorable,
HC014-4008841234345583,HC-ONC-014,ovarian_met,Clear_cell,Oligometa_curativeintent,51,Female,1,26.7,2,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,1,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,1,29,9.4,Negative,ALK-,WT,HER2-,0,BRCA2,MSS,0.0,0.0,16.4,0,4.75,0,1,80,None,0,0,0,0,0,0,0,1,0,0,0,None,0,0,0,8,0,0,0,Olaparib_maint_BRCA,PR,27.28,0,1,2.78,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,61.52,1,Disease_progression,1,1,1,,,HRD+,11.8,,,
HC014-4275100645242464,HC-ONC-014,gastric_met,Adenocarcinoma,Palliative_systemic,37,Female,2,31.7,3,III,0,42.1,Late_recurrence,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.5,0,7.02,0,1,81,None,0,0,0,0,0,0,0,0,0,0,0,None,1,0,1,3,0,0,0,EOX,PD,18.12,0,0,7.53,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,20.8,0,Censored,1,0,0,,,,,,,
HC014-7636123861403912,HC-ONC-014,ovarian_met,Endometrioid,Palliative_systemic,48,Female,2,24.4,3,IV,1,0.0,Synchronous,0,0,0,1,0,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,1,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.5,0,6.82,0,0,25,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,4,0,0,0,NIRAPARIB_maint,PD,24.81,0,0,4.64,Olaparib,SD,6.89,0,1,0.5,NA,NA,0.0,0,0,0.0,2,0.0,39.39,1,Intercurrent_illness,1,1,0,,,Unknown,257.8,,,
HC014-2437948373865716,HC-ONC-014,crc_met,Adenocarcinoma,Oligometa_curativeintent,46,Female,0,28.8,3,III,0,28.6,Late_recurrence,1,0,1,0,0,0,0,0,0,1,0,0,1,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,31.2,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,4.5,0,1.27,1,0,52,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,2,0,0,0,FOLFOXIRI_Bev,SD,13.9,0,0,0.85,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,35.83,1,Disease_progression,1,1,0,,,,,,,
HC014-8903863869773062,HC-ONC-014,crc_met,Adenocarcinoma,Best_supportive_care,52,Female,3,17.5,3,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,1,0,0,0,0,0,2,Oligometastatic,0,0,0,0,0,None,0,0,0,0,28.4,Negative,ALK-,WT,HER2-,0,WT,pMMR,0.0,0.0,3.6,0,18.98,0,0,63,None,0,0,0,0,0,0,0,0,0,0,0,None,0,1,1,10,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,44.44,1,Disease_progression,1,1,0,,,,,,,
HC014-9112717375692035,HC-ONC-014,gastric_met,Adenocarcinoma,Palliative_systemic,42,Female,1,31.6,3,II,0,9.1,Metachronous,0,0,1,0,0,0,0,0,1,0,0,1,0,0,3,Oligometastatic,0,0,0,0,0,None,0,1,0,0,5.7,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,32.1,0,21.31,0,0,33,None,1,1,8,3,0,0,0,0,0,0,0,None,0,0,0,6,0,0,0,Pembro_FP,SD,10.61,0,0,2.24,Trastuzumab_deruxtecan_HER2,SD,6.15,0,1,8.35,NA,NA,0.0,0,0,0.0,2,0.0,4.69,1,Disease_progression,0,0,0,,,,,,,
HC014-9699474842798146,HC-ONC-014,renal_met,Clear_cell,Oligometa_curativeintent,46,Female,0,23.6,3,III,0,26.3,Late_recurrence,1,1,0,1,0,1,0,0,0,0,0,0,0,1,3,Oligometastatic,1,6,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,10.8,0.0,4.8,0,14.34,1,0,40,None,1,1,5,1,0,0,0,0,0,0,0,None,0,0,0,0,0,0,0,Nivo_Ipi,PR,11.05,0,0,2.71,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,91.89,1,Disease_progression,1,1,1,,,,,1.0,Intermediate,
HC014-6505044206393505,HC-ONC-014,pancreatic_met,Adenocarcinoma,Oligometa_curativeintent,43,Female,0,28.4,7,IV,1,0.0,Synchronous,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,1,30,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.8,0,43.76,1,0,62,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,1,0,0,0,Gemcitabine_mono,SD,12.11,0,0,2.27,Gemcitabine_Cisplatin,PD,1.02,0,0,7.56,FOLFOX,PD,4.35,0,0,1.09,4,0.0,14.48,1,Disease_progression,1,0,0,,,,,,,
HC014-7889207256121932,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,77,Male,1,27.2,6,IV,1,0.0,Synchronous,0,0,1,1,0,0,1,0,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,0,None,0,0,0,0,22.3,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.5,0,25.15,0,0,15,None,1,1,3,1,0,0,0,0,0,0,0,None,0,0,0,2,0,0,0,FOLFOX_Bev,PR,2.13,0,0,6.03,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,101.93,0,Censored,1,1,1,,,,,,,
HC014-7779102021434318,HC-ONC-014,nsclc_met,Adenocarcinoma,Palliative_systemic,64,Female,0,32.6,1,II,0,22.0,Metachronous,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,40.1,0.0,2.4,0,20.72,0,1,79,None,1,1,8,2,0,0,0,0,0,0,1,Denosumab,0,0,0,5,0,0,0,Carbo_Paclitaxel_Pembro,PR,11.8,0,0,1.03,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,83.69,1,Intercurrent_illness,1,1,1,,,,,,,
HC014-1029820485226452,HC-ONC-014,prostate_met,Adenocarcinoma,Maintenance,66,Male,2,32.7,3,IV,1,0.0,Synchronous,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,0.9,1,6.74,0,0,79,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,0,2,0,0,0,Enzalutamide_ADT,PR,40.34,0,1,1.51,Olaparib,PD,7.47,0,1,3.2,Abiraterone_Pred,PR,4.93,0,1,0.5,4,0.0,6.74,1,Disease_progression,0,0,0,,2267.7,,,,,
HC014-9605541248567855,HC-ONC-014,ovarian_met,High_grade_serous,Best_supportive_care,78,Female,3,26.1,2,III,0,7.4,Metachronous,1,0,0,0,0,0,1,1,1,1,0,0,0,0,4,Polymetastatic,0,0,0,0,0,None,0,1,1,12,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,1.5,0,22.11,0,0,42,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,1,8,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,24.39,1,Disease_progression,1,1,0,,,HRD+,136.8,,,
HC014-9394641658370099,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Best_supportive_care,70,Female,3,27.1,0,I,0,6.8,Metachronous,1,0,1,0,1,0,0,1,0,0,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,1,29,33.5,Negative,ALK-,WT,HER2_1plus,0,WT,MSS,0.0,15.5,9.1,0,14.0,0,0,27,None,0,0,0,0,0,0,0,0,0,0,0,Denosumab,1,0,0,3,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,29.45,1,Disease_progression,1,1,0,ER+PR+,,,,,,
HC014-7335988512527274,HC-ONC-014,prostate_met,Adenocarcinoma,Oligometa_curativeintent,71,Male,1,30.5,0,III,0,37.0,Late_recurrence,1,0,1,0,1,0,0,0,0,0,0,0,0,0,2,Oligometastatic,0,0,0,0,1,None,0,0,0,0,21.2,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.9,0,8.17,0,1,59,None,1,1,5,3,0,0,0,0,0,0,0,Zoledronic_acid,0,0,1,3,0,0,0,Apalutamide_ADT,PR,23.12,0,0,3.41,Enzalutamide,PR,3.57,0,1,5.83,NA,NA,0.0,0,0,0.0,2,0.0,6.43,1,Unknown,0,0,0,,84.8,,,,,
HC014-1942393280172830,HC-ONC-014,melanoma_met,Melanoma,Best_supportive_care,65,Male,3,19.1,3,II,0,10.6,Metachronous,0,0,0,1,0,0,0,0,1,0,1,1,0,0,4,Polymetastatic,0,0,0,0,0,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,61.6,0.0,22.2,0,8.68,0,0,29,None,0,0,0,0,0,0,0,0,0,0,0,None,1,1,0,7,0,0,0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,0,0.0,42.1,0,Censored,1,1,0,,,,,,,0.0
HC014-7502122290605304,HC-ONC-014,crc_met,Adenocarcinoma,Palliative_systemic,69,Male,0,20.1,4,II,0,50.6,Late_recurrence,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,17.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,4.6,0,25.08,1,1,56,None,1,0,0,0,0,0,0,0,0,0,0,None,0,0,0,2,0,0,0,FOLFIRI_Cetuximab,CR,1.59,0,0,4.06,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,28.59,1,Unknown,1,1,0,,,,,,,
HC014-9029047250867598,HC-ONC-014,melanoma_met,Melanoma,Maintenance,57,Male,2,34.9,1,III,0,12.3,Metachronous,1,0,0,0,1,1,0,0,0,1,0,0,0,0,3,Oligometastatic,1,1,0,1,1,None,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,42.7,0.0,18.7,0,8.72,1,1,43,None,1,0,0,0,0,0,0,0,0,0,0,Denosumab,1,0,0,9,0,1,0,Pembrolizumab_mono,PR,7.14,1,0,2.13,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,9.92,32.76,0,Censored,1,1,0,,,,,,,0.0
HC014-9851778793307242,HC-ONC-014,gastric_met,Adenocarcinoma,Oligometa_curativeintent,73,Female,1,30.2,7,IV,1,0.0,Synchronous,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,Oligometastatic,0,0,0,0,0,None,0,0,0,0,10.2,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.7,0,14.25,0,1,15,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,FLOT,PD,14.29,0,0,3.91,Irinotecan,SD,0.52,0,0,4.79,Trastuzumab_deruxtecan_HER2,PD,7.15,0,1,3.22,3,0.0,13.26,1,Disease_progression,1,0,0,,,,,,,
HC014-4770794221949474,HC-ONC-014,melanoma_met,Melanoma,Palliative_systemic,74,Male,1,28.4,3,IV,1,0.0,Synchronous,0,0,1,0,1,1,0,0,0,1,0,0,0,0,4,Polymetastatic,1,4,0,0,1,Bone_pain,0,0,0,0,37.2,Negative,ALK-,WT,HER2-,0,WT,MSS,29.8,0.0,16.1,0,4.28,1,0,52,None,1,0,0,0,0,0,0,0,0,0,0,Denosumab,0,0,1,6,0,1,0,Relatlimab_Nivolumab,SD,11.82,1,0,1.43,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,75.17,1,Disease_progression,1,1,1,,,,,,,0.0
HC014-1688153494021684,HC-ONC-014,prostate_met,Adenocarcinoma,Palliative_systemic,59,Male,0,28.1,3,III,0,35.5,Late_recurrence,1,0,1,0,1,0,0,0,0,1,0,0,0,0,3,Oligometastatic,0,0,0,0,1,None,0,0,0,0,21.4,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,5.2,1,4.84,1,0,49,None,0,0,0,0,0,0,0,0,0,0,0,None,0,0,0,7,0,0,0,Abiraterone_ADT,PR,33.79,0,1,0.65,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,93.58,1,Disease_progression,1,1,1,,13.2,,,,,
HC014-7369267966854176,HC-ONC-014,nsclc_met,NOS,Palliative_systemic,48,Female,0,25.6,2,IV,1,0.0,Synchronous,0,0,1,0,1,1,0,0,0,0,0,0,1,0,4,Polymetastatic,1,2,0,1,1,None,0,0,0,0,16.1,Exon19del,ALK-,Other_KRAS,HER2-,0,WT,MSS,10.3,0.0,4.3,0,5.53,1,1,85,None,1,0,0,0,1,0,0,0,0,0,0,Zoledronic_acid,0,0,0,1,0,1,0,Dacomitinib,PR,4.31,0,0,4.83,Docetaxel_Nintedanib,SD,3.19,0,0,0.78,Docetaxel_mono,PD,2.22,0,0,6.43,6,11.28,7.44,1,Disease_progression,0,0,0,,,,,,,
HC014-5456275823201522,HC-ONC-014,bladder_met,Urothelial_carcinoma,Palliative_systemic,61,Male,2,32.7,3,III,0,9.5,Metachronous,1,1,0,0,1,0,0,0,0,1,0,0,0,0,2,Oligometastatic,0,0,0,0,1,Hypercalcemia,0,0,0,0,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,11.0,0,7.55,0,0,80,None,1,0,0,0,0,0,0,0,0,0,1,Denosumab,1,0,0,4,0,0,0,Carbo_Gem_Avelumab,PD,18.48,1,0,1.61,Pembrolizumab_mono,SD,3.21,1,0,0.95,Enfortumab_Vedotin,PD,3.24,0,0,2.31,4,0.0,12.64,1,Disease_progression,1,0,0,,,,,,,
HC014-1145825325818156,HC-ONC-014,breast_met,Invasive_carcinoma_NOS,Palliative_systemic,59,Female,0,29.8,5,III,0,15.9,Metachronous,1,0,1,1,1,1,0,0,0,1,0,0,0,0,5,Polymetastatic,1,1,0,1,1,None,0,0,0,0,22.2,Negative,ALK-,WT,HER2_0,0,WT,MSS,0.0,48.3,2.7,0,6.78,0,1,75,None,1,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,0,0,0,6,0,0,0,Carboplatin_Gemcitabine,SD,49.78,0,0,0.85,NA,NA,0.0,0,0,0.0,NA,NA,0.0,0,0,0.0,1,0.0,55.93,1,Disease_progression,1,1,0,ER-PR-,,,,,,
HC014-5537467251111445,HC-ONC-014,pancreatic_met,Adenocarcinoma,Palliative_systemic,43,Female,2,30.2,4,IV,1,0.0,Synchronous,0,0,0,1,1,0,0,1,0,1,0,0,0,0,4,Polymetastatic,0,0,0,0,1,None,0,0,1,24,0.0,Negative,ALK-,WT,HER2-,0,WT,MSS,0.0,0.0,2.3,0,34.75,0,0,59,None,0,0,0,0,0,0,0,0,0,0,0,Zoledronic_acid,1,0,1,5,0,0,0,Gemcitabine_Abraxane,PD,1.64,0,0,4.37,Gemcitabine_Cisplatin,SD,3.08,0,0,1.54,Olaparib_BRCA,PD,0.97,0,1,5.34,3,0.0,6.55,1,Disease_progression,0,0,0,,,,,,,